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Abstract 
 
The monitoring of illicit drugs is now of major importance. Key areas of analysis 
include the detection of illicit use by drivers, workplace testing, forensic investigations 
and general monitoring to detect or reduce abuse. Thus, the development of a highly 
sensitive and reliable array-based assay for saliva, an assay-friendly matrix for detection 
of illicit drugs, would be of major benefit. This thesis describes the production and 
affinity maturation of antibodies for the detection of illicit drugs and their application in 
ELISA, Biacore surface plasmon resonance -based biosensor assays and, finally, in a 
multidrug-based assay. 
The first phase of this work focused on the development of a repertoire of antibody 
fragments against various illicit drugs including morphine-3-glucuronide (M3G), 
amphetamine and tetrahydrocannabinol (THC). Antibody libraries were generated from 
murine, avian and leporine immune systems. A number of antibody fragments were 
produced, purified and characterised by SDS-PAGE, Western blotting and ELISA.  
A pre-characterised, murine anti-M3G, whole IgG structure was used for conversion to 
scFv and Fab antibody fragments. This permitted SPR-based comparative studies 
regarding the validity of using either scFv or Fab fragments in current high throughput 
screening strategies. The Fab fragment revealed an apparent off rate 40-fold higher than 
that of the scFv, that did not translate to higher affinity for the target in question. A 
murine anti-amphetamine Fab fragment demonstrated a 3-fold higher affinity than that 
of the parent IgG clone.  
Diverse leporine immune libraries were utilised in the development of novel 
recombinant Fab and scFv fragments against amphetamine and THC. Subsequently the 
antibodies were solubly expressed in Escherichia coli, and fully characterised with 
respect to their binding capabilities on ELISA and Biacore-based analytical platforms.  
The next phase of the work involved the in-vitro affinity maturation of the anti-M3G 
Fab and anti-THC scFv fragments. The wild-type antibodies were used as templates for 
22 
construction of mutant recombinant antibody libraries. Initial mutagenesis strategies 
exploited error prone-PCR, DNA shuffling, light-chain shuffling and various methods 
of site-directed mutagenesis to generate improved affinity antibody fragments. Kunkle-
style, site-directed mutagenesis, proved to be the most successful method for the 
generation of an anti-M3G Fab mutated library. The highest affinity anti-THC clones, 
characterised by ELISA, were carried forward for light-chain shuffling and subjected to 
specifically-tailored affinity selection conditions. Comparative gene and amino-acid 
sequence analyses were carried out on the wild-type and selected mutants and 
confirmed the presence of mutations in the selected CDR’s. 
The final phase of this research involved the incorporation of the antibodies onto multi-
analyte assay formats. Optimisations were carried out with respect to immobilisation 
strategies, surface chemistries, recombinant antibody fragment selection, use of drug-
protein conjugates and detection strategies. 
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Chapter 1 
 
1.0 Introduction 
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1.1 Drugs of abuse 
 
1.1.1 Opioids 
  
Heroin is the most commonly abused opiate, due to its highly addictive nature and 
availability. Heroin can be administered orally, intravenously, intranasally or by 
inhaling vapours of the heated powder. Heroin is rapidily metabolized to 6-
monacetylmorphine (6-MAM). This is the only metabolite specifically associated with 
heroin abuse. 6-MAM is then hydrolysed to morphine, which is rapidly converted to 
morphine-3-glucuronide (M3G) and to a lesser extent, morphine-6-glucuronide (M6G), 
via glucuronidation, as shown in figure 1.1.1.1. M3G and M6G detected in urine 
account for 55 % and 10 %, respectively, of the administered dose (Zheng et al., 1998). 
 
Morphine is a highly potent opiate analgesic drug and it is the primary active ingredient 
is opium. The content of morphine in raw opium ranges from 2-25% of its total weight. 
Commercial or medicinal opium is standardized to contain 10% morphine. Although 
codeine is naturally present in opium (at levels as low as 0.3%) a large portion of 
morphine is used in the manufacture of codeine and other compounds used in 
prescription pain relief medicines. Morphine abuse has escalated in recent years and a 
significant portion of the morphine refined from opium is used in the manufacture of 
semi-synthetic derivatives including, heroin, and dihydrocodeine. Slang terms or street 
names for morphine, used among addicts include, “dreamer”, “miss emma” and “morf”. 
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Figure 1.1.1.1 Metabolic pathway of heroin and morphine. 
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1.1.2 Amphetamine  
 
Amphetamines and other related compounds are a group of drugs which act by 
increasing the concentrations of serotonin and dopamine in the brain (Puder et al., 
1988). Amphetamines were initially introduced as a treatment for obesity under various 
market brand names. The prescription drugs used for treatment of attention deficit 
disorder (ADD) and attention deficit hyperactivity disorder (ADHD) are also members 
of the amphetamine drug group. However, they are now a commonly misused drug 
among young people. Amphetamines are a Class B drug in the United Kingdom 
although methamphetamine has been upgraded to a Class A drug under the misuse of 
drugs act, 1971. Slang terms or street names used among abusers includes, “meth”, 
“ice”, “crystal” and “glass”.  
Amphetamines are available in d- and l- isomeric forms and also in the racemic mixture 
form (Cone et al., 1993). Amphetamines can be administered orally and intravenously. 
The most commonly abused form is 3,4-methylenedioxymethamphetamine (MDMA), 
also known as ecstasy, as shown in figure 1.1.2.1.  
 
 
 
Figure 1.1.2.1 Structures of amphetamine, methamethamine and the most commonly 
abused synthetic derivative, MDMA (ecstasy). 
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It is important to consider that derivatives of the drug are widely used in medicinal 
allergy and cold formulations when developing a detection system for amphetamine 
abuse (Cone et al., 1993). Compounds such as ephedrine and phenylpropanolamine are 
amphetmaine derivatives used in non-prescription cold medication. They demonstrate 
very high structural similarity with the illicit compounds  (figure 1.1.2.2). 
 
 
 
 
Figure 1.1.2.2 Structure of “over the counter” cold medication, ephedrine, and the 
commonly abused drugs, methamphetamine and MDMA. (Braithwaite et al., 1995) 
 
Amphetamine is largely unaffected during metabolism with more than 60% being 
excreted unchanged. However, amphetamine is metabolised to some extent (> 35%) via 
deamination, oxidation and hydroxylation. Deamination produces phenyl acetone, 
which is then oxidized to benzoic acid followed by excretion in urine in hippuric acid 
and glucuronide-conjugated forms. Amphetamine is also oxidized to p-
hydroxyamphetamine by the hydroxylation of the phenolic ring (figure 1.1.2.3).  
Saliva is a more suitable matrix for the detection due to the influence of urinary pH on 
the levels of amphetamines measured in urine. The reason for this is that salivary pH 
remains constant, even under conditions used to induce pH changes in urinary 
conditions, such as ingestion of sodium bicarbonate (Wan et al., 1978).  
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Figure 1.1.2.3 Schematic representation of the metabolic pathway of amphetamine  
(adapted from Karch, 1998). Amphetamine is metabolised via deamination, oxidation 
and hydroxylation and finally excreted in urine as hippuric acid and glucuronide 
conjugates. 
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1.1.3 Tetrahydrocannabinol 
 
Cannabis is a genus of flowering plants. It is a dioecious plant with both male and 
female plants producing good quality hemp for use in the textile industry. The female 
plants produce the highest quality canabinnoids. Canabinoids make  up the primary 
psychoactive compounds of the plant with tetrahydrocannabinol (THC), as shown in 
figure 1.1.3.1, being the primary psychoactive substance in the plant. It it thought that 
THC plays a similar role in plant life to caffeine or nicotine in that it may act as a form 
of protection against herbivores. Medicinal use of THC in the treatment of migraine and 
pain management has been reported (Campbell et al., 2001).  
In its pure, cold form, THC, is a glassy solid and is completely insoluble in water. THC 
demonstrates good solubility in most organic solvents such as ethanol and butane. Its 
insolubility is an important factor in this work as it renders it difficult for use in 
immunoassay development. In the human body, THC is metabolised to 11-hydroxy-
delta-9-THC (11-OH-THC). This metabolite remains psychoactive until it is further 
oxidised to 11-nor-9-carboxy-delta-9-THC (THC-COOH). Over 50% of THC’s are 
excreted in faeces while THC-COOH excreted in the urine acounts for ~ 20% of total 
THC. 
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Figure 1.1.3.1 Structure of tetrahydrocanabinnol, the primary phsycoactive constituent 
in cannabis, and its metabolism in the human body to the inactive form 11-nor-9-
carboxy-delta-THC. 
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1.2 Levels of detection and cutoffs 
 
Current international guidelines recognized by the Substance Abuse and Mental Health 
service Administration (SAMSHA) and the National Institute of Drugs of Abuse 
(NIDA) are available only for matrices such as plasma and urine. Internationally 
recognized screening (RIA) and confirmation (GC-MS) cut-off levels for detection in 
saliva were updated in 2005 by the division of workplace programs and outlined on 
www.workplace.samsha.gov and in table 1.2.1 below. An extensive list of cut-off 
levels for drugs of abuse in saliva samples was presented in Clarke et al. (2005). The 
relevant figures are listed in table 1.2.2.  
 
Table 1.2.1 Cut-off concentrations of drugs of abuse in urine  
 
Drug Screening cut-off  
(ng/ml) 
Confirmation cut-off 
(ng/ml) 
Amphetamine 1000 500 
THC 50 15 
Morpine 300 300 
 
Table 1.2.2 Cut-off concentrations of target analytes in saliva applied to the OraSure  
Technologies Inc. Intercept EIA kit. (adapted from Clarke et al., 2005) 
 
Test Group Cut-off (ng/ml) Calibrator compound 
Amphetamine 
specific 
100 d-Amphetamine 
Cannabinoids 1 THC 
Opiates 10 Morphine 
 
1.3 Methods of drug detection 
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Methods for the detection of drugs of abuse in clinical samples include thin-layer 
chromatography (TLC), gas chromatography coupled with mass spectroscopy (GC-
MS), (Ewald et al., 2007), high performance liquid chromatography (HPLC) and 
capillary electrophoresis (CE) (Lurie et al., 1998), raman spectroscopy (Eliasson et al., 
2008). GC-MS is the primary test for the confirmation of the presence of drugs of abuse 
in biological samples. However, this method would typically be performed on samples 
that had been previously screened using more rapid methods, such as immunoassay. 
Recent studies reporting on head-space solid phase micro-extraction, illustrate 
complementary techniques and are suggested for use alongside some of the more 
traditional methods outlined above (Fucci et al., 2003).  
 
Immunoassays require less preparative steps. They are highly characterised with very 
specific antibodies available. The initial set-up costs of a traditional analytical 
laboratory are quite large and it can take a significant amount of time per sample 
analysis. Various expensive instruments are required for a functioning analytical 
laboratory, for example, use of liquid–liquid extraction (LLE) and solid phase extraction 
(SPE) combined with HPLC / GC / CE (Zhang et al., 2008), while a single 
immunoassay is capable of analysing multiple samples simultaneously without the need 
for large instrumental costs. Each of these elements impacts on the cost effectiveness 
and speed of using an immunoassay as an initial screening system prior to further 
analysis in an analytical laboratory (Zhang et al., 2008; Braithwaite et al., 1995) The 
extensive preparation of the samples required in order to run chromatographic tests is 
well documented (Xu et al., 2007). Modified solvent extraction and solid phase 
extraction techniques are also used and commercial kits are available. The 
chromatographic methods, which are most commonly used for drugs of abuse are 
concisely reviewed by Braithwaite et al. (1995).  
 
33 
The main types of immunoassay used for detection include enzyme-linked 
immunosorbant assay (ELISA), enzyme-multiplied immunoassay techniques (EMIT), 
fluorescence polarisation immunoassays (FPIA) and up-converting phosphor 
technology. These immunoassays are regarded as the initial qualitative testing method, 
with chromatographic techniques mentioned previously providing quantitative 
confirmatory results. However, several research groups are moving away from this 
ideology due to the advent of antibody-based microarrays. The increase and widespread 
abuse of multiple drugs has hastened the need for an easy and fast technique with the 
ability to detect a wide range of drugs from low sample volumes. There are a number of 
factors to be considered in order to improve on existing techniques. The development of 
rapid “on the spot” testing for drugs of abuse makes the move from conventional 
analytical techniques to easy-to-use biosensors absolutely essential. New detection 
methods must be user-friendly so as to allow the test to be carried out by non-lab-
trained personnel such as law enforcement officials and counselors. 
 
1.3.1 Immunoassays  
 
The basis of all enzyme immunoassays is the binding of an antibody to its cognate 
antigen. The interaction is detected using an antibody-coupled enzyme which converts a 
colourless substrate to a coloured or luminescent product. Two broad classifications of 
immunoassay are competitive and non-competitive. A schematic of a competitive assay 
is shown in Figure 1.3.1.2. One of the most common rapid assay formats currently 
available are the dip-stick or test strip immunoassays. These involve antibodies being 
coated on surfaces such as nitrocellulose strips. Test strip assays often employ a 
competitive immunoassay format and lateral flow. The format is shown in figure 
1.3.1.1. An example is the One-Step Rapid Opiates Test, (Craig Medical, USA), for 
detection of opiates in urine.  Further examples of this type of immunoassay are 
outlined later in the text. 
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Ogert et al. (1992) developed what they describe as a fast, reliable, inexpensive system, 
which requires little user input for the detection of cocaine in urine. The system consists 
of antibodies specific for benzoyleconine, the primary metabolite of cocaine, 
immobilized on the surface of a continuous flow immunosensor. The basis for detection 
is bound labelled antigen competing with free unlabelled drug in the sample. Upon 
testing the assay appeared to have very high specificity with cross reactivity tests 
resulting in fluorescence intensities close to zero even at microgram concentrations of 
various other drugs.  While this system is not technologically much more advanced than 
that of a simple competitive immunoassay such as ELISA, the novel element lies in its 
portability and ease of use. This is a good example of an ideal system that if applied to 
saliva testing, would meet all requirements for a totally non-invasive, rapid and easy to 
use system. A simplified schematic is outlined in figure 1.3.1.1. 
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Figure 1.3.1.1 Diagrammatic example of lateral flow immunoassay for the detection of 
drugs in a sample. An example of this type of assay is the Smartclip-rapid test for drugs 
of abuse, from Envitec. The development of the two lines, a test line and a control line, 
indicates a negative test for the targeted drug (i).  The development of the control line 
and absence of the test line indicates a positive result (ii).  The absence of a control line 
in the window indicates an invalid result regardless of the test line result (iii). 
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Figure 1.3.1.2 Schematic of a competitive ELISA. Antigen is immobilised on the 
surface of the wells. A mixture of sample containing free antigen and a known constant 
concentration of antibody is applied to the blocked wells.  Competition occurs 
between the immobilized antigen and the free antigen for binding to the antibody. A 
labeled secondary antibody, which recognizes the bound antibody, is added. Substrate is 
added to each well and the resulting change in absorbance is measured. Based on an 
initial antibody titration curve the intensity of the response from the competitive ELISA 
is inversely proportional to the concentration of antigen in a test solution. 
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1.3.1.1 Enzyme-Multiplied Immunoassay Technique 
 
Enzyme-multiplied immunoassay technique (EMIT) is a homogenous competitive 
assay.  The drug antigen is labelled with an enzyme and mixed with a solution of 
sample antigen and antibodies. Competitive binding takes place and the binding of the 
antibody, to the drug attached to the enzyme, sterically hinders the active site of the 
enzyme thereby preventing enzyme activity. When unlabelled free antigen is added, it 
competes with the labelled antigen for binding to the antibody. The greater the level of 
antigen added, the greater the level of unbound enzyme-labelled antigen, resulting in 
greater enzymatic activity. Behring Diagnostics Inc. supply a number of EMIT kits for 
the detection of cannabinoids, opiates, cocaine and amphetamine. The EMIT kits 
efficiency in drug detection was reported by Lu and Taylor (2005). 
 
1.3.1.2 Biosensors 
 
A biosensor is an analytical device that incorporates a biological recognition component 
(DNA, enzymes, micro-organism or antibodies) and a transducer element 
(electrochemical, optical, acoustic or thermal), which together allow analysis to relate 
the concentration or properties of the analyte to a measurable electronic signal. A 
biosensor has the potential to be a rapid, sensitive, highly specific, quantitative system 
that needs minimum sample preparation and can be used by relatively unskilled 
personnel. As illicit drug abuse continues to rise worldwide there is a need for a 
detection system with these characteristics. 
Biosensors are comprised of three elements:  
1. A sensitive biological element specific for a particular analyte e.g. a cell 
receptor, antibody or enzyme. 
2. A transducer, which makes use of some change that occurs during the reaction; 
e.g. electrochemical, piezoelectric or optical.  
3. The output or signal is proportional to the concentration of analyte detected. 
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Examples of the technology are surface plasmon resonance (SPR) - based biosensors 
such as the Biacore series. They have considerable advantages over other technologies, 
including the following: 
• there are no labeling requirements - this involves less preparatory work and 
eliminates steric and other problems sometimes encountered when labeling 
antibodies or antigens.   
• the reactions are monitored in ‘real-time’, thereby providing rapid, quantitative data.   
• the stability of the sensor surface can be monitored.  
• the systems are fully automated and can handle large amounts of samples.   
• the assays developed require little or no sample preparatory steps.  Reports include 
assay development in cell culture supernatant, urine and saliva (Fanning, 
unpublished data, Dillon et al., 2003 and Brennan et al., 2003).  
• the multi-channel analysis feature means that interactions can be monitored over 
different immobilized-ligand sensor surfaces and provide direct comparison between 
cross-reactive substances. 
• The amounts of materials required for immobilisation of ligands are minimal.  
 
Biosensor technology has not been exploited to its full potential with regard to illicit 
drug testing to date. There are a number of examples of their use in related areas that 
demonstrate promise for the technology.  This includes detection of animal growth 
hormones in urine (Elliot et al., 1998), optimising antibody structural format for use in 
illicit drug testing (Townsend et al., 2006) and the use of electrochemical 
immunosensors for detection of hormones in livestock (Lu et al., 2007).  
Biacore and its application in recombinant antibody characterisation is detailed in full in 
chapter three.  
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1.4 Matrices used for the detection of drugs 
 
Traditionally, drug detection has focused on matrices such as blood and urine but recent 
advances in sensitivity have permitted the use of matrices, such as, sweat and saliva. 
(Hofman et al., 2001). Intra-nasally administered or ingested drugs have a large impact 
on contamination of the sample. It is important to account for these contaminants in 
order to reduce the occurrence of false positives. However, it is now generally accepted 
that there is high correlation between salivary and plasma drug concentration once the 
drug was eliminated from the buccal cavity (Huestis et al., 2004). Many advantages of 
measuring drugs in saliva are based on the non-invasiveness of the procedure. For this 
reason the collection of whole / mixed saliva is the practical option, suggesting that any 
assay being developed should take this into consideration. Practical considerations and 
usefulness of a number of matrices are outlined in Tables 1.4.1 and 1.4.2. 
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Table 1.4.2 Metabolism and characteristics of selected drugs in saliva. 
 
Drug Form of drug 
found in saliva 
Comment 
Cocaine Cocaine, 
Benzoylecgonine 
(BEC) 
Cocaine appears initially followed by lower quantities of 
BEC.  Significant correlation between mood effects and 
cocaine concentration in saliva and plasma is reported 
(Kato et al., 1993) 
THC 
(Tetrahydrocannabinol) 
THC Found mainly as a contaminant and not passed from 
plasma to saliva. (Gross et al., 1995) 
Amphetamines Parent drug S/P >1.0.  Saliva is the preferable matrix as 
concentrations measured in urine are too highly 
dependant on urinary pH.  (Wan et al., 1978) 
Heroin Morphine Rapid metabolism of heroin to morphine with a longer 
elimination half-life. (Braithwaite et al., 1995) 
 
 
1.5 Commercially available tests  
 
There are a number of commercially available tests for detection of the presence of 
illicit drugs in oral fluid.  Many of these tests target opiates in particular. These include, 
Cozart® Rapiscan oral fluid drug test systems for opiates and cocaine, Toxiquick® 
from Biomar Systems GmbH, On-site Oraline® IV s.a.t, Drugwipe® by Securetec, 
ORALscreen™ from Avitar Inc., Intercept™ by Labone (Orasure technologies), 
Salivascreen 5™ from Kabat Enterprises and the Smartclip from Envitec. This section 
describes a number of these devices in detail and a summary is provided in Table 1.5.2. 
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The ability to detect recent drug use is invaluable in the area of criminal investigation 
and drug withdrawal clinics. It was shown that subjects under investigation often under 
report recent drug use (Wish et al., 1997; Yacoubian et al., 2000). Urinalyses was the 
accepted standard for drug testing in the past. With the innovation of Intercept oral s 
pecimen collection device (IOSCD®) a number of field studies have compared the two 
matrices, saliva and urine, (Moore et al., 2001; Niedbala et al., 2001b; Yacoubian et al., 
2001; Yacoubian et al., 2002).  A summary of agreement between analysis in urine and 
oral fluid, using IOSCD® (Yacoubian et al., 2002), is shown in Table 1.6.1. It is 
essential to note here that the urinanalysis testing was carried out via EMIT while the 
oral fluid analysis was carried out via ELISA and therefore cannot be regarded as an 
infallible comparison.   
 
Table 1.5.1 Agreement between urinalyses and oral fluid determination (%) using 
Intercept oral specimen collection device IOSCD® 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yacoubian also reports that both the urinalyses and IOSCD® cost $10 per sample. 
However, the IOSCD was favoured by subjects and staff due to its small size, ease of 
use and minimal personal invasiveness. 
  
Drug Tested Percentage 
agreement (%) 
Methadone 
 
96 
Cocaine 93 
Opiates 
 
96 
Marijuana 
 
89 
Benzodiazepines 
 
100 
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One study reported by Kacinko et al. (2004), compared the sensitivity, specificity and 
efficiency of the Cozart® Rapiscan oral fluid drug test (Opiates CRS) to a microplate 
EIA oral fluid kit and to gas chromatography / mass spectrometry (GC/MS). The opiate 
CRS device is preset with a positive cut-off level of 30ng/ml. Three opiate ELISA cut-
offs were used: 2.5, 30 (UK cut-off) and 40 ng/ml (SAMHSA proposed cut-off). Four 
opiate GC/MS cut-offs were used: 2.5, 15 (UK confirmation cut-off), 30 and 40 ng/ml. 
At current UK cut-off levels of 30 ng/ml and SAMHSA proposed levels of 40 ng/ml, 
sensitivity, specificity and efficiency were comparable. In cases where the higher cut-
off was implemented there were a lower number of false negatives demonstrated. 
Performance characteristics of the opiate CRS were >96% and >91% when compared to 
the ELISA and GC/MS, respectively. (Cut-off levels were obtained from 
www.samhsa.gov). 
 
A similar study was carried out while testing for cocaine. Biermann et al. (2004) 
reported on an immunological quantitative test device, toxiquick®. A 1-2ml oral fluid 
sample was taken, the test strip was submerged in the sample for approximately 10 
seconds, read and recorded. Blood samples were taken in parallel and the serum results 
were analysed by GC-MS for comparison. False positives were < 10% for all drugs, 
including, amphetamines, methamphetamines, cocaine, opiates and methadone with the 
exception of cannabinoids which resulted in 20% false negatives. The authors conclude 
that positive results should be confirmed by serum analysis. This review has highlighted 
the major advantages of oral fluid testing including the ease of use and speed of 
analysis. However, with regard to this particular device, the police found that it was 
often difficult to read the result without getting a second and third opinion.    
 
It is clear that the research into on-site OF testing is making positive progress over the 
past number of years. Very high false negatives (30% in some cases) were recorded 
when OF testing was compared to GC-MS for THC detection in earlier studies (Kintz, 
et al., 1999; Samyn et al., 2000). In 2006 the oraline® demonstrated very low numbers 
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of false negatives (<10%). Sensitivity and specificity of 69.2% and 91.6%, respectively, 
were shown when compared to GC-MS (Crimele et al., 2006). 
 
In a study carried out by Cone et al. (2002) oral fluid specimens were analysed by the 
Intercept MICRO-PLATE Enzyme immunoassay (EIA) (Orasure technologies, 
Bethlehem, PA). Relevant controls were provided including an interesting valid 
specimen control. This contained human antibody as a confirmatory control to 
demonstrate that the sample was of human origin.  Oral fluid sample were analysed for 
IgG content and each specimen response was compared to the IgG calibrator value. Any 
specimen with an IgG concentration equal to or greater than the calibrator was deemed 
valid. The definition of a valid specimen is one that is human-derived and has an 
adequate volume for testing (Connell et al., 1993). However, once the “presumptive 
positive” oral fluid specimens were identified, all samples were confirmed and 
quantified by GC-MS-MS.  
 
The introduction of multi-analyte chip platforms into the drug detection arena is very 
exciting. There are a number of commercial kits that use this technology. Randox 
have developed a biochip array technology system called evidence investigator. The 
device enables simultaneous measurement of analytes using a single drop of sample on 
the biochip. This drugs of abuse array permits detection of 10 different substances 
including amphetamines, methamphetamines, cocaine, barbiturates, cannabinoids, 
benzodiazepines and opiates. Another company at the top of this field is the Cozart 
group who in 2006, together with Philips Corporate Technologies, announced their 
intention to develop a new biosensor platform consisting of a microfluidic cartridge 
with an integrated magnetic biochip. The focus of their product development is the 
decrease of sample volume, testing time and size of the actual device. A number of 
other commercially available tests are compared and contrasted in Table 1.5.2. 
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Well - developed and defined immunoassay strategies, such as those mentioned 
previously, have paved the way for the development of recombinant antibody-based 
microarrays for drugs of abuse. Microarrays have already been exploited very 
successfully in the fields of both proteomics and genomics and are a potential lead-
technology in point-of-care diagnostics. Antibody-arrays could be spotted onto plastic 
chips and used for multiple illicit drug detections. Careful selection/engineering of large 
antibody arrays would ensure high sensitivity and specificity and would eliminate false 
positives. The availability of a vast array of antibodies to interrogate any given sample 
would also provide a far greater chance of detecting ‘newly developed’ designer drugs 
of abuse. Integration of this approach with enhanced fluorescence signal amplification 
could provide significant improvements in sensitivity that may become of increased 
significance for the detection of new drugs having significant effects at very low 
concentrations. This array approach is particularly advantageous, as it offers high 
sensitivity, large sample throughput and low cost and is thus ideal for large screening 
programmes. 
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1.6 Introduction to the immune system 
 
The immune system consists of two major defence systems. Innate and acquired 
immunity. However, in reality these systems are closely integrated. 
 
1.6.1 Innate immunity 
  
The first of these systems is the innate immune response, innate immunity is present 
before any exposure to an antigen and is the bodies primary defence line against 
pathogens. It is largely non-specific but very fast acting in its response and is 
characterised by two separate elements. 
I. Physical barriers such as skin, mucous membranes, secretions such as stomach 
acid, tears and sweat.  
II. The internal chemical and cellular mechanisms, such as phagocytosis, 
antimicrobial proteins, inflammatory response and natural killer cells. 
 
If the first barrier of physical defense is compromised the second component of the 
innate immune system takes over.   
Phagocytosis: Phagocytosis involves the ingestion of invading micro-organisms by 
white blood cells known as phagocytes. There are 4 types of phagocytic cells, 
neutrophils, monocytes (macrophage), eosinophils and dendritic cells. Once engulfed by 
macrophage, microbes are destroyed in vacuole - lysosome fusion via lysosomal 
enzymes and other toxic compounds (this process is similar in other phagocytes).  
Inflammatory response:  Upon invasion, chemicals are released which signal 
increased blood flow, dilation and vascular permeability in the effected area. The 
resulting increased permeability allows for enhanced delivery of antimicrobial proteins 
and clotting elements. Increasing blood flow to the injured area also permits faster 
delivery of neutrophils and monocytes.  One of the most active signalling chemicals is 
histamine which is released from mast cells. 
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Antimicrobial proteins:  Antimicrobial proteins include the serum proteins that make 
up the complement system. Substances on the surface of microbes trigger the 
complement system leading to lysis of invading cells and inflammation.  
Natural killer cells: Natural killer cells seek out cells that fail to display the major 
histocompatability complex (MHC) class I molecules and release apoptosis inducing 
chemicals.  
The innate immune system is not described in detail as it is the exploitation of the 
acquired immune system which is the focus of this research. 
 
1.6.2 Acquired Immunity 
 
The major differentiaton between the innate and the acquired immune response is the 
specificity of the latter. The acquired response can be sub-divided into two categories: 
I. Humoral response (mainly antibody production) 
II. Cell-mediated response (mainly T lymphocytes) 
The body is populated by two major types of lymphocytes; B lymphocytes and T 
lymphocytes (helper T cells and cytotoxic T cells). The combined effort of these two 
lymphocytes with input from antigen presenting cells (APC’s) results in the secretion of 
soluble antibody into the blood stream. The humoral or antibody response involves the 
combination of both B-cell and Helper T-cell activation resulting in the production and 
secretion of soluble immunoglobulins into the blood stream. The cell-mediated response 
requires the activation of cytotoxic T-cells, which cause immediate cell death via 
apoptosis. The action of each of the T helper cell, T cytotoxic cell and B cell and how 
their co-operation is essential in the immune response is outlined in figure 1.6.2.1. 
 
Cytotoxic T-cells directly kill cells that are infected with a virus or some other 
intracellular organism, preventing the spread of the microorganism before it has time to 
proliferate. Helper T-cells are crucial for stimulating responses to extracellular invaders 
such as, parasites or mycoplasma. They function by secreting cytokines which in turn 
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stimulate the action of macrophage and antibody-producing B cells. The T-cell response 
depends on the direct contact between the target cell and the surface bound TCR (T-cell 
receptor). Unlike the B-cell antigen receptors the TCR are not secreted.  
The T-cells only activate when foreign antigen peptides are displayed in association 
with an MHC molecule. The MHC molecule is critical in the immune response and as 
such T-cell responses are said to be MHC restricted. The MHC molecules can be 
subdivided into two categories; MHC class I and MHC class II. 
 
MHC class I: Collect peptides derived from proteins synthesised in the cytosol and 
display fragments of these proteins on the cell surface awaiting contact with the 
Cytotoxic T-cell. MHC class I have the ability to bind self-peptides acting as a monitor 
for the immune system. 
MHC class II: Bind peptides derived from proteins in intracellular membrane bound 
vesicles and display peptides from pathogens living in marcophage vesicles or 
internalised by phagocytic cells.   
 
1.6.2.1 Antigen presentation by MHC class II molecules 
 
MHC class II molecules are primed for action once they are synthesised.  Upon 
synthesis in the lumen of the endoplasmic reticulum they are transported together with 
an additional invariant chain to the endosome containing the antigen of interest. After 
antigen collection from the endosome the MHC molecule carries it to the surface of the 
cell where the peptide can be recognised by the CD4+ T-cells. This is the primary 
differentiation between the CD4+ and CD8+ T-cells. Instead of directly killing the cell 
via apoptosis, the CD4+ T-cells trigger a signalling cascade resulting in the release of 
numerous cytokines.  
 
The CD4+ helpher cells are further subdivided, depending on the origin of the antigen 
presenting cell, into TH1 and TH2.  (The TH1 pathway is primarily responsible for the 
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cell mediated immunity and not the humoral response and is therefore not as important 
in this discussion). 
TH2: is essential for the humoral immune response and secretes a number of cytokines 
inlucding IL-4, IL-5, IL-10 and IL-13. These cytokines are key to class switching in B-
cells,  for IgE production, positive feedback devices promoting more TH cells to enter 
the TH2 pathway and activation of eosinophils.  
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Figure 1.6.2.1 A schematic representing the overall acquired immune response is 
shown. 
An overview of the acquired immune response is illustrated in 1. Upon activation, the 
helper T cells stimulate the hummoral response directly and indirectly, by contact with 
B cells and secreting cytokines, respectively. A more detailed illustration of the action 
of the B cell is presented in 1a – 1c and the action of the cytotoxic T cell in 2a – 2c.  
(1a) The invading bacteria is engulfed and degraded by the macrophage thus displaying 
the foreign peptide antigen along with the MHC class II on the cell surface. (1b) Once 
activated, the helper T cells, which recognise this display, binds to the B-cell via 
specific receptors. The B-cell is now activated. (1c) The activated B-cell proliferates 
into both memory and antibody-secreting plasma B cells. The antibodies secreted are 
specific to the antigens of the original engulfed bacteria. 
(2a) The active cytotoxic T-cell comes into contact with the MHC class I – antigen 
complex, leading to T-cell activation. (2b) Perforin molecules and proteolytic enzymes 
are released from the T-cell, the granzymes enter the target cell via the newly formed 
pores. (2c) Apoptosis is initiated and cell death occurs immediately.  
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1.7 Antibody structure 
 
An antibody molecule is organised into three structural units. The two Fab units are 
responsible for antigen binding while the third unit, the Fc portion, is involved in 
complement triggering and cell receptor binding. The whole molecule is made up of 4 
chains, two identical light chains which span each Fab portion and two identical heavy 
chains spanning the whole molecule.  
 
There are five classes of immunoglobulin, IgG, IgM, IgA, IgD and IgE. IgM is the first 
class of antibody to be produced in the primary immune response.  
 IgM’s are pentamers therefore demonstrate high avidity for multimeric antigens 
which may mask their often low affinity.  
 IgA exist as both monomers and dimmers. IgA are responsible for defending the 
externally exposed areas of the body and exist in abundance in saliva, sweat, 
tears, gastrointestinal tract and the nasal passage.  
 IgD acts as the antigen receptor / cell surface receptor on B cells. 
 IgE is responsible for initiating the inflammatory response and is present at only 
low levels in normal circulation. 
 IgG is the most abundant class of antibody produced (Roitt et al., 1994). In IgG, 
the Fab arm is linked to the Fc portion via a polypeptide chain called the hinge. 
The IgG subclasses are distinguishable in this hinge area. These subclasses are 
IgG1, IgG2, IgG3 and IgG4 in humans and IgG1, IgG2a, IgG2b and IgG3 in 
mice.   
 
Commercial immunoassays for small haptens are mostly reliant on whole monoclonal 
or polyclonal antibodies rather than recombinant antibody fragments. Antibody 
fragments very often have lower affinity than there full size parental antibodies (Huston 
et al., 1996). To combat this, specifically tailored panning strategies and in-vitro affinity 
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maturation of anti-hapten antibody fragments are employed (section 1.9.4, 1.9.5 and 
chapter 5). Recent advances in recombinant antibody technology have permitted the 
increased exploitation of scfv and Fab fragments over whole IgGs for commercial 
detection kits etc.  (Chames et al., 1998; Li et al., 2000; Charlton et al., 2001). These 
smaller molecules retain the specificity of the larger whole antibody molecule but can 
be engineered for superior performance and unique applications (Holliger and Hudson, 
2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7.1 Structure of whole IgG molecule with domain nomenclature. Each heavy 
chain is folded into two domains in the Fab arms. The light chain forms two domains 
which only associate with the Fab arms. The heavy chains are composed of VH, CH1, 
CH2 and CH3 domains. The light chains are composed of VL and CL domains. All 
domains are paired except the CH2 domain. Each domain has a molecular weight of 
roughly12,000 depending on the specific antibody. Each Fab is 50,000 and each whole 
IgG molecule is 150,000 daltons in weight.  
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1.8 Generation of antibody diversity. 
 
The DNA encoding immunoglobulins is found in three unlinked gene groups  
1. κ L-chain 
2. λ L-chain 
3. H-chain 
 
Kappa and lambda chain genes are located on chromosome 2 and chromosome 22, 
respectively,  and heavy chain genes are located as a gene family on chromosome 14. 
The κ L-chain group has one gene segment encoding the constant (C) κ regions. The λ 
L-chain group has 4 gene segments encoding the constant (C) λ regions. The H-chain 
variable region is encoded by V (variable), D (diversity) and J (joining) gene segments 
while the L-chain is encoded by just V (variable) and J (joining) gene segments. 
Regions of highly conserved amino acids are interrupted by three separate regions of 
highly variable segments known as the complementarity determining regions (CDR’s) 
The CDR’s interact forming the point of antigen contact of each antibody. VL and VH 
germline segments encode two CDR’s each. The third CDR is made up by the 
recombination of the VJ (VDJ in the case of heavy chains) region, thus it is this CDR 
that is widely regarded as having the most variability (Alt et al., 1987).  
 
During B-cell development it randomly chooses from its H-chain gene group one V, 
one D and one J gene segment for translocation. It then selects from the λ or κ gene 
group one V and one J for gene translocation. This means the genes are brought into 
close contact with each other through a looping out process, mediated by lymphoid-
specific recombinase enzyme complex (Roth and Craig, 1998). The first step involves 
bringing the D and J regions in contact, thus looping out the intervening DNA. The 
second recombination step involves bringing the V regions in contact with the DJ 
regions. This final recombination step determines the antibody specificity (figure 
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1.8.1). However, it is the constant regions which determine the isotype/class of the 
antibody produced.  
 
Figure 1.8.1 Schematic representation illustrating the recombinational arrangement of 
the DNA encoding V (variable), D (diversity) and J (joining) and C (constant) gene 
segments. The coding mechanism determines the antibodies specificity and the constant 
region chosen determines the isotype of the antibody produced. 
1.8.1 Somatic hypermutation 
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Somatic hypermutation (SHM) introduces further diversity into the antibody sequence 
and occurs at a rate of 10-5 to 10-3 per base per generation over the lifespan of the B-cell 
(Li et al., 2004). These mutations are predominantly point mutations in the V(D)J unit 
of the antibody V genes that occur in mutation hotspots. It is as a result of this process 
that antibodies with increased affinities for the target antigen are produced (Benjamini 
et al., 2000). The exact mechanism of SHM is not fully understood, however, recent 
experimental evidence supports the theory that activation-induced cystidine deaminase 
(AID) is key to the process (Poltoratsky et al. 2000) It is thought that deamination of 
cytosine to uracil in DNA by AID precedes the activity of UNG, a uricil DNA 
glycosylase, creating single base mutations in place of the uricil residues (Petersen-
Mahrt et al., 2002) The uracil bases are removed by the repair enzyme, uracil-DNA 
glycosylase. Error-prone DNA polymerases are then recruited to fill in the gap and 
create mutations. Such mutations, in the rapidly proliferating B-cells, result in the 
production of thousand’s of B-cells possessing various specificities. The highest 
affinity antibody expressing B cell can then be selected and proliferated. 
 
Further genetic rearrangement of antibody genes gives rise to the antibody class. 
Ultimately, this process allows the expression of an antibody with an antigen-specific 
binding site but with different C region genes. Thus giving rise to antibodies with a 
single antigenic specificity but with different effector functions.  
 
Overall, antibody diversity is generated by means of both  
• Antigen independent events 
o The availablitly of multiple germline genes  
o The random combination of V, D and J segments for the H-chain or V 
and J segments for the L-chain.  
o Pairing of different combinations of VL and VH chains occuring 
randomly. 
58 
• Antigenic dependant 
o At DNA level where somatic mutation can lead to higher affinity 
antigen recognition and binding. 
Somatic affinity maturation processes play a major role in the design of in-vitro 
recombinant antibody affinity maturation strategies, this is outlined in greater detail in 
chapter five. 
 
 
1.8.2 Antibody fragments: Single chain Fv and Fab fragments 
To date, hybridoma technology involving immunizations is still the most widely used 
method of antibody generation (Persson et al., 2008). However, since the first cloning 
of antibody repertoires in the last 20 years, (Huse et al., 1989; Ward et al., 1989) and 
the successful production of antibody fragments in bacteria, (Skerra and Pluckthun, 
1988) phage display (see section 1.9) as a powerful tool in antibody generation has 
come forward (Hust and Dubel, 2004).  Constant regions, as shown in figure 1.9.1, are 
fundamental to the biological effector function of the antibody, however, antibody 
manipulation for use in diagnostics and therapeutics can be achieved through 
fragmentation of the whole molecule. A whole antibody can be broken into several 
fragments. Recent advance in molecular engineering techniques have facilitated the 
production of antibody fragments via methods other than enzymatic or chemical 
cleavage. Recombinant antibody technology has permitted the production of antibodies 
from a variety of species such as mice (DillionB et al., 2003), rabbits (Li et al., 2000), 
chickens (Andris-Widhopf et al., 2000) llama, (Yau et al., 2003) and sharks (Dooley et 
al., 2003).  A number of antibody fragments can be produced using recombinant 
antibody engineering, including Fab, scFv and Fv. The Fv fragment is the smallest 
fragment which comprises the complete antigen binding site, one VL with 3 CDR’s and 
one VH with 3 CDR’s. While Fab and Fc fragments can be cleaved off the whole 
molecule and remain relatively stable this is not the case with the smaller Fv region. 
This Fv fragment is not sufficiently stable for use in immunoassays etc. as it lacks the 
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stabilizing disulphide bond or serine glycine linker present in the Fab and scFv, 
respectively, (Glockshuber et al., 1990). A linker is usually introduced between the VH 
and VL to produce a single-chain Fv (scFv). This results in improved folding and 
stability (Freund et al., 1993). This linker can be incorporated in either of two 
orientations VH - linker - VL or   VL - linker - VH. The linker can also vary in length, the 
longer linker (20 amino acids) giving a higher proportion of monomeric molecules 
while a shorter length linker (5 amino acids) favors dimeric scFv formation. The CDR is 
the smallest antibody capable of binding to an antigen, however, it is completely 
impractical for use in immunanalysis. Scfv’s are the smallest useable antibody fragment 
as they contain the complete antigen-binding site (Brichta et al., 2005). Antibody 
fragments (Figure 1.8.1.1) generally have lower avidity than the whole molecule, 
however, small molecules have improved pharmacokinetic properties due to their 
shorter retention times, more efficient target tissue penetration and clearance (Colcher et 
al., 1998). 
 
Figure 1.8.1.1 Monovalent antibody fragments capable of binding antigen. (a) CDR, 
smallest fragment capable of antigen recognition, (b) scfv and (c) Fab. 
 
In the research described in this thesis both scFv (b) and Fab (c) fragments are 
developed against a number of different target antigens since there is an ongoing debate 
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as to which structure is the more advantageous. The scFv library construction is 
simplified due to the single overlap extension PCR required. The smaller scFv fragment 
has the ability to multimerise which can enhance avidity for antigens. However, if later 
attempts are made to improve the affinity of the antibody, improvement may arise from 
changes in the multimerisation rather than improvements in the affinity of the antibody 
combining site. scFvs are expressed very efficiently in E. coli. However, the Fab 
construct is also a very stable, well characterised protein fragment. They do not 
generally multimerise which means that they can be converted to whole antibody format 
while maintaining or improving antigen affinity. Improvements in affinity via in vitro 
methods of the Fab construct generally results from improvements in antigen binding 
sites and are not simply due to multimerisation of the antibody fragment as is often the 
case with scFv’s. The most significant disadvantage of working with Fabs is their 
general lower expression levels in E. coli. 
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1.9 Phage Display 
 
Filamentous bacteriophage are a group of viruses that only infect bacteria and are not 
capable of human infection. They are made up of two components, consisting of genetic 
material and a protein coat. Phage contain a circular single-stranded DNA genome 
encased in a long protein capsid cylinder. Filamentous bacteriophage infect E. coli via 
pili formed as a result of the bacteria harboring the F` factor encoding proteins. It is, 
therefore, necessary to select for the bacteria harbouring this F` factor as it tends to 
separate from the cells rendering them insensitive to infection by the phage.   
 
The Ff phage particle is approximately 6.5 nm in diameter and 930 nm in length (Barbas 
et al., 2001). Each of the bacteriaphage genomes encodes 11 genes.  pVIII, the major 
coat protein, makes up nearly the entirety of the capsid. The minor capsid proteins pIII 
and pVI which make up the infecting tip of the phage particle are present in several 
copies.  The pIII is made up of three distinct domains each linked together via glycine 
rich regions. Figure 1.9.1 illustrates the display of the recombinant antibody fragment 
on the pIII. The first domain (N2) is required during the infection process for 
translocation of the DNA into the cytoplasm. The second domain (N2) is involved in 
binding to the F pilus of the bacteria. pVII and pIX cap the other end of the phage 
capsid, with all capsid proteins being integral cyctoplasmic membrane proteins prior to 
assembly (Simons et al., 1981; Endemann and Model, 1995 ; Webster, 1996).  Infection 
is reported to be a multistep process requiring interactions with the F conjugative pilus 
and the bacterial TolQ, R, and A cytoplasmic membrane proteins. These are bacterial 
proteins that appear necessary for maintaining the integrity of the bacterial outer 
membrane (Lazzaroni et al., 1999). Assembly also requires three non-capsid phage-
encoded proteins, pI, pIV and pXI. ATP and bacterial thioreductase are also necessary 
in the elongation process during assembly. 
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Figure 1.9.1 A schematic illustration of the disulphide bond between the pIII at the tip 
of the phage particle and the displayed recombinant antibody fragment 
 
1.9.1 Infection 
 
Infection begins with the binding  of one end of the phage to the conjugative pilus. The 
pilis is recognized by the N2 amino terminal of gene III. Once this recognition has 
occurred the pilus retracts bringing the pIII end of the phage particle closer to the 
surface of the bacterium. The extent of this retraction or exactly how it works is not 
known (Lubkowski et al., 1999). The chromosomal Tol Q, Tol R and Tol A genes are 
required to integrate the capsid protein into the bacterial cytoplasmic membrane and to 
translocate the DNA into the cytoplasm. Tol Q, R and A proteins are part of the Tol 
system which maintains outer membrane integrity in E. coli. Tol Q has three 
transmembrane helices in the cytoplasmic membrane. Tol R is present in the periplasm 
with its amino terminus embedded in the cytoplasmic membrane. Tol A has three 
domains with each domain joined by a glycine rich region. The amino terminal, domain 
1, anchors Tol A in the cytoplasmic membrane. The central region, domain 2, basically 
consists of  a long helical region connecting D1 and D3. The carboxyl terminal, domain 
3, interacts with the outer membrane for activity (Click and Webster, 1997). The N1 
domain of the pIII protein is thought to interact with D3 bringing the outer and inner 
membranes into closer proximity. The N2 domain then also interacts with D3 resulting 
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in the insertion of the pIII protein into the inner membrane. The phage genome can then 
by translocated into the bacterial cytoplasm host cell. (Karlsson et al., 2003). 
 
1.9.2 Replication and Assembly 
 
Once the viral DNA is in the cytoplasm it is acted on by bacterial enzymes resulting in 
covalently closed, supercoiled, double stranded DNA called the parental replicative 
form (RF) DNA. Translated phage proteins are replicated via the ‘rolling-circle’ mode 
of replication. During assembly the viral DNA is extruded through the membrane and 
concomitantly enveloped by coat proteins (Weiss and Sidhu, 1997). The ends of the 
virion particle are capped with the four minor coat proteins - III, VI, VII and IX. The 
entire surface is coated with pVIII, it has been shown that both pVIII and pIII 
accommodate polypeptide fusion at their amino terminal. It is this physical linkage 
between phenotype and genotype that is exploited in phage display technology. 
 
1.9.3 Phagemid vectors 
 
In the past the DNA of interest was cloned directly into the whole phage genome. 
However, it is now possible to clone into a phagemid vector instead. A phagemid is a 
plasmid that contains a phage-derived origin of replication (major intergenic region) as 
well as its own plasmid origin of replication and it can be packaged in the phage coat. A 
phagemid can not produce infective phage particles alone. Phagemids are packaged as 
phage particles in the same fashion as phage DNA itself as long as they are propagated 
in cells which are superinfected with helper phage. Helper phage provide all the 
necessary phage-derived proteins and enzymes for phage replication. However, the 
helper phage posses a modified intergenic region, causing it to be replicated and 
packaged less efficiently than the wild type. This ensures that the genotype-phenotype 
are produced in the same single phage.   
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1.9.3.1 pComb3XSS vector used for anti-amphetamine Fab construction 
 
The pComb3 phagemid vector series is a well-established system for phage display 
(Barbas et al., 1991). The pComb3 vectors are designed to express antibodies and other 
proteins on the surface of phage and also to express these proteins in soluble form.  
VL CL
ompA
SDLac Z
Sfi 1
Sac 1
VH CH1 H6 HA
Amber 
codon
Gene III
pelB
SD
Xho 1
Spe 1
trp
Nhe 1
Sfi 1
Xba 1
 
Figure 1.9.3.1.1 Map of the cloning regions of the pComb3X phagemid vector. The 
single lac Z promoter allows expression of the whole light and heavy chains. The 
presence of two Shine Dalgarno (SD) gives rise to separate polypeptide chains. A trp 
terminator provides transcription termination. The leader sequence ompA directs light 
chain to the periplasm while the pelB leader directs the heavy chain and coat protein III. 
The amber codon permits soluble expression of the protein in nonsuppressor strains of 
bacteria. The six-histidine tag allows for IMAC purification and the hemagglutinin tag 
permits detection of the protein via the use of an anti-HA secondary antibody during 
screening. 
 
 
The pComb3X vector has a number of important aspects that make it suitable for Fab 
display in particular.  This vector was an improved design based on the original 
phagemid vector pComb3. 
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• Instead of the original repeated lacZ promoter and pelB leader sequences it uses 
just one lac promoter followed by a combination of ompA and pelB. This directs 
expression of antibody light chain and heavy chain-pIII fusion proteins, 
respectively.  
• pIII has a huge impact on the phage display system. It was discovered to be 
406bp which, in its full-length form, causes immunity to superinfection by 
helperphage. Therefore a truncated pIII, aa203-406, fragment is used which 
serves as the fusion partner for the displayed proteins. Phage display vectors are 
classified according to the coat protein used and the number of coat protein 
genes present. PComb3X belongs to type 3 + 3. Varying numbers of wild-type 
pIII can be displayed on their surface due to the two types of pIII; wild-type, 
produced by the helper phage and the fusion protein produced by the phagemid. 
These two pIII’s compete for incorporation during phage assembly (Barbas et 
al., 1991). 
• 6-Histidine (HIS) tag permits protein purification via IMAC. 
• Hemagglutinin (HA) tag facilitates detection using the highly sensitive 
secondary antibody, anti-HA  
• An amber condon has been inserted between the Sfi 1 restriction site and the 5’ 
end of the gene III fragment allowing for soluble expression in non-supressor 
cells without removing the gene III. When phage are grown in SupE, suppressor 
strains of E. coli, the amber codon is read as a glutamine and the antibody fusion 
protein is displayed on the phage. In non-supressor strains of E. coli the same 
amber codon is read as a stop codon and soluble antibody is secreted. 
Sfi 1 restriction sites, allow insertion of the gene of interest in the correct orientation and 
facilitates the design of large libraries with minimal steps. 
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1.9.3.2 pAK 100 and pAK 400  
 
The pAK vector system (Krebber et al., 1997) is designed to aid purification, detection, 
multimerisation and modification and can be used for both phage display and antibody 
expression. The pAK system was designed for scFv expression. A variety of vectors, 
pAK 100, 200, 300, 400, 500 and 600 are available for use with the Krebber system. 
The vectors used in this research were the pAK 100 and pAK 400.  
 
Figure 1.9.3.2.1 Map of the cloning regions of the pAK 100 and pAK 400 phagemid 
vectors.  
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There are a number of important design features of this phagemid vector series; 
• Like the pComb series, it uses the very rare cutting restriction enzyme - Sfi 1. 
This restriction site is very rarely found in antibody genes. 
• The tetracycline resistance cassette (TetR) present in all pAK vectors ensures 
identification of sufficiently cut vector. Uncut vector contamination is a 
common contamination of antibody libraries, with the loss if Tet resistance in 
efficiently cut vector, contamination is easily avoided. 
• It contains the truncated version of gene III as was discussed previously in 
relation to the pComb3 vector series. 
• The lacI repressor gene is encoded on the vector to ensure strain independent lac 
promoter repressor. 
• The strong upstream terminator tHP together with the inclusion of glucose 
eliminates any background expression. 
• The synthetic Shine-Dalgarno sequence in combination with a pelB leader 
sequence permits only moderate levels of expression. 
• Despite the pAK 100’s ability to allow soluble expression (albeit low levels) 
pAK 400 has been designed for compatible high level expression via the 
stronger Shine-Dalgarno (SDT7g10). 
• pAK 400 permits IMAC purification via the 6-His tag. 
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1.9.4 Construction of a hapten-specific phage display library 
 
A phage display antibody library consists of recombinant antibody fragments displayed 
on the surface of phage. Antibody genes are isolated from the spleen, bone marrow, 
hybridoma cell line, a naïve or synthetic source and fused to the phage genome 
(Hoogenboom et al., 1998; Sheedy et al., 2007). Naïve genetic material has no prior 
exposure to the antigen of interest while the immune library is generated from 
lymphocytes of an animal immunised with the antigen of interest (Marks et al., 1991). 
The genetic material coding for the antibody (phagemid vector) is engineered so that the 
phage partical posesses both the individual genotype (gene) and phenotype (displayed 
protein) (Schmitz et al., 2000).  After construction, the library is exploited for isolation 
of hapten-specific antibody fragments  a process known as “bio-panning” (see section 
1.9.5).  It has been reported that antibodies selected from naïve libraries have 
significantly lower affinities than those from immune libraries (Charlton et al., 2001). 
The affinity is comparable to that of a primary immune response as the synthetic or 
naïve fragments have not undergone somatic hypermutation and other in vivo 
maturation steps. Li et al. (2000) reported anti-herbicide antibodies posessing sub-
nanomolar affinities from a hapten-specific immune library. Such affinities are achieved 
through development of a suitably stringent and specifically tailored panning strategy. 
This is discussed in section 1.9.5 and also throughout all chapters in this thesis. 
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Figure 1.9.4.1  Schematic representation of a phage display library construction. 
 
1.9.5 Phage-display for the selection of hapten-specific antibodies  
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The design of an appropriate panning strategy is essential for the isolation of any 
recombinant antibody fragment with optimal affinity and binding specificity for the 
target antigen.  Phage selection through panning depletes the population of non-specific 
phage displaying clones while enriching the repertoire of clones harboring specific 
binding capabilities for the target antigen. The genetic material of the antibody is 
engineered so that it is included in the viral genome but also displayed on the surface of 
the phage particle (Schmitz et al., 2000) A commonly used biopanning strategy is 
carried out on solid surface immobilized antigen, either on immunotubes (Krebber et 
al., 1997) or microtitre wells (Barbas et al., 2001). Methods other than solid phase 
panning include the use of streptavidin-coated magnetic beads for immunomagnetic 
separation of specific phage from non-specific phage pools (Santala and Saviranta, 
2004).  
 
Immune libraries are widely reported as the optimal source of anti-hapten antibodies 
where selection is carried out against the hapten-protein conjugate. Various 
modifications to the panning protocal are introduced to enchance the enrichment of 
positive clones: 
 
• Decrease conjugate coating concentration from one round to the next round (Lu 
et al., 2003). 
• Increase washing times between successive rounds of panning (Lu et al., 2003). 
• Subtractive panning (the phage pool is preincubated with the carrier protein 
prior to incubation with the hapten-protein conjugate) (Chames et al., 1998; 
Barbas et al., 1993). 
• Competition elution with free hapten (Chames et al., 1998). 
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After panning strategies have been optimized the next step in obtaining anti-hapten 
antibodies with high specificity is in vitro affinity maturation. Recombinant antibody 
engineering methods will be introduced and discussed in chapter 5. 
 
 
Figure 1.9.5.1 Schematic illustration of a typical phage selection process for the 
enrichment of antigen-specific phage clones. The phage library is incubated with the 
target antigen on a solid support surface. Phage that display antigenic-specific 
antibodies bind to the target surface while all non-specific antibody displaying phage 
are removed by washing. Elution of positive phage is achieved via various chemical 
additions. The positive phage are re-infected into E.coli for further rounds of selection 
and enrichment. Phage pools are analysed by polyclonal phage ELISA and individual 
clones are analysed by monoclonal phage ELISA. 
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1.10 Research aims 
 
The main aim of the work presented in this thesis was the production of novel 
genetically – derived antibody fragments for the detection of the illicit drugs. The work 
describes the production characterisation of recombinant antibodies using phage display 
technologies against Morphine-3-glucoronide, amphetamine and tetrahydrocanabinnol.  
for immobilisation for future use on a low density microarray platform technology.  
 
An anti-morphine-3-glucoronide Fab fragment was constructed using the previously 
reported anti-M3G scFv fragment as a template (Brennan et al, 2003). This Fab 
fragment was characterised and used in comparison studies with the scFv fragment in 
Biacore competitive and kinetic analysis studies (Chapter 3). This study revealed the 
importance of antibody fragment choice i.e. scFv or Fab and screening method for large 
libraries of potential clones. This study also facilitated a puplication in Biosensors and 
Bioelectronics.  
 
Genetical material for an anti-amphetamine Fab fragment construction was sourced 
from a pre-existing anti-amphetamine IgG-secreting hybridoma (Fanning, 2001) in 
chapter 4. This Fab fragment was applied to the development of both ELISA and 
Biacore competitive studies. Comparison studies between the Fab and the parent 
monoclonal antibody illustrate a 3 fold improvement in affinity after conversion to Fab. 
An scFv library was constructed from the parent Fab DNA however no specific 
antibody was found, this is discussed in detail. 
 
Several in-vitro affinity maturation strategies were examined in chapter 5. The study 
focused on improving the anti-M3G Fab fragment. Specific CDR’s in the heavy and 
light chain were targeted. “Wild-type eliminating” and “mutated” phage display 
libraries were generated using a combination of the Kunkle style mutagenesis and the 
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commonly used oligonucleotide doping strategy NNK and NNS. An anti-M3G specific 
mutant was successfully selected and characturised. This work was exceptionally 
interesting given the current lack of progress on mutationally improving anti-hapten 
antibodies such as those described in this thesis. 
 
Chapter 6 describes the construction of an anti-tetrahydrocannabinol scFv immune 
library. The genetic material was extracted from a leporine spleen which had been 
exposed to the drug-protein conjugate.  Soluble scFv antibodies were isolated, espressed 
and purified from the library. A mutant phage display library was generated using a 
positive scFv-secreting clone as the heavy chain template and light chain shuffling was 
employed to optimise heavy – light chain pairing. Selected clones were compared 
through sequencing and affinity analysis.  A multi analyte assay was set up on the 
biacore 3000 using the anti-M3G and anti-Amphetamine Fab fragments and also the 
anti-THC scFv fragment.  
 
Chapter 7 provides a summary of research, conclusions and some proposed future work. 
 
74 
 
 
 
 
 
 
Chapter 2 
 
2.0 Materials and Methods 
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2.1 General Formulations 
 
2.1.1 Reagents  
All reagents and antibodies were of analytical grade and purchased from Sigma-Aldrich 
Chemical Co. (Poole, Dorset, England), unless otherwise stated. 
 
Reagents  Supplier 
DNA Purification System 
Wizard Mini Prep Kit 
Promega Corporation, 2800 Wood Hollow 
Rd., Madison, WI 53711-5399, USA. 
 
Cy 5 reactive dye 
 
Amersham Pharmacia Biotech AB, 
SE-751 84, Uppsala, Sweden. 
 
Ni-NTA resin 
Sequencing services 
QIAquickNucleotide removal kit 
QIAprep Spin M13 kit 
Buffer PN 
QIAgen, QIAgen House, Fleming Way, 
Crawley, West Sussex, UK. 
BamH1 enzyme 
T4 DNA ligase 
T7 DNA polymerase 
Taq polymerase 
Biosciences, 13 Charlemont Tce., Crofton 
Rd., Dun Laoghaire, Co. Dublin. 
 
Tryptone 
Agar Technical 
Yeast Extract 
Oxoid, Basingstoke, Hampshire, 
 RG24 8PW, UK. 
 
Acetic acid / Hydrochloric acid Riedel de-Haen AG, Wunstorfer, Strabe 
40, D-30926, Hannover, Germany 
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Amphetamine – BSA 
Tetrahydrocanabinnol – BTG 
Tetrahydrocanabinnol – BSA 
 
Fitzgerald Industries International Inc. 
Concord, MA 01742-3049, USA 
PCR Oligonucleotides MWG-Biotech Ltd., Milton Keynes 
Milk Marvel Chivers Ireland Ltd, Coolock 
Dublin 5 
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2.1.2 Equipment  
Equipment Supplier 
3015 pH meter Jenway Ltd., Gransmore Green, Felsted, 
Dunmow, Essex, UK. 
 
Titertek Twin reader Plus 
 
Medical Supply Company (MSC), 
Damastown, Mulhuddart, Dublin 15, 
Ireland. 
 
Eppendorf AGB Scientific ltd., Dublin Industrial 
Estate, Glasnevin, Dublin 9 
Hermle Z233MK-2 (microcentrifuge) Alpha Technologies Ltd., The Leinster 
Technology Centre, Blessington Industrial 
Estate, Blessington, Co. Wicklow, Ireland. 
Beckman centrifuge (J2-21) Beckman-Coulter Inc., 4300N Harbour 
Boulevard, Fullerton, CA 92834-3100, 
USA. 
 
Biometra PCR machine 
 
Anachem Ltd., Anachem House, Charles 
St., Luton, Bedfordshire, UK.  
 
Hybaid PCR machine BioRad, BioRad House, Maylands Ave., 
Hemel Hempstead, Hertfordshire, UK. 
 
Grant waterbath (Y6) Grant Instruments (Cambridge) Ltd., 29 
Station Rd., Shepreth, Royston, 
Hertfordshire, UK. 
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Orbital incubator Sanyo Gallenkamp plc, Monarch Way, 
Belton Park, Loughborough, Leicester, 
UK. 
 
Tomy Autoclave (SS 325) Mason Technology, Greenville Hall, 228 
South Circular Rd., Dublin 8, Ireland. 
 
UV-160A spectrophotometer Shimadzu Corp., Albert-Hahn-Str. 6-10, 
47269 Duisburg, Germany. 
 
Safire2 Platereader Tecan Austria GmbH, Untersbergstrasse 
1a, A-5082 Grodig / Salzburg, Austria. 
 
Vivaspin Concentrator 5000 MWCO Vivascience AG, Sartorius Group, 30625 
Hannover, Germany. 
 
Stuart platform shaker (STR 6) Lennox, John F Kennedy Industrial Est., 
Naas Rd., Dublin 12, Ireland. 
 
Image Master VSD gel documentation 
system 
Amersham Pharmacia Biotech AB, 
SE-751 84, Uppsala, Sweden.   
 
Nanodrop ND-1000 Lab tech International, East Sussex 
BN8 5NN, United Kingdom. 
 
Nunc maxisorb 96-well plates NUNC, Kamstrup DK, Roskilde, Denmark 
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2.1.3 Culture media formulations 
All E.coli strains, containing specific phagemid vectors, were grown in their optimal 
media. All media formulations are included in the table below. 
Culture Media Formulation  
2x Tryptone Yeast extract (2x TY) medium Tryptone                          16g/l 
Yeast extract                    10g/l 
NaCl                                 5g/l 
 
Luria Broth medium 
  
Tryptone                          10g/l 
Yeast extract                    5g/l 
NaCl                                10g/l 
 
Super Broth medium MOPS                             10g/l 
Yeast Extract                   20g/l 
Tryptone                          30g/l 
 
Terrific Broth medium Tryptone                          12g/l 
Yeast extract                    24g/l 
Glycerol                           4ml/l 
KH2PO4                                     17mM 
K2HPO4                                               72mM 
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Super Optimal Catabolite (SOC) medium 
 
Tryptone                         20g/l 
Yeast extract                   5g/l 
NaCl                                0.5g/l  
KCl                                2.5mM 
MgCl2                                                  20mM 
Glucose                          20mM 
 
2.1.4 Secondary antibodies 
Antibody  Enzyme - label Source 
Anti – polyhistidine  Horseradish peroxidase Mouse 
Anti - flag No label Rabbit 
Anti - Goat  Horseradish peroxidase / Alkaline 
phosphatase 
Rabbit  
Anti – rabbit  Horseradish peroxidase / Alkaline 
phosphatase 
Goat 
Anti - M13 bacteriaphage Horseradish peroxidase Mouse 
Anti – human kappa light 
chain 
Horseradish peroxidase Goat 
Anti – Haemaglutinain  Horseradish peroxidase Mouse 
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2.1.5 Buffers 
Buffer name  Composition 
Phosphate buffered saline 
(PBS) 
0.15M NaCl 
2.5mM KCl 
10mM Na2HPO4 
18mM KH2PO4 
pH 7.4  
 
Tris-acetate/EDTA 
electrophoresis buffer (TAE) 
40mM Tris-acetate  
1mM EDTA 
pH 8.0 
 
Tris-EDTA sucrose buffer 
(TES)  
200mM Tris-HCl 
0.5M Sucrose 
0.5mM EDTA, pH 8.0  
 
SCC buffer 200 mM Tris-HCl 
100 mM MgCl2 
500 mM NaCl  
10 mM DTT 
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2.1.6 Bacterial Strains Used 
Bactrerial Strain  Genotype 
XL-1 Blue E. coli RecA endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F′proAB lacIq Z∆M15 Tn10 (Tetr)] 
 
TG1 E. coli F´ traD36 lacIq (lacZ)M15 proA+B+/supE (hsdM-
mcrB)5 (rk-mk+McrB-) thi (lac-proAB) 
 
TOP 10 F’ E. coli F'{lacIq Tn10(TetR)} mcrA delta(mrr-hsdRMS-mcrBC) 
phi80lacZdeltaM15 deltalacX74 deoR recA1 araD139 
delta(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG  
 
JM83 E. coli λ_ ara  (pro-lac) rpsL thi φ80 dlacZ  M15λ_ 
 
CJ236 E. coli 
 
FΔ(HindIII)::cat (Tra+ Pil+ CamR)/ ung-1 relA1 dut-1 
thi-1 spoT1 mcrA 
 
2.1.6.1 Maintenance of Bacterial Stocks 
 
A working stock of bacteria was streaked on LB agar plates containing the appropriate 
antibiotic. A glycerol stock was prepare by growing an overnight culture from a single 
colony. This was stored in 15% (v/v) glycerol at -80oC. 
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2.1.7 Antibodies 
 
2.1.7.1 Anti-amphetamine monoclonal antibody 
 
A monoclonal antibody, clone 4EP18E, directed against amphetamine, was obtained 
from Dr. Lorna Fanning, Dublin City University (Fanning, 2002). 
 
2.1.7.2 Anti morphine – 3 – glucuronide (M3G) scFv 
 
A recombinant scFv specific for M3G was obtained from Dr. Joanne Brennan, Dublin 
City University (Brennan et al., 2003). 
 
2.2 Hapten-Protein Conjugates 
 
2.2.1 Production of M3G-OVA conjugates 
 
Morphine-3-glucuronide was coupled to OVA (ovalbumin) using standard carbodiimide 
coupling chemistry. Briefly, a 1ml solution of 50 mg/ml of M3G (in 1ml of  20 mM 
HCl) was made up to a volume of 5ml with 0.2 M borate buffer, pH 9.0. NHS (N-
hydroxysuccinimide) and EDC (N-ethyl-N-(dimethyl-aminopropyl) carbodiimide 
hydrochloride) were added to yield a final concentration of 0.1 M and 0.4 M, 
respectively. The solution was incubated to room temperature for 10 mins without 
agitation. OVA, prepared in 0.2 M borate buffer and at a molar ratio of 1:100 to M3G, 
was added dropwise to the activated solution with stirring. The solution was incubated 
at room temperature with gentle stirring for 2 hours and dialysed against 100 volumes of 
PBS (phosphate buffer saline, pH 7.4, 0.1M) overnight at 4oC. 
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2.2.2 Conjugate concentration determination  
 
Conjugate concentration was estimated using the nanodrop spectrophotometer. 
 
2.2.3 Commercial conjugates  
 
Amphetamine – BSA (bovine serum albumin) was obtained from Fitzgerald Industries 
International, MA, USA. The conjugation was achieved through the methylenedioxy 
group situated at the para-position of the phenyl ring. 
Tetrahydrocanabinnol-BTG (bovine thyroglobulin) and Tetrahydrocanabinnol-BSA 
were obtained from Fitzgerald Industries International, MA, USA. THC-BTG was 
conjugated through the delta-9 position and THC-BSA was linked via the carboxyl 
carbon at the delta-9 position. 
 
2.3 Immunisation for Recombinant Antibody Production 
 
2.3.1 Immunisation schedule for the production of a recombinant library 
 
Day 1 
Mice were immunised by intraperitoneal injection and rabbits were immunised by sub-
cutaneous injection with an emulsion (250µl) consisting of a 1mg/ml solution of 
peptide-protein conjugate mixed 1:1 with Freunds Complete Adjuvant. 
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Day 21  
Mice, and rabbits were re-immunised intraperitoneally and sub-cutaneously, 
respectively, using an emulsion (250µl) consisting of a 1mg/ml solution of peptide-
protein conjugate mixed 1:1 with Freund’s incomplete adjuvant. 
 
Day 28  
Tail bleeds were taken from the mice, 5ml peripheral blood from the ear vein was taken 
from rabbits and 5 ml of peripheral blood from wing vein was taken from chickens to 
determine antibody titre against the respective antigens. 
 
Day 52  
The mice were boosted intraperitoneally, and rabbits and chickens are boosted sub-
cutaneously, using an emulsion (250µl) consisting of a 1mg/ml solution of peptide-
protein conjugate mixed 1:1 with Freund’s incomplete adjuvant. 
 
Day 59  
Once the antibody titre was at sufficient levels (> 1/ 500,000) the animals were 
immunised intravenously (3-4 days prior to sacrifice) with the conjugate (250 µl at 1 
mg/ml). 
Antiserum recovery 
 After the 3-4 days, the animal was sacrificed and the blood and spleen recovered. 
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2.3.2 Preparation of serum for Estimation of Antibody Titre and specificity 
 
For titre estimation the blood collected was allowed to clot at 4oC overnight. It was then 
centrifuged at 13,000 rpm for 15 mins and supernatant removed for antibody titre 
determination by direct and competitive ELISA. 
 
2.3.3 Direct Enzyme-linked immunosorbent assay (ELISA) for Antibody Titre.  
 
Levels of antibody in serum from immunised animals were measured using ELISA.  
One series of wells were coated with 100µl of a 5µg/ml solution of drug protein 
conjugate (In the case of THC, THC-BSA was used) and incubated overnight at 4oC. A 
second series of wells were coated with the protein (protein used as conjuagate) alone, 
and incubated overnight at 4oC. The plates were washed three times with 0.1% (v/v) 
PBS/Tween and three times with PBS. The plates were then blocked with 200µl of 4% 
(w/v) Milk Marvel / PBS (M/PBS) for 1 hour at 37oC. Serial dilutions of serum were 
carried out in 1% MPBST, from 1/200 – 1/1,638,400 and 100µl of each dilution was 
added to the wells and allowed to bind at 37oC for 1 hour. The plates were washed 
again, three times with 0.1% (v/v) PBS/Tween and three times with PBS. 100 µl of 
commercial goat anti-rabbit IgG antibody, labelled with horseradish peroxidase at a 
dilution of 1 / 2,000 was added to the wells. The plates were washed again, three times 
with 0.1% (v/v) PBS/Tween and three times with PBS. Bound antibody was detected 
using o-phenylenediamine (o-PD), in 0.05M phosphate citrate buffer, pH the 5.0, and 
0.4 mg/ml of urea hydrogen peroxidase) chromogenic substrate. Absorbances were read 
after 30 min at 450nm.  
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2.4 Methods for the development of a recombinant antibody library 
  
2.4.1 RNA extraction and Complementary DNA synthesis. 
 
Total RNA, was extracted from the anti-amphetamine antibody-secreting clone, 
4EP18E, previously described by Fanning (2002), using Trizol reagent. It was then used 
for cDNA synthesis.  
For the generation of an immunised recombinant antibody library; the spleen from an 
immunised rabbit was removed aseptically. The spleen was placed in an ‘RNase-free’ 
50ml tube and weighed on an analytical balance. 2ml of Trizol reagent was added for 
every 100mg of spleen. The spleen was totally homogenized using a pre-autoclaved and 
baked head unit and the suspension transferred to an 85ml Oakridge ‘RNase-free’ tube. 
The suspension was left for 5 mins to ensure the complete dissociation of nucleoprotein 
complexes. Chloroform (0.2ml per ml of Trizol reagent) was added to the mixture and 
the tube was shaken vigorously for 15 secs and the resulting mixture was incubated at 
room temperature for 15 mins. After 15 mins, the mixture was centrifuged at 17500g for 
20 min at 4oC. The suspension separates into three distinct layers, with the top aqueous 
layer containing the RNA. This was transferred to a new ‘RNase-free’ Oakridge tube 
and the RNA was precipitated out of solution by addition of 0.5 ml Isopropanol per ml 
of Trizol used. The RNA suspension was left at room temperature for 5-10 min and 
centrifuged at 17,500g for 25 min. RNA forms a gel-like pellet on the side and the 
bottom of the tube. The supernatant was removed and the pellet was washed with 75% 
(v/v) ethanol (1ml of ethanol per ml of Trizol used) and vortexed. This was centrifuged 
at 17,500g for 10 min at 4oC. The RNA pellet was allowed to airdry and then dissolved 
in molecular grade water. The RNA was dissolved via gentle shaking. 
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2.4.2 Complementary DNA Synthesis 
 
Complementary DNA (cDNA) was synthesized by reverse transcription using the 
SuperScript Preamplification System for First Strand cDNA Synthesis (Life 
Technologies, Cat #18089-011).  
 
Table 2.4.2.1 List of components and their concentrations for use in cDNA synthesis. 
Component Concentration per reaction (50 µl) 
MgCl2 5mM 
10X Buffer  1X 
dNTP mix 1mM 
RNase ® ribonuclease inhibitor 1 U/μl 
Oligo dT’s 0.5 μg/μl 
AMV RT 15 U 
RNA 7 – 10 μg 
Nuclease – free H2O Up to 20 μl 
 
The cDNA synthesis mixture was incubated at room temperature for 10 minutes to 
allow annealing of the primers. The reaction was then incubated at 42oC for 1 hour and 
DNA analysed by agarose gel electrophoresis (section 2.4.3). 
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2.4.3 Agarose gel electrophoresis  
 
Agarose gel electrophoresis was used for DNA analysis. Briefly, agarose was dissolved 
in 1X TAE buffer at the required concentration (1 – 3% (w/v)) and boiled until the 
solution cleared. In the case of DNA to be used solely for analysis, 0.5 μg / ml of the 
intercalating dye, ethidium bromide (EtBr) was added to the gel. 1X SYBER Safe™ 
DNA gel stain in DMSO (Invitrogen Cat # S33102) was added for visualization, where 
the DNA was to be extracted and purified from the gel. Unlike ethidium bromide, 
SYBER Safe does not require exposure to UV light for visualization and, therefore, the 
DNA is not damaged by this light. However, EtBr was required for photographing gels 
for records as they were photographed using a UV image analyzer.  
 
2.4.4 Construction of chimeric anti-amphetamine Fab from cDNA 
 
Anti - amphetamine chimeric Fab was amplified from the prepared cDNA, using 
recommended PCR assembly methods (Andris-Widhopf et al., 2000; Steinberger et al., 
2000; Barbas et al., 2001). Human CH1, Cκ region was sourced from the pCOMB3X 
vector series, which contain standard Fab fragment inserts (Andris-Widhopf et al., 
2000). Fab constructs were synthesized with the mouse Vλ region in association with 
both Cκ regions.  
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2.4.4.1 The list of chimeric mouse/human Fab primers used in variable heavy and 
light chain amplifications are detailed below. 
 
VH5` Sense Primers 
 
MHyVH1-F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTR MAG CTT CAG GAG 
TC 3` 
 
MHyVH2 – F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTB CAG CTB CAG CAG 
TC 3` 
 
MHyVH3 – F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG CAG CTG AAG SAS TC 
3` 
 
MHyVH4 – F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTC CAR CTG CAA CAR TC 
3` 
 
MHyVH5 – F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTY CAG CTB CAG CAR TC 
3` 
 
MHyVH6– F 
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5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTY CAR CTG CAG CAG 
TC 3` 
 
MHyVH7– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTC CAC GTG AAG CAG 
TC 3` 
 
MHyVH8– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AAS STG GTG GAA TC 
3` 
 
MHyVH9– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AWG YTG GTG GAG 
TC 3` 
 
MHyVH10– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG CAG SKG GTG GAG 
TC 3` 
 
MHyVH11– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG CAM CTG GTG GAG 
TC 3` 
 
MHyVH12– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AAG CTG ATG GAR 
TC 3` 
MHyVH13– F 
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5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AAG CTG ATG GAR 
TC 3` 
 
MHyVH14– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTR AAG CTT CTC GAG 
TC 3` 
 
MHyVH15– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AAR STT GAG GAG 
TC 3` 
 
MHyVH16– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTT ACT CTR AAA GWG 
TST G 3` 
 
MHyVH17– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTC CAA CTV CAG CAR CC 
3` 
 
MHyVH18– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AAC TTG GAA GTG 
TC 3` 
 
MHyVH19– F 
5` GCT GCC CAA CCA GCC ATG GCC CTC GAG GTG AAG GTC ATC GAG 
TC 3` 
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VH3` Reverse Primers  
 
MhyIgGCH1 – B1  
5` CGA TGG GCC CTT GGT GGA GGC TGA GGA GAC GGT GAC CGT GGT 
3` 
 
MhyIgGCH1 – B2 
5` CGA TGG GCC CTT GGT GGA GGC TGA GGA GAC TGT GAG AGT GGT 
3` 
 
MhyIgGCH1 – B3 
5` CGA TGG GCC CTT GGT GGA GGC TGC AGA GAC AGT GAC CAG AGT 
3` 
 
MhyIgGCH1 – B4  
5` CGA TGG GCC CTT GGT GGA GGC TGA GGA GAC GGT GAC TGA GGT 
3` 
 
VK5` Sense Primers  
 
MSCVK - 1 
5` GGG CCC AGG CGG CCG AGC TCC AYA TCC AGC TGA CTC AGC C 3`  
 
MSCVK – 2  
5` GGG CCC AGG CGG CCG AGC TCC AYA TTG TTC TCW CCC AGT C 3`  
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MSCVK - 3 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTG TGM TMA CTC AGT C 3` 
 
MSCVK - 4 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTG TGY TRA CAC AGT C 3` 
 
MSCVK - 5 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTG TRA TGA CMC AGT C 3` 
 
MSCVK - 6 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTM AGA TRA MCC AGT C 3` 
 
MSCVK - 7 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTC AGA TGA YDC AGT C 3` 
 
MSCVK - 8 
5` GGG CCC AGG CGG CCG AGC TCC AYA TYC AGA TGA CAC AGA C 3` 
 
MSCVK - 9 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTG TTC TCA WCC AGT C 3` 
 
MSCVK – 10 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTG WGC TSA CCC AAT C 3` 
 
MSCVK - 11 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTS TRA TGA CCC ART C 3` 
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MSCVK - 12 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTK TGA TGA CCC ARA C 3` 
 
MSCVK - 13 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTG TGA TGA CBC AGK C 3` 
 
MSCVK - 14 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTG TGA TAA CYC AGG A 3` 
 
MSCVK - 15 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTG TGA TGA CCC AGW T 3` 
 
MSCVK - 16 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTG TGA TGA CAC AAC C 3` 
 
MSCVK - 17 
5` GGG CCC AGG CGG CCG AGC TCC AYA TTT TGC TGA CTC AGT C 3` 
 
VK3` Reverse Primers 
 
MHybJK12 – B 
5`AGA TGG TGC AGC CAC AGT TCG TTT KAT TTC CAG YTT GGT CCC 3` 
 
MHybJK4 – B 
5`AGA TGG TGC AGC CAC AGT TCG TTT TAT TTC CAA CTT TGT CCC 3` 
 
MHybJK5 – B 
96 
5`AGA TGG TGC AGC CAC AGT TCG TTT CAG CTC CAG CTT GGT CCC 3` 
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Table 2.4.4.1.1 PCR components for V region (heavy and light chain) amplification. 
Component Concentration per reaction Volume (µ l) 
Sense primer mix (heavy / 
light chain) 
0.06nM  1 
Reverse primer mix (heavy / 
light chain) 
0.06nM  1 
 
10 X Buffer 1 X 5 
MgCl2 1.5 mM 3 
dNTP`s 0.2 mM 1 
cDNA 8 μg / reaction x 
Taq Polymerase 5 U / reaction 0.25 
Molecular grade H2O Up to 50 μl y 
 
Table 2.4.4.1.2 PCR conditions for antibody V region amplifications 
Temperature Time (seconds) 
94oC 120   
94oC 15 
56oC 30 
72oC 90 
Repeat step, 2 – 4, 30 times 
72oC 600 
4 oC -- 
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2.4.4.2 Primers for the applification of human Cκ region and pelB leader sequence 
from a cloned human Fab fragment. 
 
 
HKC – F  sense 
5` CGA ACT GTG GCT GCA CCA TCT GTC 3` 
 
Lead – B reverse 
5` GGC CAT GGC TGG TTG GGC AGC 3` 
 
Human CH1 primers 
 
HIgGCH1 – F sense 
5` GCC TCC ACC AAG GGC CCA TCG GTC 3` 
 
dpseq reverse 
5` AGA AGC GTA GTC CGG AAC GTC 3` 
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Table 2.4.4.2.1 PCR conditions for C region (heavy and light chain) amplification. 
Component Concentration per reaction Volume (µ l) 
HKC – F / HIgGCH1 – F 0.05nM  1 
Lead – B / dpseq 0.05nM 1 
10 X Buffer 1 X 5 
MgCl2 1.5 mM 3 
dNTP`s 0.2 mM 1 
PComb3X plasmid  2 μg / reaction x 
Taq Polymerase 5 U / reaction 0.25 
Molecular grade H2O Up to 50 μl y 
 
Table 2.4.4.2.2 PCR conditions for antibody C region amplifications. 
Temperature Time (seconds) 
94oC 120   
94oC 15 
56oC 30 
72oC 90 
Repeat step, 2 – 4, 30 times 
72oC 600 
4 oC -- 
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2.4.5 Purification of PCR reaction products 
 
All PCR products were excised and purified following agarose gel electrophoresis. 
Purification was carried out using Eppendorf Perfectprep Gel clean - up kit. The correct 
bands were identified via the transilluminator, excised using a sterile scalpel, transferred 
to a sterile microcentrifuge tube and weighed. Three volumes of binding buffer were 
added to each gel slice, inverted 3 times to mix and incubated at 55oC for 15 min or until 
the gel slice had been fully dissolved. One volume of isopropanol was added. The 
mixture was poured into a spin column and centrifuged for 2 min at 14,000 rpm at 4oC. 
The flow through was discarded and the spin column was washed with 750 μl of wash 
buffer, the column was centrifuged for 2 min at 14,000 rpm. The flow through was 
discarded. The column was centrifuged once again to ensure all residual wash buffer has 
been removed before elution. The spin column was transferred to a sterile 
microcentrifuge tube and 30 μl ‘nuclease – free’ H2O was added. The column was 
centrifuged for 1 min at 14,000 rpm to elute the DNA. Purified DNA was either used 
immediately in splice by overlap extension PCR or stored at -20 oC until required.  
 
2.4.6 Splice by Overlap Extension PCR. 
 
Variable and constant heavy and light chains were annealed and amplified using splice by 
overlap extension (SOE) to produce an 800bp light chain and an 800 bp heavy chain. 
The 3` end of the pelB sequence on each of the heavy and light chains serves as the 
overlap region in the final SOE PCR. 
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2.4.6.1 Mouse VH and Human CH1 SOE primers 
 
LeadVH sense 
5` GCT GCC CAA CCA GCC ATG GCC 3` 
dpseq reverse 
5` AGA AGC GTA GTC CGG AAC GTC 3` 
 
Mouse VL and Human CK SOE primers 
 
RSC – F sense 
5` GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC 3` 
 
Lead – B reverse 
5` 5` GGC CAT GGC TGG TTG GGC AGC 3` 
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Table 2.4.6.1.1 PCR components for C region (heavy and light chain) amplification. 
Component Concentration per reaction Volume (µ l) 
LeadVH / RSC – F 0.05nM  1 
dpseq / Lead – B 0.05nM  1 
10 X Buffer 1 X 5 
MgCl2 1.5 mM 3 
dNTP’s 0.2 mM 1 
Purified PCR product 
(VL, CK  / VH, CH1)  
100 ng of each / reaction x 
Taq Polymerase 5 U / reaction 0.25 
Molecular grade H2O Up to 50 μl y 
 
Table 2.4.6.1.2 PCR conditions for antibody C region amplifications 
Temperature Time (seconds) 
94oC 120 
94oC 15 
56oC 30 
72oC 90 
Repeat step, 2 – 4, 15 times 
72oC 600 
4 oC -- 
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2.4.6.2 Chimeric Mouse/Human Fab primers used in the final overlap PCR to 
combine the chimeric light chain –pelB fragment and the Fd fragment. 
 
RSC – F sense 
5` GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC 3` 
 
dp – EX reverse 
5` GAG GAG GAG GAG GAG GAG AGA AGC GTA GTC CGG AAC GTC 3` 
 
Table 2.4.6.2.1 PCR components for final Fab construct  amplification. 
Component Concentration per reaction Volume (µ l) 
 RSC – F 0.05nM  1 
dp –EX  0.05nM  1 
10 X Buffer 1 X 5 
MgCl2 1.5 mM 3 
dNTP’s 0.2 mM 1 
Fd and light chain 100 ng of each chain / reaction x 
Taq Polymerase 5 U / reaction 0.25 
Molecular grade H2O Up to 50 μl y 
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Table 2.4.6.2.2 PCR conditions for final Fab construct amplification 
Temperature Time (seconds) 
94oC 120 
94oC 15 
56oC 30 
72oC 90 
Repeat step, 2 – 4, 15 times 
72oC 600 
4 oC -- 
 
 
2.4.7 Methods for the conversion of an anti-M3G scFv fragment to a chimeric Fab 
format. 
 
Methods are as outlined in the previous sections 2.4.4 – 2.4.6 with the following 
changes in protocol. 
 
2.4.7.1 Construction of the Cλ – associated Fab. 
 
To facilitate the construction of the Cλ – associated Fab the reverse primer M-H-CL5 –
B, was designed to amplify the mouse Vλ sequence and also to introduce a human Cλ 
sequence tail. The Cλ region along with the pelB leader sequence was amplified from 
the pComb3XSS vector using HLC-F and Lead-B. This Vλ PCR product was gel 
purified, as previously outlined, and combined with Cλ purified product to give the final 
λ light chain construct. 
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VK3` Reverse Primer 
 
M-H-CL5 –B 
5` CGA GGG GGC AGC CTT GGG CTG ACC TAG GAC AGT CAG TTT GG 3` 
 
 Human Cκ region and pelB leader sequence primers 
 
HLC – F sense 
5` GGT CAG CCC AAG GCT GCC CCC 3` 
 
Lead – B reverse 
5` GGC CAT GGC TGG TTG GGC AGC 3` 
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2.4.8 Methods for the conversion of an anti-Amphetamine Fab to scFv format and 
construction of an anti-THC rabbit scFv. 
 
2.4.8.1 Amplification of variable heavy and light chains from the anti – amphetamine 
Fab discussed in previous sections. 
 
A standard primer mix compatible with the pAK vector system, as described by 
Krebber et al., (1997), was used for the assembly of mouse scFv fragments.  
 
2.4.8.1.1 Mouse scFv primers used in variable heavy and light chain amplification. 
 
Variable light chain back primers 
 
LB1 5′gccatggcggactacaaaGAYATCCAGCTGACTCAGCC3′ 
LB2 5′gccatggcggactacaaaGAYATTGTTCTCWCCCAGTC3′ 
LB3 5′gccatggcggactacaaaGAYATTGTGMTMACTCAGTC3′ 
LB4 5′gccatggcggactacaaaGAYATTGTGYTRACACAGTC3′ 
LB5 5′gccatggcggactacaaaGAYATTGTRATGACMCAGTC3′ 
LB6 5′gccatggcggactacaaaGAYATTMAGATRAMCCAGTC3′ 
LB7 5′gccatggcggactacaaaGAYATTCAGATGAYDCAGTC3′ 
LB8 5′gccatggcggactacaaaGAYATYCAGATGACACAGAC3′ 
LB9 5′gccatggcggactacaaaGAYATTGTTCTCAWCCAGTC3′ 
LB10 5′gccatggcggactacaaaGAYATTGWGCTSACCCAATC3′ 
LB11 5′gccatggcggactacaaaGAYATTSTRATGACCCARTC3′ 
LB12 5′gccatggcggactacaaaGAYRTTKTGATGACCCARAC3′ 
LB13 5′gccatggcggactacaaaGAYATTGTGATGACBCAGKC3′ 
LB14 5′gccatggcggactacaaaGAYATTGTGATAACYCAGGA3′ 
LB15 5′gccatggcggactacaaaGAYATTGTGATGACCCAGWT3′ 
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LB16 5′gccatggcggactacaaaGAYATTGTGATGACACAACC3′ 
LB17 5′gccatggcggactacaaaGAYATTTTGCTGACTCAGTC3′ 
LBλ 5′gccatggcggactacaaaGATGCTGTTGTGACTCAGGAATC3′ 
 
Variable light chain forward primers  
 
LF1 5′ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTGATTTCCAGCTTGG3′  
LF2 5′ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAGCTTGG3′ 
LF4 5′ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTTATTTCCAACTTTG3′ 
LF5 5′ggagccgccgccgcc(agaaccaccaccacc)2ACGTTTCAGCTCCAGCTTGG3′  
LFλ 5′ggagccgccgccgcc(agaaccaccaccacc)2ACCTAGGACAGTCAGTTTGG3′ 
Variable heavy chain back primers 
 
HB1 5′ggcggcggcggctccggtggtggtggatccGAKGTRMAGCTTCAGGAGTTC3′   
HB2 5′ggcggcggcggctccggtggtggtggatccGAGGTBCAGCTBCAGCAGTC3′ 
HB3 5′ggcggcggcggctccggtggtggtggatccCAGGTGCAGCTGAAGSASTC3′ 
HB4 5′ggcggcggcggctccggtggtggtggatccGAGGTCCARCTGCAACARTC3′ 
HB5 5′ggcggcggcggctccggtggtggtggatccCAGGTYCAGCTBCAGCARTC3′ 
HB6 5′ggcggcggcggctccggtggtggtggatccCAGGTYCARCTGCAGCAGTC3′ 
HB7 5′ggcggcggcggctccggtggtggtggatccCAGGTCCACGTGAAGCAGTC3′ 
HB8 5′ggcggcggcggctccggtggtggtggatccGAGGTGAASSTGGTGGAATC3′ 
HB9 5′ggcggcggcggctccggtggtggtggatccGAVGTGAWGYTGGTGGAGTC3′ 
HB10 5′ggcggcggcggctccggtggtggtggatccGAGGTGCAGSKGGTGGAGTC3′ 
HB11 5′ggcggcggcggctccggtggtggtggatccGAKGTGCAMCTGGTGGAGTC3′ 
HB12 5′ggcggcggcggctccggtggtggtggatccGAGGTGAAGCTGATGGARTC3′ 
HB13 5′ggcggcggcggctccggtggtggtggatccGAGGTGCARCTTGTTGAGTC3′ 
HB14 5′ggcggcggcggctccggtggtggtggatccGARGTRAAGCTTCTCGAGTC3′ 
HB15 5′ggcggcggcggctccggtggtggtggatccGAAGTGAARSTTGAGGAGTC3′ 
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HB16 5′ggcggcggcggctccggtggtggtggatccCAGGTTACTCTRAAAGWGTSTG3′ 
HB17 5′ggcggcggcggctccggtggtggtggatccCAGGTCCAACTVCAGCARCC3′ 
HB18 5′ggcggcggcggctccggtggtggtggatccGATGTGAACTTGGAAGTGTC3′  
HB19 5′ggcggcggcggctccggtggtggtggatccGAGGTGAAGGTCATCGAGTC3′ 
 
Variable heavy chain forward primers 
 
HF1 5′ggaattcggcccccgaggcCGAGGAAACGGTGACCGTGGT3′  
HF2 5′ggaattcggcccccgaggcCGAGGAGACTGTGAGAGTGGT3′ 
HF3 5′ggaattcggcccccgaggcCGCAGAGACAGTGACCAGAGT3′ 
HF4 5′ggaattcggcccccgaggcCGAGGAGACGGTGACTGAGGT3′   
 
2.4.8.2 Amplification of variable heavy and light chains from the rabbit cDNA 
 
Anti-tetrahydrocannabinol scFv was amplified from the prepared cDNA, using 
recommended PCR assembly methods (Andris-Widhopf et al., 2000; Barbas et al., 
2001).  
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2.4.8.2.1 The list of scFv primers used in variable heavy and light chain amplification 
are detailed below. 
 
Vk5 Sense Primers 
 
RSCVK1 
5` GGG CCC AGG CGG CCG AGC TCG TGM TGA CCC AGA CTC CA 3` 
 
RSCVK2 
5` GGG CCC AGG CGG CCG AGC TCG ATM TGA CCC AGA CTC CA 3` 
 
RSCVK3 
5` GGG CCC AGG CGG CCG AGC TCG TGA TGA CCC AGA CTG AA 3` 
 
Vk3 Reverse Primers, long linker 
 
RKB9j1o-BL 
5` GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC 
GCC ACC AGA GGA TAG GAT CTC CAG CTC GGT CCC 3` 
  
RKB9jo-BL 
5` GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC 
GCC ACC AGA GGA TAG GAT CTC CAG CTC GGT CCC 3` 
 
RKB42jo-BL 
5` GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC 
GCC ACC AGA GGA TTT GAC SAC CAC CTC GGT CCC 3` 
 
Vλ5 Sense Primers 
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RSCλ1 
5` GGG CCC AGG CGG CCG AGC TCG TGC TGA CTC AGT CGC CCT 3` 
 
Vλ3 Reverse Primer, long linker 
 
RJλo-BL 
5` GGA AGA TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC ACC 
GCC ACC AGA GGA GCC TGT GAC GGT CAG CTG GGT CCC 3` 
 
VH5 Sense primers 
 
RSCVH1 
5` GGT GGT TCC TCT AGA TCT TCC CAG TCG GTG GAG GAG TCC RGG 3` 
 
RSCVH2 
5` GGT GGT TCC TCT AGA TCT TCC CAG TCG GTG AAG GAG TCC GAG 3` 
 
RSCVH3 
5` GGT GGT TCC TCT AGA TCT TCC CAG TCG YTG GAG GAG TCC GGG 3` 
 
RSCVH4 
5` GGT GGT TCC TCT AGA TCT TCC CAG SAG CAG CTG RTG GAG TCC GG 3` 
 
111 
VH3 Reverse primers 
 
RSCG-B 
5` CCT GGC CGG CCT GGC CAC TAG TGA CTG AYG GAG CCT TAG GTT GCC 
C 3` 
 
Overlap Extension primers 
 
RSC-F (sense) 
5` GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC 3` 
 
RSC-B (reverse) 
5` GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC CAC TAG TG 3` 
 
2.4.9 Recombinant Fab library construction 
 
2.4.9.1 Preparation of pComb3XSS vector 
 
A single colony of XL - 1 Blue (Stratagene, La Jolla, CA, USA) containing the required 
vector (pComb vector series, kindly provided by Prof. Carlos Barbas, (Scripps Research 
Institute) was isolated and grown overnight in 10ml LB media, plus 30 μg / ml 
tetracycline, at 37oC and 220rpm. The plasmid was isolated and purified using the 
Wizard Plus SV Miniprep kit, according to the manufacturers instructions. 
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2.4.9.2 Restriction digest of Fab insert and pComb3XSS vector using Sfi 1 
 
The Fab fragment and vector were digested with Sfi 1 in New England Biolabs, Buffer 2 
(10 mM Tris–HCl, 50 mM NaCl, 10 mM MgCl2 and 1 mM DTT)  
Component PComb3XSS Fab fragment 
Buffer 1X 1X 
BSA 1X 1X 
Sfi 1 200 units 300 units 
DNA 28 μg 8 μg 
H2O Up to 100 μl  Up to 200 μl 
 
 
The digest was run for 5 hours at 50oC. The vector, stuffer fragment and Fab fragment 
were gel purified and quantified. 
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2.4.10 Ligation of Fab gene into pComb3X 
 
Purified digests of Fab, vector and stuffer fragment were ligated at a DNA : vector ratio 
of 1:1 and a 1 / 20 dilution of T4 DNA Ligase  at 16oC overnight.  
 
2.4.10.1 Preparation of Electrocompetent XL - 1 Blue cells with high transformation 
efficiency. 
 
Electroporation is the most efficient method for obtaining high transformation efficiency 
cells. A single XL – 1 Blue colony was grown overnight in 5 ml SB (Super Broth) plus 
30 μg / ml tetracycline at 37oC and 220 rpm. 1.5 ml of this overnight culture was seeded 
into 500 ml SB, 1% (w/v) glucose, 5 ml MgCl2 and no antibiotics. This culture was 
grown at 37oC and 220 rpm until the OD at 600nm had reached 0.8.  The culture flasks 
and centrifuge bottles were chilled at 4oC for 15 min. 10% (v/v) glycerol was prepared 
and stored at 4oC. From this point onwards all steps were performed as rapidly as 
possible and kept at 4oC. The cultures were centrifuged in chilled bottles at 4000 rpm 
and 4oC for 20min. The supernatant was poured off and the pellet was resuspended in 
10% (v/v) glycerol and centrifuged again at 4000 rpm, 4oC for 20min. The last step was 
repeated one more time. The final pellet was resuspended in 25 ml 10% (v/v) glycerol 
and transferred into pre-chilled 50 ml polypropylene tubes and centrifuged at 3500 rpm, 
4oC for 20min. Twenty 1.5 ml screwcap microcentrifuge tubes were set up in a dry ice / 
ethanol bath. The supernatant was carefully discarded leaving 2 ml covering the pellet. 
The pellet was resuspended in this remaining 2ml volume and stored at -80oC in 300 μl 
aliquots until required for use. 
 
2.4.10.2 Transformation of E. coli XL – 1 Blue with vector plus insert 
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The ligation mixture was precipitated with ethanol in order to remove any excess salt, 
which may cause arcing, prior to electroporation. The competent cells were thawed on 
ice along with the desalted ligation mixture. The DNA and competent cells were mixed 
and transferred to 2mm Gene Pulser ® Cuvettes (Bio - Rad Cat no # 165 – 2086). The 
cells were pulsed at 2500 V, 200 Ώ. 5 ml of SOC media was immediately added to the 
cells and transferred to a 15 ml polypropylene tube. The culture was incubated at 37oC 
and 200 rpm for 1 hour. Cells were plated on LB agar plates with carbenicillin and 
grown overnight at 37oC. Plates were scraped using LB liquid media, library stocks 
were prepared with the addition of 20 % (v/v) glycerol and flash frozen in liquid 
nitrogen and stored at – 80oC. 
 
2.5 Biopanning of a recombinant antibody library against amphetamine. 
 
2.5.1 Rescue of Fab displaying phage 
 
Initial library rescue was performed by inoculating 100ml SB with 50 μg/ml 
carbenicillin and 1% (w/v) glucose, with 100 μl frozen library stock. This was grown at 
37oC at 200 rpm until the OD at 600nm reached 1.0. The culture was centrifuged at 
4000 rpm, 4oC for 10 mins and the pellet resuspended in the absence of glucose in 
200ml SB (plus 50 μg/ml carbenicillin). The culture was then infected with 6 x 1011 
M13KO7 helper phage and allowed to grow at 37oC at 220 rpm for 2 hours. 70 μg/ml 
kanamycin was added to the culture which was then incubated overnight at 37oC at 220 
rpm.  
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2.5.2 PEG / NaCl precipitation of phage 
 
The 200 ml overnight rescued library was centrifuged in sterile centrifuge bottles at 
4000 rpm at 4oC for 20 min. The supernatant was poured into a fresh sterile bottle and 8 
g PEG and 6 g NaCl were added and allowed to dissolve for 5 min at 37oC. The 
supernatant mix was allowed to stand on ice for 30 min. It was then centrifuged, with 
the brake turned off, at 9000 rpm at 4oC for 15 min. The supernatant was carefully 
decanted and the phage pellet was allowed to air-dry for 10 min at room temperature. 
The phage pellet was resuspended in cold sterile filtered 1% (w/v) BSA. This phage 
preparation was ready for immediate biopanning. Alternatively it can be stored in 1% 
(w/v) sodium azide (handle sodium azide with care and PPE should be worn at all 
times) at 4oC for future panning although it must be reamplified unless prepared fresh 
on the same day. 
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2.5.3 Panning of specific anti-amphetamine Fab – displaying phage  
 
8 wells of a Nunc maxisorb plate were coated with amphetamine – BSA conjugate at 
4oC overnight. For initial rounds of panning 10 μg/ml coating concentration was used. 
This was reduced to 5 μg/ml and 2 μg/ml in further rounds of panning. The coating 
solution was discarded and the wells were blocked with 150 μl 3% (w/v) sterile filtered 
BSA for 2 hours at 37oC. Meanwhile 2 x 2 ml XL – 1 Blue cultures were grown at 37oC 
and 220 rpm until they reached an OD at 600 nm of 1.0. The blocking solution was 
discarded and the freshly prepared phage solution was added at 100 μl per well. The 
phage solution was left to bind for 2 hours at 37oC. The wells were washed with 
repeatedly with PBS and PBST. The bound phage were eluted with 100 μl of 10 mg/ml 
sterile filtered trypsin at 37 oC for 30 min. Alternatively, free antigen elution was 
employed in later rounds of panning. Elution time was increased to 1 hour for this 
strategy and the free antigen concentration was 100 μM. The solution in the wells was 
pipetted vigorously up and down in order to remove all bound phage and then added to 
a 2 ml XL – 1 Blue culture. The phage were allowed to infect for 20 min at room 
temperature. A sample of this infected culture was taken and diluted 100 – fold and 
plated on LB agar plus carbenicillin plates for output titering. The volume of the 
remaining infected culture was increased to 8 ml by addition of 6 ml SB (plus 50 μg/ml 
carbenicillin) and was incubated at 37oC and 220 rpm for 1 hour. The culture was 
centrifuged at 4000 rpm and 4oC for 10min. The pellet was resuspended in 1 ml SB and 
plated on LB plus carbenicillin. The plates were incubated overnight at 37oC.  
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2.6 Screening of anti – amphetamine Fab - displaying phage 
 
2.6.1 Preparation of soluble expressing clones for a Monoclonal ELISA and master 
plate construction 
 
A 96 well sterile culture plate was filled with 200 μl of 2XTY, 1% (w/v) glucose, 100 
μg/ml carbenicillin and 30μg/ml tetracycline. Each well was inoculated with a single 
colony from the phage titre plates, leaving two wells as non-inoculated control wells. 
The plate was incubated at 37oC and 220rpm overnight. This was deemed the master 
plate and was frozen at -80oC with 15% (v/v) glycerol. A second plate was prepared 
with 180 μl of 2XTY, 1% (w/v) glucose, 100 μg/ml carbenicillin and 30 μg/ml 
tetracycline. 20 μl from each well of the master plate was transferred to the 
corresponding well on this second plate and incubated at 37oC and 220rpm for 10 hours. 
The plate was centrifuged at 2500 rpm for 15 min. 1mM IPTG was made up in 2XTY, 
100 μg/ml carbenicillin and 30 μg/ml tetracycline and added to each well and the plate 
was incubated at 30oC and 220rpm overnight. 
 
2.6.2 Monoclonal ELISA 
 
A plate was coated with 100 μl of 1 μg/ml amphetamine – BSA and incubated overnight 
at 4oC. The coating solution was discarded and 200 μl of 5 % (w/v) MPBS was added to 
the wells, the plate was incubated at 37oC for 1 hour. The plate was washed three times 
with PBS and PBST. The culture plate was centrifuged at 4000 rpm, 4oC for 20 min. 
The supernatant was mixed 1 / 2 with 2 % (w/v) MPBST and 100 μl of this solution was 
added to corresponding wells on the assay plate. The individual clones were incubated 
on the plate at 37oC for 1 hour. The solution was discarded and the plates were washed 
3 times with PBS and PBST.  
100 μl of anti – HA – HRP - labelled antibody was added to each well and incubated at 
37oC for 1 hour. The plate was washed 3 times with PBS and PBST. 100 μl of 3, 3`, 5`, 
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5`- Tetramethylbenzidine dihydrochloride (TMB) substrate, diluted to1 mg/ml in 0.05 
M citric phosphate buffer, pH 5, was added to each well. The reaction was allowed to 
proceed for 15 min at which time it was stopped via the addition of 10 % (v/v) HCl. The 
absorbance was read at 450nm.  
 
 
 2.6.3 Soluble expression and lysate preparation of positive clones on small scale  
  
Positive clones resulting from the monoclonal phage ELISA were plasmid prepared as 
outlined in section 2.6.1. One μl of the prepared DNA was electroporated into 
electrocompetent Top 10 F’ cells, prepared as described in 2.6.3. 10 single colonies 
were picked into 5ml SB (plus 50 µg/ml carbenicillin) and grown all day at 37oC and 
220 rpm. 2mM IPTG was added to each culture and allowed to induce at 30oC and 220 
rpm overnight. Immediately following IPTG addition 10 μl of each culture was streaked 
on a plate for individual clone backup stocks. The next day the cultures were 
centrifuged at 4000rpm and 4oC for 15 min.The pellets were resuspended in 300 μl PBS 
and were subjected to freeze / thaw 3 cycles in order to lyse the cells. The lysed cells 
were centrifuged at 14000 rpm and room temperature for 10min to eliminate cell debris 
from the cleared lysate. 
 
2.6.4 ELISA on soluble expressed clones  
 
A 96 – well microtitre plate was coated with 100 μl of 2 μg/ml amphetamine overnight 
at 4oC. The plate was blocked with 200 μl 5% (w/v) MPBST at 37oC for 1 hour. The 
plate was washed 3 times with PBS and PBST. The lysate was mixed 1 / 2 with MPBST 
and 100 μl was applied to the appropriate well on the assay plate and incubated at 37oC 
for 1 hour. The plate was washed 3 times with PBS and PBST. 100 μl of anti-HA-HRP-
labelled antibody was added to each well and incubated at 37oC for 1 hour. The plate 
was washed 3 times with PBS and PBST. 100 μl of 3, 3’ 5, 5`- Tetramethylbenzidine 
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dihydrochloride (TMB) substrate diluted 1 mg/ml in 0.05 M citric phosphate buffer, pH 
5, was added to each well. The reaction was allowed to proceed for 15 min at which 
time it was stopped via the addition of 10 % (v/v) HCl. The absorbance was read at 
450nm.  
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2.7 Antibody Expression and Purification conditions 
 
2.7.1 Large scale expression of Fab fragments in pComb3X 
 
The positive Fab clone was introduced into E. coli Top 10 F’ (Invitrogen) via 
electroporation before plating on LB agar plus 100 μg/ml carbenicillin plates. Single 
colonies were inoculated in 10 ml SB, 1% (w/v) glucose and 50 μg/ml carbenicillin, 
which were incubated at 37oC, 220 rpm overnight.  1.5 ml of the starter cultures was 
seeded into 500ml SB, 1% (w/v) glucose and 50 μg/ml carbenicillin and incubated for 8 
hours at 37oC and 220 rpm. Cultures were centrifuged at 4000 rpm and 4oC for 20min. 
The pellets were re-suspended in fresh SB with 50 μg/ml carbenicillin with no glucose 
added. The cultures were allowed to recover at 30oC for 1 hour prior to induction with 
1mM IPTG. The induced cultures were incubated at 30oC and 220 rpm overnight. 
Cultures were centrifuged at 4000 rpm and 4oC for 20 min. The pellets were re-
suspended in 25 ml column loading buffer consisting of 50 mM NaH2PO4; pH 8.0, 300 
mM NaCl and 5 mM imidazole. The cell suspension was sonicated under the following 
settings, 5 sec pulses at 50% amplitude for 90 sec and 5 sec pulses at 70% amplitude for 
20 sec. Each of the aforementioned protocols was performed twice. The lysed cell 
suspension was centrifuged at 11000 rpm, 4oC for 30 min. The cleared lysate was semi 
– purified using immobilized metal affinity chromatography (Ni – NTA Qiagen) 
 
2.7.2 Purification by IMAC 
 
The 500 ml terrific broth culture of induced cells was centrifuged at 12,000 rpm for 10 
minutes at 4oC. The pellets were resuspended in 30 mls of sonication buffer (1 x PBS + 
500 mM NaCl + 20 mM Imidazole). The resuspend pellet was aliquoted into thirty 2 ml 
centrifugation tubes and each sample sonicated on ice using the appropriate setting 
(Amp 40 for 45 seconds with 3 second intervals). The samples were centrifuged at 
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14,000 rpm for 10 minutes at 4oC and the lysate was passed through a 0.2 µm filter to 
remove any additional cell lysate. Four mls of nickel NTA resin slurry (Qiagen) was 
added to a column. The column was equilibrated with 30 mls of running buffer 
(sonication buffer + 1 % (v/v) Tween). The filtered lysate was passed through the 
column once and the flow-through collected. The column was washed with 30 mls of 
running buffer to remove any non-specifically binding proteins. The recombinant 
antibody fragment was eluted with 20 mls of 100 mM sodium acetate solution, pH 4.4. 
The eluted antibody fragment was collected in 1.5 ml centrifugation tubes (final volume 
500 µl in each tube) containing 50 µl 10 x PBS (filtered through a 0.2 µm filter) and 50 
µl 100 mM NaOH. 
 
2.7.3 Immunoblot analysis of protein purification 
 
An Immunodot analysis was performed on each eluted fraction. A fraction volume of 
2.5 µl was spotted onto Whatmann chromatography paper. The blot was blocked with 3 
% (w/v) BSA for 1 hour at room temperature. The appropriate enzyme-labelled 
secondary antibody was added to the blot for 1 hour at room temperature. After washing 
the blot (3 x PBS Tween and 3 x PBS) the liquid substrate was added and each signal 
spot that developed signified the presence of the eluted recombinant antibody. These 
fractions were pooled together and added to a spin column with a 5000 Dalton MWCO 
(Vivaspin, Sartorious). This was centrifuged at 4,000 rpm at 4oC until the sample was 
concentrated to a volume of 500 µl. 5 ml of filtered PBS was added to the column. This 
was stored overnight on ice overnight at 4oC. The following day the sample was 
centrifuged at 4,000 rpm at 4oC until the sample was concentrated to 500 µl aliquot. The 
concentration of protein was calculated on the nanodrop and a SDS-PAGE and Western 
blot performed. The recombinant antibody was stored in 20 µl aliquots at -20oC until 
required.  
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2.7.4 Sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) 
 
 
SDS-PAGE analysis was used to assess protein purity and to determine the apparent 
molecular mass of proteins.  Protein electrophoresis was performed using an Atto dual 
minislab AE-6450 gels under reducing conditions, by the method previously described 
by Laemmli (1970). Samples for analysis were diluted with the sample loading dye (4:1, 
sample: buffer) and boiled for 10 mins. The sample (20µl) was added to the gel and 
electrophoresed alongside appropriate molecular weight markers. Prestained molecular 
weights were also electrophoresed when the gels were being prepared for western blot 
analysis (See Section 2.7.4). Initially the gels were electrophoresed at 15mA per plate 
until the samples migrated through the stacking gel and electrophoresed at 30mA per 
plate until the sample had migrated to the end of the gel. SDS-PAGE gels were stained 
for 2 hours using Coomassie blue staining solution to allow visualisation of the protein 
bands, and then destained overnight in destaining solution (described in Table 2.7.3.1). 
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Table 2.7.4.1 Composition of buffers required for SDS- PAGE and Western blotting. 
Buffer Composition 
30 % acylamide 29.2 g acrylamide 
0.8 g bis – acrylamide 
100mls dH2O 
Store at 4 oC 
4x Separating buffer 75 ml 2M Tris – HCl, pH 8.8 
4 ml 10% (w/v) SDS  
21 ml dH2O  
Store at 4oC 
4x Stacking buffer 50 ml 1M Tris – HCl, pH 6.8 
4 ml 10 % (w/v) SDS 
46 ml dH2O 
Store at 4oC 
Ammonium persulphate 50 mg ammonium persulphate 
500 µl dH2O 
Make fresh before each use 
10 X Electrophoresis buffer 30 g tris base (25mM) 
14.4 g glycine (129mM) 
10 g SDS  
Make up to 1L with dH2O 
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Sample buffer 0.6 ml 1M Tris – HCl, pH 6.8 
5 ml 50% (v/v) glycerol 
2 ml 10% (w/v) SDS 
0.5 ml 2- mercaptoethanol 
1 ml 1% (w/v) bromophenol blue 
0.9 ml dH2O 
Store at -20oC 
Coomassie blue staining solution 500 mg Coomassie brilliant blue R-250  
125 ml methanol 
50 ml acetic acid 
Make up to 500ml with dH2O 
Destaining solution 150 ml methanol 
50 ml acetic acid 
300 ml dH2O 
Transfer buffer 50 ml 10X Electrophoresis buffer 
100 ml methanol 
350 ml dH2O 
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2.7.4.2 Composition of SDS –PAGE Gels 
Separating Gel 10ml / plate (15% (v/v)) 2.5 ml 4x separating buffer 
5.0 ml 30 % (v/v) acrylamide 
2.5 ml dH2O 
150 µl ammonium persulphate 
10 µl TEMED 
Stacking Gel 5 ml / plate (5% (v/v)) 1.25 ml 4x stacking buffer 
833 µl 30 % (v/v) acrylamide 
2.877 ml dH2O 
50 µl ammonium persulphate 
10 µl TEMED 
 
 
2.7.5 Western blot analysis 
 
Proteins were transferred from SDS-PAGE gels to nitrocellulose membrane by 
electophoretic means using a BioRad semi-dry blotter. The SDS-PAGE gel, 1 piece of 
nitrocellulose and 6 pieces of Whatman chromatography paper were soaked in transfer 
buffer for 15 mins. The proteins on the gel were transferred to the membrane for 20 
mins at 15V.   The membrane was blocked with 5% (w/v) MPBST overnight at 4°C. 
The blocked membrane was then washed extensively three times with PBS and three 
times with PBST. An appropriate enzyme-labelled secondary antibody (see section 
2.1.4), diluted to 1/2000, was added and the blot incubated and washed as before. Color 
development was then observed following addition of the appropriate substrate, and the 
reaction stopped by addition of 50mM EDTA.  
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2.8 ELISA analyses 
 
2.8.1 Direct Enzyme-linked immunosorbent assay (ELISA).  
 
Direct ELISA was performed according to standard ELISA protocol for recombinant 
antibodies (Barbas et al., 2001) with the following modifications: the scFv and FAb 
were detected using anti-HIS-HRP (Qiagen) and anti-HA-HRP secondary antibodies, 
respectively. Specific antibody binding was detected using o-phenylenediamine (o-PD) 
ELISA substrate. Absorbances were read after 30 min at 450nm. This method was used 
to optimise antibody and coating antigen concentrations in a checkerboard ELISA 
format.  
 
2.8.2 Competition Enzyme-linked immunosorbent assay (ELISA). 
 
Competition ELISAs were performed separately for each antibody construct under 
conditions determined by direct ELISAs: microtitre plate wells were coated with 
100µl/well drug-protein conjugate (2 µg/ml in PBS), overnight at 4oC. These plates 
were then washed three times with PBS and PBST and blocked with 300µl/well PBS/M 
(PBS/5% (w/v) milk protein) for 1h at 37oC. 50 µL scFv or FAb were then added to 
each well in the presence of serially-diluted (PBS/2% (w/v) milk marvel) concentrations 
of free analyte (50µl) and incubated at 37oC for 1hour. Plates were then washed 10 
times with distilled water and antibody binding detected, as described for direct ELISA.  
 
2.9 Biacore assay conditions 
 
Analysis was performed using Biacore 3000 instrument and data analysis was 
performed using BIAevaluation 3.0 (BIAcore, St Albans, Hertfordmidshire, UK). 
Research grade CM5 sensor chips were employed in all analyses with Hepes-buffered 
saline, pH 7.0, (HBS) (10mM Hepes, 150 mM NaCl, 3.4 M EDTA and 0.025% (v/v) 
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Tween 20) as running buffer. HBS was 0.2µm filtered, degassed and syringe filtered 
(0.45µm) immediately before use.  
 
2.9.1 Preconcentration Studies 
 
Immobilisation of hapten – conjugate to the sensor chip surface was optimised via a 
preconcentration step. This allowed the optimal pH conditions to be identified. The 
carboxymethylated suface of the chip is negatively charged at pH values above pH 3. 
The desired pH conditions for electrostatic immobilisation are such that result in the 
ligand possessing an overall positive charge. Therefore, a buffer with a pH lower than 
the pI of ligand is required. Sodium acetate buffer is used in preconcentration studies 
due to its low ionic strength thus maximising ionic interactions between ligand and chip 
surface. 100 µg/ml solutions of hapten – conjugate were made up in 10 mM sodium 
acetate at a range of varying pHs in the range 3.8 – 5.0. These were passed over the 
underivatised chip surface and the pH which gave the highest degree of electrostatic 
interaction was chosen as the optimal pH for immobilisations. 
 
2.9.2 Immobilisation of hapten - conjugate on sensor chip surface. 
 
M3G-OVA conjugate immobilization was carried out according to standard amine 
coupling chemistry.  
 
2.9.3 Immobilisation of Hapten directly on sensor surface. 
 
Direct immobilisation of M3G on the sensor chip surface was performed as follows: the 
carboxylmethylated dextran surface of the sensor chip was activated by mixing equal 
volumes of  0.1M NHS (N-hydroxy-succinimide) and 0.4M EDC (N-ethyl-N-(dimethyl- 
periplasaminopropyl) carbodiimide hydrochloride) and injecting the mixture over the 
sensor chip surface for 8 min at a flow-rate of 5 µl /min. The chip surface was then 
128 
capped with 1M ethylene diamine (pH 8.5) for 10 min (flow-rate 5 µl /min). M3G 
(100µg/ml diluted in EDC/NHS) was incubated at room temperature for 3 min., before 
injection over the chip surface for 20 min at a flow-rate of 10 µl /min. To complete the 
reaction, unreacted sites on the chip were capped with 1M ethanolamine. The surface 
was then regenerated 5 times with 40 mM NaOH prior to use.  
 
 
2.9.4 Non – specific binding studies 
 
Antibody samples were passed over proteins i.e. BSA or OVA immobilised on the 
sensor chip surface, in order to rule out non – specific binding to the conjugate in 
question and to ensure recognition was to the hapten and not the carrier or the 
conjugation linkage chemistry. 
 
2.9.5 Inhibition studies  
 
To prepare samples for Biacore sensor analysis, antibodies were diluted in HBS 
buffer (pH 7.4). Concentration standards of M3G (ranging from 318 to 1.25 x 106pg/ml) 
were then prepared in HBS buffer. When using the M3G-coated sensor surfaces, each 
concentration standard was incubated separately with an equal volume of a 1/60 dilution 
of the Fab (1/120 final dilution) and a 1/25 dilution of the scFv (1/50 final dilution) for 
30 min at room temperature before being passed over the chip at a flow-rate of 5 µl/min 
to examine antibody binding profiles. Preparations of the Fab were diluted to 1/20 and 
the scFv to 1/8 for use on the M3G-OVA immobilized chip. Final antibody 
concentrations were pre-determined to provide a signal of approximately 300 RU on 
each respective surface, in the absence of competing antigen. M3G and M3G-OVA-chip 
surfaces were both fully regenerated using a single 15 second pulse of 40mM NaOH at 
a flow-rate of 20 µl /min. A control sample containing no M3G was included in each 
run to provide maximal signal for R/R0 calculations. Analyses at each free M3G 
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concentration were carried out in triplicate on 3 separate occasions for assay variability 
studies. 
 
2.9.6 Kinetic analysis of the binding of the anti – M3G scFv and anti – M3G Fab 
using Biacore. 
 
Biacore analysis was performed to examine the binding kinetics of both scFv and Fab. 
Analyses were performed using a directly coupled M3G chip surface which generated a 
maximum resonance signal of 100RU when saturated with either scFv or Fab antibody 
fragments. Rmax of approximately 100RU, is designated by Biacore as optimal for 
kinetic studies. This provided an appropriate surface for comparison studies and was 
within the parameters recommended by Biacore for kinetic analysis. Individual samples 
consisting of 90µl of either IMAC-purified scFv or Fab were passed over the chip 
surface at a flowrate of 30µl/min. Following analysis, bound antibody fragments were 
eluted using 40mM NaOH until the resonance signal returned to baseline value. The 
sensogram obtained from injecting non-specific antibody fragment in PBS plus 25mM 
imidazole diluted in HBS (mimicking a nickel-purified antibody buffer preparation) was 
used to normalise the sensograms obtained from both Fab and scFv binding to M3G. 
The dilutions for both antibody fragments used were as follows; 1/10, 1/20, 1/40, 1/80, 
1/160, 1/320 in HBS. At each concentration reference surface readings were subtracted 
and the data corrected automatically for baseline and then analysed using 
BIAevaluation. Apparent Kd constants were derived as those that were consistent over 
the analyte concentration ranges. Mass transfer limitations were determined to be 
negligible  
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2.10 Multimerisation Analysis 
 
2.10.1 HPLC Assay conditions  
 
Size exclusion HPLC analysis was carried out using the Phenomenex, BioSep – SEC – 
S – 3000, 300nm x 7.80nm. All assays were performed at a flowrate of 0.5 ml/min 
using an injection volume of 50 µl. The mobile phase was PBS (pH 7.4). All samples 
were examined at neat dilutions in PBS. Protein molecular weight standards for HPLC 
(Sigma) included bovine serum albumin (BSA), 66KDa; chicken egg albumin, 45KDa; 
crbonic anhydrase, 25KDa; and beta lactalbumin, 14.5 KDa. 
 
2.10.2 Native polyacrylamide gel electrophoresis conditions 
 
Antibody multimerisation was also examined by native polyacrylamide gel 
electrophoresis (Laemmli, 1970). In non-denaturing gel electrophoresis the molecular 
weight standards used were the same as those described for use with HPLC. 
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2.11 Kunkle-style mutagenesis of the anti-M3G fab fragment. 
 
The mutagenesis strategy used is outlined in Kunkle et al., (1990). Amendments to the 
procedure are outlined in sections 2.11.3.1 – 2.11.3.3.  
 
2.11.1 Primer design. 
 
M3G CDRH1-Fstop 
ACTGGCTACACATTCAGTTAATAATAATAATAATGGGTAAAGCAGAGGCCT 
 
M3G CDRH1-Rstop 
AGGCCTCTGCTTTACCCAATTATTATTATTATTACTGAATGTGTAGCCAGT 
 
M3G CDRL2-Fstop 
TTCACTGGTCTAATAGGTTAATAATAATAATAATAATAAGGTGTTCCTGCCA
GATTC 
 
M3G CDRL2-Rstop 
GAATCTGGCAGGAACACCATTATTATTATTATTATTATTACCTATTAGACCA
GTGAA 
 
M3G CDRL3-Fstop 
GAGGCAATATATTTCTGTTAATAATAATAATAATAATAATAATAATTCGGTG
GAGGAACCAAA  
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M3G CDRL3-Rstop 
TTTGGTTCCTCCACCGAATTATTATTATTATTATTATTATTATTAACAGAAAT
ATATTGCCTC 
 
M3G CDRH1-Fmut 
ACTGGCTACACATTCAGTNNSNNSNNSNNSNNSTGGGTAAAGCAGAGGCCT 
 
M3G CDRH1-Rmut 
AGGCCTCTGCTTTACCCASNNSNNSNNSNNSNNACTGAATGTGTAGCCAGT 
 
M3G CDRL2-Fmut 
TTCACTGGTCTAATAGGTNNSNNSNNSNNSNNSGCTCCAGGTGTTCCTGCC 
 
M3G CDRL2-Fmut 
GGTCTAATAGGTGGTACCNNSNNSNNSNNSNNSGGTGTTCCTGCCAGATTC 
 
M3G CDRL2-Rmut 
GAATCTGGCAGGAACACCSNNSNNSNNSNNSNNGGTACCACCTATTAGACC 
 
M3G CDRL2-Rmut 
GGCAGGAACACCTGGAGCSNNSNNSNNSNNSNNACCTATTAGACCAGTGAA 
 
M3G CDRL3-Fmut 
TTCTGTCTTCTATGGTACNNSNNSNNSNNSNNSTTCGGTGGAGGAACCAAA 
 
M3G CDRL3-Fmut 
GAGGCAATATATTTCTGTNNSNNSNNSNNSNNSAACCATTTGGTGTTCGGT 
 
M3G CDRL3-Rmut 
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TTTGGTTCCTCCACCGAASNNSNNSNNSNNSNNGTACCATAGAAGACAGAA 
 
M3G CDRL3-Rmut 
ACCGAACACCAAATGGTTSNNSNNSNNSNNSNNACAGAAATATATTGCCTC  
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2.11.2 Preparation of dU-ssDNA 
 
A single colony of CJ236 E. coli, containing the anti-M3G fab plasmid, was inoculated 
into 5ml 2XTY media (100µg/ml carbenicillin and 10µg/ml chloroamphenicol). The 
culture was grown overnight at 37oC while shaking at 220rpm. The overnight culture 
was seeded at a 1/100 dilution into 2 ml 2XTY (100µg/ml carbenicillin and 10µg/ml 
chloroamphenicol) and grown at 37oC while shaking at 120rpm until OD 0.5nm. When 
the OD had reached 0.5, 250µl of M13KO7 helper phage and 0.25µg/ml uridine was 
added and the volume was increased to 100ml. The 100ml culture was grown for 1 hour 
before addition of 50µg/ml kanamycin. The infected culture was grown overnight at 
37oC and 120rpm. The culture was centrifuged at 12,000rpm, 4oC for 15min. The 
supernatant was decanted into fresh tubes and the phage was PEG/NaCl precipitated on 
ice for 45min. The suspension was centrifuged at 12,000rpm, 4oC for 15min with the 
brake turned off. The supernatant was discarded and the phage pellet was resuspended 
in 2 ml sterile filtered PBS. All insoluble cell debris and endogenous DNA were 
removed by an additional 12,000rpm centrifugation step here. Single stranded DNA was 
purified from the phage prep using the Qiagen Spin M13 kit. The dU-ssDNA was 
quantified on the nanodrop.  
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2.11.3 In-vitro synthesis of heterduplex DNA 
 
2.11.3.1 Phosphorylation of the oligonucleotide 
 
Table 2.11.3.1.1 Components of phosphorylation reaction 
Component Concentration  Volume (µ l) 
Oligonucleotide 0.6µg 1 
10X buffer 1X 2 
ATP  10 mM 2 
T4 polynucleotide kinase 20 units 2 
H2O Up to 20 µl x 
 
 
Table 2.11.3.2 Reaction conditions 
Temperature Time (minutes) 
37oC 30   
65oC 10 
 
2.11.3.2 Annealing the oligonucleotide to the template dU-ssDNA 
 
Table 2.11.3.2.1Components of annealing oligonucleotide/template reaction 
Component Concentration Volume (µ l) 
Oligonucleotide 0.6µg 1 
10X buffer 1X 1 
dU-ssDNA 2 µg x 
H2O Up to 10 µl y 
 
Table 2.11.3.2.2 Reaction conditions 
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Temperature Time (minutes) 
90oC  10   
Slowly cool to 20oC 
20oC 5 
 
 
2.11.3.3 Enzymatic synthesis of covalently closed circular DNA (CCC-DNA) 
 
The following is added to the annealed oligonucleotide/template reaction mix. 
 
Table 2.11.3.3.1 Components required for the enzymatic synthesis of CCC-DNA 
Component Concentration Volume (µ l) 
ATP 10mM 1 
dNTP 10mM 5 
DTT 5 mM  1 
T4 DNA ligase 30 units 3 
T7 DNA polymerase 30 units 3 
 
Table 2.11.3.3.2 Reaction conditions 
Temperature Time (minutes) 
4 oC 5 
25oC 5 
37oC 240 
 
 
2.11.3.4 Affinity purification and de-salting the CCC-DNA 
 
137 
This was carried out using the Qiagen Qiaquick nucleotide removal kit manufacturer’s 
manual. 
 
2.12 Sequence analysis of genes encoding specific antibody fragments 
 
A single colony was grown overnight in LB media. The expression vector, containing 
gene of interest, was isolated and purified using Wizard Plus SV Miniprep kit, according 
to the manufacturers instructions. Plasmid DNA was sequenced by Qiagen. Raw data, 
forward and reverse sequences, was analysed using CHROMAS sequence analyser 
software. The DNA sequences were exported and analysed using a variety of web-based 
bioinformatics tools (see table 2.12.1) 
 
Table 2.12.1 Source of web based bioinformatics tools used for sequence analysis of 
antibody fragments. 
Tool Source 
CHROMAS www.technelysium.com.au/chromas.html 
Translate tool www.expasy.org 
BLAST www.expasy.org 
Swiss-model http://swissmodel.expasy.org 
Multialin http://prodes.toulouse.inra.fr/multalin/multalin.html 
Kabat Rules www.//acrmwww.biochem.ucl.ac.uk/abs 
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Chapter 3 
3.0 Generation of anti-amphetamine 
recombinant antibody fragments and their 
characterisation 
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3.1 Introduction 
 
3.1.1 Factors influencing antibody phage display 
 
A detailed description of the individual vector maps used in this work (pAK vector 
series and the pComb3x vector series) is given in section 1.9.3. Each component of the 
phagemid vector needs to be evaluated fully prior to the construction of an antibody 
phage display library. Each phagemid vector varies in a number of key characteristics, 
e.g. a different combination of enzyme tags, variance in display valency, use of pIII or 
pVIII display protein. Each of these has a significant influence on the panning approach 
employed and the final outcome of the experiment, although the target and recombinant 
antibody format (scFv or Fab) used is also an influency factor. While the scFv library 
construction and panning (section 1.9.5) is strongly facilitated by the smaller size and 
composition of a single polypeptide, Fab libraries are not afforded these fundamental 
advantages.  
 
The ideal antibody phage display system will result in the production and purification of 
an antibody fragment that is, at least, comparable to IgG in terms of stability, affinity 
and compatibility with current diagnostic systems (Hust and Dubel, 2004). Small 
antibody fragments such as Fv or scFv are easily produced and the yield is often higher 
than that achieved in the production of Fab fragments (Pluckthun, 1991). However, 
scFv fragments can cause problems due to the formation of multimers (examined 
extensively in chapter four) while Fab fragments are stabilized by the presence of a 
disulphide bond between the heavy chain and the light chain (Hust and Dubel, 2004). 
One significant advantage of using the Fab antibody format in diagnostics is its superior 
stability compared to the far less rigid scFv fragment (Bradbury et al., 2003) where the 
kinetic stabilization of a linker region is relied upon (Glockshuber et al., 1990).  In 
addition, the presence of a complete constant heavy chain in the Fab makes it 
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compatible for use with almost all secondary antibodies already generated and hence it 
can be used in most current detection platforms available.  
 
Despite different opinions regarding the optimal recombinant antibody format for 
diagnostic and therapeutic applications the phagemid vector used is the one parameter 
that must be carefully considered. The phage display vector / vector series must provide 
robustness, vector stability, tight control of protein-gene III fusion, easy-to-use primer 
sets, a protein assembly strategy, enzyme restriction sites for directional cloning and 
contingent for soluble protein expression (Krebber et al., 1997).  
 
3.1.2 Phagemid vectors 
 
Phage display vectors can be classified according to three characteristics (Barbas et al., 
2001). 
1. The coat protein selected for display (pIII or pVIII)? 
The two proteins involved in display of proteins on the phage particle are pIII (minor 
capsid protein) and pVIII (major capsid protein). pIII is the most commonly used capsid 
protein for phage display and while it only allows about 5 molecules to be displayed per 
single phage particle, it does package along with large fusion proteins very efficiently in 
comparison to pVIII.  
2. The display of the recombinant proteins on all or only some of the coat proteins? 
The pComb3x vector series used in this work is classified as a Type 3 + 3 vector (Smith 
and Petrenko, 1997). These phage typically display up to 5 copies of wild type pIII on 
their surface along with the fusion protein pIII from the phagemid, creating a 
competitive environment for incorporation into the virion during assembly. This process 
results in a low valency system, which favours selection of high affinity fusion proteins. 
Phage display vectors such as type 3 and type 8 + 8 exploit their high valency display 
and are used in the screening of low affinity target experiments such as anti-
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carbohydrate antibodies (Scott and Smith, 1990). These phage can display up to 200 
copies of the foreign peptide (Yau et al., 2003). 
3. The recombinant gene is cloned directly into the phage genome or on a separate 
phagemid vector? 
The pComb3x vector series does not involve direct cloning into the phage genome, 
instead it contains a second plasmid, which also encodes a phage origin of replication. 
Two – gene display systems provide the opportunity to modulate the valency of the 
displayed fusion protein, (Barbas et al., 2001), a key factor in antibody display for 
selection of the high affinity binders. This point is examined more extensively in 
chapter four.  
 
3.1.2.1 pAK vectors; 100 and 400 
 
This phagemid vector series (section 1.9.3), unlike the pComb series, consists of 6 
different vectors and includes separate vectors for display and soluble expression. The 
pAK 100 vector is used for display of foreign peptides and is classified as a 
monocistronic vector as it encodes a single lacZ promoter and also utilizes a single 
leader sequence (pelB). The pAK 400 vector encodes an amber codon, which facilitates 
switching between display and soluble expression and a c-myc tag for detection, but it 
does not encode a convenient method for purification. However, the pAK 400 vector 
excludes the gene III and encodes a stronger Shine Dalgarno sequence (SDT7g10) and a 
hexahistidine tag to allow use of IMAC purification methods and antibody detection.  
3.1.2.2 pComb3x  
 
Section 1.9.3 details this series schematically, however, there are some key points that 
require more in-depth discussion. The pComb vector series was modified so that it 
contains a single lacZ promoter and two leader sequences (OmpA and pelB). This 
bicistronic feature results in the translation of a both light and heavy chains of the 
antibody fragment from a single mRNA (Kirsch et al., 2005). The importance of the 
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bicistronic vector is most evident in Fab fragment expression as it ensures that an equal 
ratio of heavy chain to light chain is achieved. 
The human constant regions are sourced from the pComb3xTT vector, as mentioned in 
section 1.9.3. This vector contains a human anti-tetanus toxin Fab insert from which the 
human kappa light chain and human constant heavy chain can be amplified. In chapter 
four, where the anti-M3G Fab required the use of a constant lambda light chain, the 
pComb3xLamda-containing vector is used instead. This vector does not contain a 
functional antibody fragment insert. Instead it has a nonsense antibody with a human 
lambda constant region. 
 
3.2 Rationale for the construction of anti-amphetamine recombinant antibody 
fragments from an IgG genetic template. 
 
A number of groups have reported the construction and expression of small recombinant 
antibody fragments from the genetic backbone of target specific whole IgG. The fact 
that many anti-hapten antibodies rely primarily on the cavity shaped paratopes for 
antigen contact, a notion that is further developed in chapter five, implies that the 
rigidity and conservation of structure through constant chain scaffolding are vital to 
maintaining the specific anti-hapten antibody affinity. This leads one to question if an 
anti-hapten monoclonal antibody can be successfully converted into a smaller 
recombinant antibody fragment and if the cavity shaped antigen-binding site remains 
intact in the scFv and Fab structural formats.  
In the study presented here, the effects of converting an anti-amphetamine IgG to, first a 
Fab and then, a scFv fragment were examined. The variable regions of the previously 
described IgG (Fanning, 2001) were re-engineered for the expression of these small 
recombinant fragments. The characteristics of the resulting Fab fragment were 
compared to the IgG using ELISA and Biacore. The scFv expression proved 
unsuccessful, holding true to the theoretical importance of structural scaffolding to the 
affinity of the IgG.  
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3.3 Results and Discussion 
 
3.3.1 Construction of an anti-amphetamine Fab fragment from a monoclonal anti-
amphetamine antibody-secreting hybridoma 
 
3.3.1.1 Construction of chimeric anti-amphetamine Fab. 
 
The anti-amphetamine construct was constructed using the anti-amphetamine secreting 
hybridoma, 4EP18E (Fanning, 2002). Variable heavy and light chains were amplified 
from the freshly prepared cDNA, using the primers listed previously in section 2.4.8. 
The human constant heavy and constant kappa domains were amplified from the 
pComb3XTT vector. The MgCl2 concentration was optimized for each PCR reaction, 
keeping all other components constant. The concentrations varied from 1.5mM-6mM. 
The efficiency was assessed by running the PCR products side by side on a 1% (w/v) 
agarose gel and visually inspecting them. The VH and VL fragment ratio for the final 
SOE PCR was optimized by varying the ratio of each fragment while keeping all other 
components constant. This extensive optimization resulted in efficient amplification of 
the required bands with no non-specific bands being generated (Figure 3.3.1.1.1). It was 
necessary to amplify all chains VL, VH, CL and CH, separately, initially. Appropriate 
chains are then overlapped leading to the final Fab fragment construction. 
 
 
 
 
 
 
 
144 
 
Figure 3.3.1.1.1 Variable light and variable heavy chain amplifications run on a 1% 
(w/v) agarose gel alongside an appropriate MWM; 1kb plus ladder. The mouse variable 
regions products are about 400bp in size. The correctly sized DNA bands are excised, 
purified and stored until required for the final Fab light and heavy chain splice by 
overlap extension (SOE). 
 
Figure 3.3.1.1.2 Constant light and constant heavy chains are amplified from 
pComb3XTT, which encodes a cloned human Fab template, run on a 1 % (w/v) agarose 
gel alongside a 1kb plus ladder. The chimeric light and heavy chain (shown here) 
products are about 850bp in size. 
 
When all individual fragments are amplified each of the final heavy and light chains can 
be constructed using the appropriate overlapping primers. Each of the single fragment 
amplifications yielded approximately 200 ng/µl DNA when analysed at 260nm. Two 
SOE PCR’s were carried out separately, the first for the construction of the chimeric 
light chain and the second for the chimeric heavy chain. 
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Figure 3.3.1.1.3 Final SOE PCR, combining the light chain and heavy chain of the anti-
amphetamine antibodies yielding a 1600bp band. Samples were run on a 1% (w/v) 
agarose gel. 
 
The pComb3x vector and the newly constructed anti-amphetamine Fab were digested 
with Sfi 1 and run on a 1% (w/v) agarose gel for assessment. The large-scale PCR 
reaction products were gel-extracted and purified via electro-elution, as a means of 
improving the efficiency of the gel purification system.  
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3.3.1.2 Bio-panning the anti-amphetamine Fab library  
 
An anti-amphetamine monoclonal antibody-secreting clone was used as the genetic 
resource for this library construction and as a result the panning strategy is slightly 
different in comparison to that used with a large diverse immune or mutated library 
(chapter five and chapter six). The panning was designed so that it was just stringent 
enough to pull out the genotypically similar antibody to the original monoclonal but it 
did not need to be excessive. It was decided that two rounds of panning would be 
sufficient and following these a polyclonal phage ELISA was carried out. Low-level 
enrichment of positive signal from each round of panning was observed in tandem with 
good input and output titres from pan 0 to pan 2 (Table 3.3.1.2.1). 
 
Table 3.3.1.2.1 Input and output titres for all rounds of panning for anti-amphetamine 
recombinant Fab library. 
 
 Pan 0 Pan 1 Pan 2 
Input - 6 x 1011 1.8 x 12 
Output 6.3 x 107 4 x 104 1 x 105 
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3.3.1.3 Individual clone analysis 
 
While the polyclonal phage ELISA confirmed the presence of amphetamine-specific 
phage, an “insert check” pick PCR was carried with random colonies picked from the 
round 2 output titre plates. This allowed conformation and visualization of the Fab 
insert. The same clones were grown and digested with the high frequency cutting 
enzyme Alu 1 to investigate the presence of any mutations. This digest was run on a 3% 
(w/v) agarose gel in order to achieve good separation of bands (Figure 3.3.1.3.1). 
 
Figure 3.3.1.3.1 Single clones from round 2 panning output titre plates, were randomly 
chosen and digested with Alu 1 to determine the mutation rate in the library.  It is clear 
from the gel picture that the digest pattern varies widely between each clone. This is 
indicative of a high number of mutations. This may be as a result of ligation of more 
than one specific light chain.  
 
Ten colonies were picked, grown and induced with IPTG. The lysates were prepared as 
described in chapter 2. The 10 clones were screened in ELISA (Figure 3.3.1.3.2).  
148 
 
 
Figure 3.3.1.3.2 ELISA analysis carried out on 10 anti-amphetamine clone lysate 
preparations. 1 µg/ml amp-BSA was coated on the plate and binding was detected with 
an anti-HA-HRP secondary antibody. Data expressed as Abs (Absorbance). Two clones 
(6 and 8) demonstrated expression of anti-amphetamine Fab, with absorbance values 5 
times over background absorbance.  
 
Following identification of positive clones, no. 6 and no. 8 a competitive ELISA was 
carried out on the lysate preparations using a free drug range of 5000 - 1.6 ng/ml 
(Figure 3.3.1.3.3). This range allows identification of any clone expressing anti-
amphetamine Fab capable of being displaced by free amphetamine. 
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Figure 3.3.1.3.3 ELISA lysate-inhibition assay performed on Amphetamine-BSA-
coated wells comparing the binding response of clone no. 6 (blue) and clone no. 8 
(pink) versus free drug in the range of 1.6 - 5000 ng/ml. Data is expressed as A/Ao (i.e. 
signal at different free analyte concentrations are expressed as a proportion of signal in 
the presence of no competing analyte).  
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3.3.1.4 Characterisation of positive clone 
 
The Fab from clone no. 8 was chosen for further characterisation and development due 
to its significantly better performance in the inhibition ELISA compared to clone no. 6. 
It was grown up on a larger scale (500 ml culture volume) and the anti-amphetamine 
Fab was purified using the IMAC system. The appropriate dilution of the Fab 
preparation for use in the inhibition ELISA was determined. The pComb3X vector adds 
a heamaglutanin (HA) tag to the antibody fragment which facilitated screening as the 
anti-HA secondary antibody is highly sensitive. However, it is also very expensive and 
so an alternative secondary antibody was investigated. The anti-amphetamine Fab is a 
Cκ construct. This permitted the use of an anti-human-kappa secondary antibody for 
screening which is less expensive. The activity of both secondary antibodies was 
compared and no significant difference between the two was observed. Hence, all anti-
amphetamine Fab ELISA’s were carried out with the anti-human-kappa antibody. The 
anti-amphetamine Fab titre showed that the ideal dilution of the Fab for use in inhibition 
analysis was 1 in 2000 of the purified antibody preparation. All assay conditions were 
optimized (data not shown) prior to the development of the inhibition ELISA (Figure 
3.3.1.4.1). The ELISA was carried out, as outlined in section 2.8.9, with an amp-BSA 
coating concentration of 1 µg/ml. The anti-human-kappa secondary antibody was 
alkaline phosphatase-labeled and the substrate used to detect its presence was BCIP. 
The standard deviations were between 8% and 15.5%, which is the acceptable standard 
for many of the points.  
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Figure 3.3.1.4.1 ELISA inhibition assay performed on amphetamine-BSA-coated wells 
comparing Fab binding response versus competing free amphetamine concentrations. 
Data is expressed as A/Ao (i.e. signals at different free analyte concentrations were 
expressed as a proportion of signal in the presence of no competing analyte). All 
analyse were carried out in triplicate on three separate occasions. Standard deviations at 
all points examined were between 8 -15% of total signal. 
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3.3.1.5 Biacore analysis  
 
A Biacore™ competition assay was developed using an amphetamine-BSA-coated 
CM5 chip surface to determine the range of free amphetamine detection for the Fab. 
The same range of free drug, as used with the ELISA, was employed in all Biacore 
competition assays. The Fab displayed negligible non-specific binding to the BSA-
coated chip surface negating the need for pre-incubation steps with BSA.  
 
 
Figure 3.3.1.5.1 BiacoreTM inhibition assays performed on an amphetamine-BSA-
coated CM5 chip surface. Data was expressed as R/R0 (i.e. signal at different free 
analyte concentrations are expressed as a proportion of signal in the presence of no 
competing analyte). All analyses were performed in triplicate on three separate 
occasions. Standard deviations at all points examined were less than 9% of signal, with 
a mean deviation of 3 % of signal.  
 
153 
The linear range of the Fab on ELISA was shown to be 1250 - 39 ng/ml, with an IC50 
value of approximately 200ng/ml (Figure 3.3.1.5.1). The Fab construct was compared to 
the parent monoclonal anti-amphetamine antibody in an inhibition assay format (Figure 
3.3.1.5.2). The monoclonal antibody, which has been previously described by Fanning 
(2001), demonstrated a similar linear range to that of the Fab and an IC50 of 
approximately 600 ng/ml. This data would indicate that the Fab is 2/3 fold more 
sensitive than the parent monoclonal.  
 
Figure 3.3.1.5.2 BiacoreTM inhibition assays performed on an amphetamine-BSA-
coated CM5 chip surface, comparing the binding response of the Fab (solid) and 
monoclonal antibody (dashed) versus competing free amphetamine concentration. Data 
was expressed as R/Ro (i.e. signal at different free analyte concentrations are expressed 
as a proportion of signal in the presence of no competing analyte). All analyses were 
performed in triplicate on three separate occasions. Standard deviation at all points 
examined was < 5% of signal.  
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3.3.1.6 Sequencing  
 
The next stage of this work investigated the conversion of the Fab fragment to a scFv 
fragment. If the Fab was sequenced it would negate the need for mixed primer sets for 
variable heavy and light chain amplification, as the variable regions could be 
identified.Plasmid DNA was sent to MWG Biotec (Germany), for sequencing. Comfort 
reads were performed in triplicate using the primers ompseq (5` AAG ACA GCT ATC 
GCG ATT GCA G 3`) and pelseq (5` ACC TAT TGC CTA CGG CAG CCG 3`). The 
resulting nucleic acid sequence was analysed using the Chromaslite 200 software 
package, and the Expasy nucleic acid translation tool 
(http://www.expasy.org/tools/dna.html). Once the amino acid sequence had been 
obtained, it was inputted into the IgBlast search engine at the National Institutes of 
Health, National Centre for Biotechnology Information website 
(http://www.ncbi.nlm.nih.gov/igblast/). The CDR’s were identified using Kabat rules.  
Figure 3.3.1.6.1 Sequence analysis of the anti-amphetamine Fab fragment. Heavy and 
light chains CDR’s are highlighted in red and framework regions are shown in black. 
3.3.2 Conversion of the anti-amphetamine Fab to an scFv fragment. 
Framework 1 CDRL1
V M T Q S P L S L P V S L G D Q A S I S C R S S Q S L V Y S N G N T Y L H W
 Framework 2     CDRL2 Framework 3
Y L Q K P G Q S P K L L I H K V S N R F S G V P D R F S G S G S G T D F T L
 CDRL3
K I I R V E A E D L G V Y F C S Q S T H V P F T F G S G T K L E L K …………
Framework 1 CDRH1
E V M L V E S G G G L V K P G G S L K L S C A A S G F T F S N Y A M S W V R Q T P D
Framework 2 CDRH2 Framework 3
 K R L E W V S S I T S G G S T Y Y P D S V K G R F T I S R D N A R N M L Y L Q M S S
 CDRH3
L R S E D T A M Y Y C T R E S H Y G R S Y D Y F D Y W G Q G T S V T V S S A S……….
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3.3.2.1 Construction of anti-amphetamine scFv  
 
It proved difficult to choose specific primers from the Krebber scFv primer set based on 
the Fab sequence obtained. However, after test reactions it was determined that light 
chain primers, LB5 and the LFmix, and the heavy chain mix primer set would be most 
suitable for the amplification of an scFv from the Fab template. A large non-specific 
smear was evident in the SOE PCR product after visualization on a 1% agarose gel. 
After a number of optimization strategies, DMSO was added to the reaction at varying 
concentrations. Figure 3.3.2.1.1 (a) and (b) illustrate the influence of selection of the 
optimal DMSO concentration followed by MgCl2 concentration optimisation. 
  (a)       (b) 
Figure 3.3.2.1.1 SOE PCR conditions were optimized through varying concentrations 
of DMSO and MgCl2. In gel picture (a), 100 ng/ml of each fragment, VH and VL, were 
included in the reaction. Reactions in lanes 1 - 4 contain no DMSO and varying 
concentrations of MgCl2; 1.5 - 4mM, respectively, lanes 5 - 8 contain 5% (v/v) DMSO 
with varying concentrations of MgCl2; 1.5 - 4mM, respectively. Gel picture (b) 
represents further optimization carried out on the same SOE PCR using 50 ng/ml of 
each fragment, VH and VL. All other components, including 5% (v/v) DMSO, were kept 
constant except MgCl2, lanes 1 - 4; 1.5mM - 4mM MgCl2, respectively. 
 
3.3.2.2 Bio-panning and analysis of clones 
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The anti-amphetamine scFv library size was determined to be 5.1 x 107, all library 
construction controls were included and examined prior to continuing to bio-panning. 
The panning strategy used here mimicked the strategy outlined in section 3.3.2 as a 
similar theory applies here. It is more of a conversion than a full-scale diverse library 
building. Therefore, an extensive panning strategy was not necessary. 
Following two rounds of solution phase panning, a polyclonal phage ELISA was carried 
out resulting in low signal from each round of panning. A monoclonal phage ELISA 
was carried out on the round 2 output colonies to confirm the presence of specific anti- 
amphetamine scFv-displaying clones (Figure 3.3.2.2.1 (a)).  Despite the low overall 
signal this result was indicative of a potentially positive anti-amphetamine scFv library, 
therefore, the library was cut, ligated into pAK 400 and transformed into Top 10 F’ for 
soluble expression and further analysis. A soluble expression monoclonal ELISA was 
carried out according to section 2.6.2. (Figure 3.3.2.2.1 (b)) 
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Figure 3.3.2.2.1 (a) Round 1 monoclonal phage ELISA results on 92 clones. Positive 
clones are those observed as having 2 times signal over the control signal. Binding was 
detected with an anti-M13-HRP labeled secondary antibody. (b) ELISA on soluble 
expressed scFv fragments. Positive clones are those observed as having 2 times signal 
over the control signal. Binding was detected with an anti-HA secondary antibody. 
Signal developed using TMB chromogenic substrate and monitored by optical density at 
450nm. Data is expressed as absorbance read.  
 
  
Four clones were taken on to the next stage, grown and expressed. Based on the 
outcome here (Figure 3.3.2.2.1(b)), clones ASR12, ASR121, ASR135, ASR138 were 
grown in 5ml cultures and expression was induced with IPTG. Competitive analysis 
revealed clone number ASR121 was displaced by concentrations of free amphetamine.   
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Figure 3.3.2.2.2 ELISA inhibition assay performed on amphetamine-BSA-coated wells 
comparing scFv ASR121 lysate binding response versus competing free amphetamine 
concentration (156 - 10000 ng/ml). Data is expressed as A/Ao. 
 
In direct ELISA the His purified antibody fragment provided a titre of 1/1000 (Figure 
3.3.2.2.3). However, uniform signal was observed across all concentrations of free 
amphetamine drug.  The assay was repeated on three separate occasions and the result 
remained negative. This presented a problem as the clones had demonstrated some 
inhibition, albeit low levels (Figure 3.3.2.2.3), when assayed in lysate rather than 
purified antibody fragments.  
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Figure 3.3.2.2.3 Direct ELISA of the His purified anti-amphetamine scFv fragment on 
an amphetamine-BSA coated surface. Signal developed using OPD chromogenic 
substrate and monitored by optical density at 450nm. Data is expressed as absorbance 
(nm). 
 
Upon further investigation, many publications have eluded to the importance of 
structure and rigidity of an anti-hapten scFv rather than the more traditional notion of 
the importance of the CDRH3 for high affinity binding. It is thought that the antibody-
hapten interaction may be primarily dependant on the binding cavity (Persson et al., 
2008) created by the rigidity of the structure.  
This theory holds true for the problems encountered in the conversion of an IgG / Fab to 
an scFv fragment in this work. The recombinant Fab fragment demonstrated binding 
characteristics comparable albeit at a 3 fold higher affinity to that of the parent 
monoclonal antibody. However, the parent clone was essentially screened and selected 
for its ability to bind free amphetamine in the presence of the large, rigid and 
monomeric binding structure that is characteristic of an IgG. The direct conversion of 
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this antibody to a Fab fragment was successful as the Fab structure retains a certain 
level of that rigidity and scaffolding via the remaining constant heavy and light chains.   
When the genetic material was converted and expressed as an scFv fragment and 
screened via phage display it is valid to assume that the loss of any scaffolding and the 
resulting expression of  “floppy” scFv fragment will result in a binding event starkly 
different to that of the monoclonal antibody and Fab antibody fragment and that the 
optimal light chain-heavy combination may not be present for this format. Figure 
3.3.2.2.2 indicates displacement of the unpurified lysate by free amphetamine. The 
purified antibody was titred successfully against amphetamine-BSA (Figure 3.3.2.2.3) 
however; any inhibition characteristics of the scFv were lost (Figure 3.3.2.2.2). 
In order to conclude that the unsuccessful production of an scFv fragment was not 
vector-dependant and explore each available resource in the lab the scFv was ligated 
into the pComb3x vector for a second round of panning. 
However, similar results were observed as with the pAK system and no soluble 
expressing scFv fragment was obtained. Two clones from each panning strategy were 
sent for sequencing and the light chains were compared to the parent Fab fragment. 
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3.5 Conclusion 
 
This research described the construction of a Fab and an scFv fragment from the cDNA 
of a positive anti-amphetamine-secreting clone previously described by Fanning (2002). 
This monoclonal anti-amphetamine antibody exhibited an IC 50 of 600ng/ml. It is vital 
to the success of the project that the most sensitive and specific antibody is ultimately 
applied to the biochip platform. It was thought that constructing a genetically derived 
antibody fragment from this parent clone would allow improvements in affinity. The 
Fab construct displayed a 3-fold improvement in affinity compared to the IgG with an 
IC 50 of 200ng/ml. Using the Fab as the genetic template, the scFv expression was 
unsuccessful. This is strongly conclusive of the structural rigidity dependence on the 
particular light-heavy chain combination of the IgG secreted from clone 4EP18E 
(Fanning, 2002). It is highly likely that in order to successfully express the anti-
amphetamine scFv fragment, in-vitro affinity maturation steps would be required. In 
light of the dependence on structural rigidity, light chain shuffling may permit the 
optimal combination required for success. Albeit a heavy workload, construction of an 
anti-amphetamine immune library would be recommended as the next course of action.  
 
162 
 
 
 
 
 
 
 
Chapter 4 
 
4.0 Anti-Morphine-3-Glucuronide 
Recombinant Antibody Engineering - the 
implications of using an scFv or a Fab 
fragment 
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4.1 Introduction 
 
4.1.1 Biosensors  
 
A biosensor is a device which couples a biological sensing element (tissue, enzyme, 
antibody, nucleic acid, cells or whole organisms) with a transducing mechanism 
(amperometric, potentiometric, calorimetric, acoustic or optical), as mentioned briefly in 
section 1.2.1.2. When biological molecules interact a change occurs in one or more of the 
parameters associated with the interaction event. These changes can be monitored and 
translated by the transducer. The response of the biological component is translated to a 
readable signal by the transducer (Rogers, 2000). A biosensor can be divided into 4 main 
categories electrochemical, optical, piezoelectric and thermal sensors (Rodriguez-Mozaz 
et al., 2005). Specificity and sensitivity are the primary properties of any proposed 
biosensor (Marazuela et al., 2002). The specificity depends entirely on the properties of 
the biological component as it must recognize the analyte in order for an interaction to 
take place. However, the sensitivity is dependant on a combination of both the nature of 
the biological component and the type of transducer in use for detection (Byfield et al., 
1994) 
 
4.1.2 Choosing the appropriate biosensor  
 
The continuing quest for a rapid, sensitive, selective, simple, rugged, and multi-analyte 
testing device is driving biosensor development research. Antibody-based biosensors are 
very versatile with antibodies which have been specifically selected for their affinity to 
the particular antigen or group of antigens of interest (Rogers, 2006). However, of equal 
importance, in the design of a biosensor for illicit drug detection, is the transducer used. 
Optical biosensors, such as surface plasmon resonance-based biosensors, are ideal as 
they allow direct ‘label-free’, ‘real-time’ detection of illicit drugs Several commercial 
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biosensors have used surface plasmon resonance as there detection method and have 
been successfully developed for application in small molecule analysis (Brennan et al., 
2003; Dillon et al., 2003; Redshaw et al., 2007).  
  
 
4.1.3 Surface Plasmon Resonance (SPR)  
 
The majority of SPR-based biosensors have been developed based on the Kretschmann 
configuration. The BiacoreTM was used in this work and so the principal of SPR will be 
explained using the BiacoreTM system as reference.  The most common geometric set up 
(the Kretschmann configuration) is shown in figure 4.1.3.1.  
 
SPR is an optical phenomena which occurs as a result of total internal reflection of light 
at a metal-liquid interface. The SPR system basically consists of a monochromatic and 
p-polarized light source, a glass prism, a thin metal (gold) film at the base of the prism 
and a photodetector. SPR is achieved when the incident p-polarised light is directed into 
a glass prism at a fixed wavelength and at an angle equal to or greater than the critical 
angle. Under these conditions total internal reflection occurs. A small amount of light 
leeches through the boundary between the glass prism (high refractive index) and the 
sample media (low refractive index) and an evanescent field is generated. As this 
evanescent wave moves further away from the interface it decays exponentially.  
 
In the case of BiacoreTM, where the interface between the lower refractive index and 
higher refractive index is coated with gold, the evanescent wave, which passes through 
the metal surface causes the plasmons to resonate. The resulting loss in energy from the 
incident light creates a dip in the intensity of the reflected light , the angle at which this 
occurs is known as the SPR angle (θ). The SPR angle is dependant on the properties of 
the metal film, the wavelength and polarization of the incident light and the refractive 
index of the media on each side of the metal film. In BiacoreTM these factors are kept 
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constant, therefore, the SPR signal can be used to measure the biological interactions 
occurring within the evanescent field. 
When the refractive index of the sample medium is changed, i.e. when a mass change 
on the surface occurs, within this evanescent field (200-300 nm), the angle of reflected 
light changes, (θ2), (Figure 4.1.3.2). The difference between these two angles is 
measured and interpolated as a sensorgram (Figure 4.1.3.3). 
 
Figure 4.1.3.1 The basic “Kretschmann configuration”. Under conditions of total 
internal reflection at a metal-coated surface, the p-polarized light is directed into a an 
area of high refractive index (glass prism) and an evanescent wave propagates into the 
medium of lower refractive index (sample buffer) and decays exponentially. 
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Figure 4.1.3.2 Shows the working principle of SPR in the BiacoreTM instrument. 
Antigen is immobilized on the chip surface using standard EDC / NHS amine coupling 
chemistry (a). Light is focused on the gold surface by means of a prism under conditions 
of total internal reflection. When the antibody / antigen mixture is injected over the 
surface a mass change occurs thus causing a refractive index change within the 
evanescent field (b). This change results in a shift in the SPR angle which can be 
measured and relayed as a sensogram to the user 
 
 
 
 
Figure 4.1.3.3 The SPR angle is seen as a dip in the intensity of the reflected light. 
Changes in θ are displayed as a sensogram and bimolecular interactions within the 
evanescent field result in an increase in the SPR angle and thus displayed as an increase 
in the signal of the sensogram. The “real-time” difference between the two angles (θa 
and θb) is plotted as arbitrary response units (RU) against time in seconds. 
4.1.4 CM5 sensor chip 
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A key component in the Biacore TM system, is the sensor chip. The CM5 chip (Figure 
4.1.4.1) consists of three layers: glass slide, thin gold film coating and a 
carboxymethylated dextran surface. Gold is used as the metal component as it possesses 
good SPR response. This carboxymethylated dextran matrix permits covalent 
immobilisation of analytes onto the sensor chip surface. 
 
 
 
 
 
Figure 4.1.4.1 Schematic illustration of the surface of the BiacoreTM CM5 sensor chip. 
The 3 distinct layers are shown, the glass slide, the thin gold film and a 
carboxymethylated dextran layer. This layer facilitates standard carboxyl-amine 
coupling. 
  
4.1.5 Application and considerations of SPR technology for detection of small 
haptens i.e. drug molecules 
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In SPR the changes in refractive index are dependant on mass, thus, the capabilities of 
the biosensor are pushed to the limit when dealing with small molecules such as illicit 
drugs. However, the label-free approach of SPR, reduces time and cost and compared to 
fluorescent tags, it also reduces false negatives and positives caused by the label 
occluding the binding site and the hydrophobicity of the tag, respectively (Karp et al., 
2005). When developing a BiacoreTM-based assay for the detection of small molecules 
such as illicit drugs, the assay format favoured is the inhibition assay and not the capture 
method employed in the detection of larger molecules (Leonard et al., 2007).  
 
A number of SPR-based assays have been reported for the successful detection of small 
molecules such as the mycotoxins (Daly et al., 2000) and illicit drugs (Dillon  et al., 
2003; Townsend et al., 2006).  The solubility of illicit drugs presents another problem 
for SPR as dimethlysufide (DMSO) is often included in preparations to aid solubility 
(Lipsinki et al., 1997). DMSO has a high refractive index, which results in large signal 
change in the sensogram known as a “bulk effect”. One method of overcoming this 
issue is a recently developed “bulk effect” calibration method (Frostell-karlsson et al., 
2000; Ahmad et al., 2003). However, this method was analysised and validated by Karp 
et al., (2005) and it was concluded that simple control surface extraction was the most 
efficient method of correction as outlined in this work (section 4.3.3.2 and Figure 
4.3.4.4.1(b)). 
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4.2 Rationale for the conversion of the anti-M3G scFv to a Fab format 
 
The laborious techniques used in traditional antibody production have led several 
research groups to investigate the use of recombinant antibody technology, to produce 
scFv and Fab antibody fragments (Tout et al. 2001; Li et al. 2000; Rau et al. 2002; 
Brennan et al. 2003) with high-affinity for small molecules. ScFv’s are the most 
commonly used recombinant antibody format as it can be rapidly constructed, typically 
well expressed in E. coli and can exhibit high affinity and stability (Barbas et al. 2001). 
Most scFv molecules are designed with an Fv-region linking peptide based on glycine-
serine repeat sequences of 15-20 residues, which typically lead to scFv molecules which 
are labelled ‘monomeric’(Maynard and Georgiou 2000), but in the bacterial periplasm a 
portion of the scFv typically dimerizes, resulting in a mixture of monomeric and dimeric 
fragments (Mc Gregor et al., 1994).  
 
A number of groups have engineered the variable regions of scFvs for the expression of 
monovalent Fab fragments (Arndt, 1998) and Fab constructs have been used specifically 
to determine the true affinities of scFv fragments which had been modified for increased 
affinity (Rau, 2002). However, none of the above mentioned studies has specifically 
addressed the issues of SPR surface chip chemistry in relation to different antibody 
structural formats and whether it is appropriate to convert scFvs to Fab format, to ensure 
a monovalent binding population for use in SPR analyses.  
 
Monovalent antibodies are frequently used to measure binding constants (George et al., 
1995) as monovalency prevents the formation of antigen-bridge complexes, which 
result in an increase in binding avidity (Mac Kenzie et al., 1996). The monovalency of 
binding ligand interaction is especially important with regard to kinetic analysis on 
Biacore and, thus, also in cases where new antibody panels are ranked according to 
affinity (Li et al. 2000; Lu et al. 2003; Stacy et al. 2003, Fredericks et al. 2004). Kinetic 
characterization reveals the rate at which the immune complex both associates and 
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dissociates, thereby providing a stringent measure for tailoring and selecting reagents 
(Quinn and O’Kennedy, 2001). The interaction between a soluble, monovalent analyte 
and an immobilized monovalent ligand can be interpreted in terms of pseudo-first-order 
kinetics, but heterogenicity of the binding ligand and possible multivalency can cause 
deviations from pseudo-first-order behaviour (O’ Shannessy et al. 1996)  
 
In the study presented here, the effects of SPR chip surface chemistry and antibody 
valency on the function of a model anti-morphine-3-glucoronide SPR assay is 
investigated. The variable regions of a previously described anti-M3G scFv (Brennan, 
2003), were re-engineered for the expression of monovalent Fab fragments. The 
characteristics of the resulting scFv and Fab fragments were then compared using 
ELISA, SDS-PAGE, HPLC and BiacoreTM.  
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4.3 Results and Discussion  
 
4.3.1 Construction and expression of anti – M3G Fab 
 
After electroporation of E. coli XL-1 Blue, the finished anti-M3G Cκ-Fab construct 
gave 3.1 x 107 total transformants, with a vector self-ligation background of < 0.1%. 
After the biopanning process had been performed, very poor signal was observed in 
phage ELISA against M3G-OVA. In subsequent ELISA characterization of soluble 
antibody, the Cκ-Fab demonstrated high sensitivity when used at a 1/200 dilution and 
exhibited a range of detection (IC50 of 1.4ng/ml), which was similar to that of the parent 
scFv (Figure 4.3.1.1).  
 
When this Cκ-Fab construct was examined using Biacore, no binding was observed to 
either the M3G surface or to the reference (OVA) surface. The scFv was analysed on 
the same surface and demonstrated a strong binding response. This was indicative of a 
problem with the Fab construct and not in the assay itself. On examination of the parent 
scFv sequence/gene, it was discovered that the antibody fragment was constructed with 
a lambda variable light chain. It was thought that expression may be improved by the 
more compatible constant and variable light chains. 
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Figure 4.3.1.1 ELISA inhibition assay performed on M3G-OVA-coated wells 
comparing Fab (blue) and scFv (red) binding response versus competing free M3G 
concentration. Signal developed using OPD chromogenic substrate and monitored by 
optical density at 450nm. Data expressed as A/A0 (i.e. the signal at different free analyte 
concentrations are expressed as a proportion of signal in the presence of no competing 
analyte). All analyses were preformed in triplicate on three separate occasions. Standard 
deviations at all points examined were ≤ 10%. 
 
The Cκ-Fab was therefore converted to a Cλ-Fab construct, as it was postulated that use 
of a more compatible pairing of light chain constant and variable regions might improve 
the structural stability, secretion and, therefore, overall activity of the final Fab product. 
In the second Fab panning series, a strong ELISA signal was observed by the second 
round for the Cλ-Fab construct. No concomitant increase in signal was observed against 
control antigen (OVA). 
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4.3.2 Anti - M3G scFv and Fab comparison studies prior to application to BiacoreTM 
 
When expressed in parallel, both the scFv and the Cλ-Fab produced large quantities of 
high titre, high activity antibody. In western blot analyis the Fab and scFv ran in parallel 
due to the denaturing properties of the SDS-PAGE (Figure 4.3.2.1). In direct ELISA, 
the His-purified and concentrated (to 1ml final volume) antibody preparations provided 
titers of 1/81,000 and 1/20,000 for scFv and Fab, respectively. ELISA conditions for 
each antibody were optimized for maximal sensitivity (data not shown) and for both 
scFv and Fab, the optimal well coating concentration was determined to be 3 µg/ml 
M3G-OVA. At an optimal dilution of 1/15,000, the scFv was shown to have a detection 
range for free M3G of 305 - 312,500 pg/ml, with an IC50 value of 30,000pg/ml (Figure 
4.3.2.2). The anti-M3G Cλ-Fab was used at a 1/5000 dilution, therefore, having several 
times more specific activity than that observed for the similarly expressed and purified 
Cκ-Fab. The Cλ-Fab was further shown to have a detection range of 152 - 19,500 pg/ml, 
with an IC50 value of 1.4ng/ml (Figure 4.3.2.2).  
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Figure 4.3.2.1 Western blot analysis of the immobilised metal affinity chromatography 
(IMAC)- purified Fab and scFv fragments. The 28 kD and 39kD bands are highlighted 
above. 
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Figure 4.3.2.2 ELISA inhibition assay performed on M3G-OVA-coated wells 
comparing Fab (blue) and scFv (red) binding response versus competing free M3G 
concentration. Signal developed using OPD chromogenic substrate and monitored by 
optical density at 450nm. Data expressed as A/A0 (i.e. signal at different free analyte 
concentrations are expressed as a proportion of signal in the presence of no competing 
analyte). All analyses were preformed in triplicate on three separate occasions. Standard 
deviations at all points examined were ≤ 10%. 
 
In a number of previously described chimeric Fab library construction methodologies, 
the light chain V regions (both κ and λ) of mice (Barbas et al., 2001), rabbits (Rader et 
al., 2000) and chickens (Andris-Widhopf et al., 2000) are spliced onto a single human 
Cκ region. This is presumably due to the dominance of the Vκ in the immunoglobulin 
repertoires of mice and rabbits (Barbas et al., 2001; Popkov et al., 2003), meaning that 
Vλ clones are likely to be infrequent in resulting immune recombinant antibody 
libraries. However, the observation outlined here that Fab light chain function and 
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overall antibody binding activity were improved by combining the Vλ region (isolated 
from a murine scFv library) with a Cλ region, as opposed to Cκ, implies that the use of a 
Cλ scaffold in Fab library construction might improve the isolation of lambda-associated 
Fabs. 
 
4.3.3 Biacore analysis of constructs 
 
Having established a functional anti-M3G FAb construct, BiacoreTM competition assays 
were then developed, using both M3G-OVA and M3G - coated SPR surfaces, to 
determine the range of free M3G detection of both the Fab and scFv.  
 
4.3.3.1 Preconcentration studies 
 
A preconcentration step is necessary prior to immobilisation of the drug-protein 
conjugates to the carboxymethylated dextran chip surface. This step ensures maximum 
efficiency of the immobilisation method. 10mM sodium acetate solutions were made up 
to different pH’s with 10% (v/v) acetic acid. The pH range used in this study was 3.8 - 
5.0. Solutions of M3G-OVA were made up in each pH buffer and injected over an 
underivatised flow cell at a flow rate of 5 µl / min for 2 minutes. The results of the 
preconcentration step are shown in Figure 4.3.3.1.1. The optimal pH for M3G-OVA 
immobilisation was determined to be 4.0. 
 
Immobilisation strategies were carried out as outlined in section 2.9.2 and 2.9.3. The 
M3G-OVA  flow cell and reference OVA flow cell immobilisation profiles are shown 
in Figure 4.3.3.1.2 and Figure 4.3.3.1.3. 
 
178 
 
 
Figure 4.3.3.1.1 Biacore based analysis of the preconcentration of the M3G – OVA 
conjugate to the surface of the CM – dextran chip surface. The low ionic strength of 
sodium acetate buffer favours electrostatic interaction between the positively charged 
protein (below the proteins pI) and the negatively charged dextran layer. The optimal 
pH for the immobilisation of the M3G – OVA conjugate was found to be pH 4.0. 
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Figure 4.3.3.1.2 Sensogram respresenting the immobilisation of M3G-OVA onto a 
CM5 dextran chip surface 
(1) – HBS buffer injection and baseline measurement recorded. 
(2) – The carboxymethylated surface was activated when a mixture of EDC and NHS 
(0.02M and 0.05M, respectively) was injected over the flow cell at a flow rate of 5 µl / 
min for 7 minutes. 
(3) – HBS injection. Activation was confirmed by the increase of ~ 150 RU from 
baseline (1) 
(4) – A solution of 100 µg / ml of M3G-OVA in sodium acetate buffer, pH 4.0, was 
injected over the flow cell at a flow rate of 5 µl / min for 20 minutes. 
(5) – A HBS injection removed all unbound conjugate and the quantity of immobilised 
M3G-OVA was recorded as the change in response units from (3) 
(6) – The flow cell was capped / deactivated with an injection of 1M ethanolamine, pH 
8.5. All non-covalently attached conjugate was also removed at this injection point. 
(7) A HBS injection permited the recording of the new (immobilised surface) baseline. 
Approximately 11,000 RU’s of M3G-OVA were immobilised on the flow cell. 
4.3.3.2 Inhibition assay development 
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A similar range of free M3G was employed as in the ELISA inhibition assay, with 
samples being injected over each chip in a pre-programmed order and each injection 
followed by a regeneration step. Both antibodies displayed negligible non-specific 
interactions with immobilized OVA and the modified CM-dextran surface, negating the 
need for pre-incubation steps of antibodies with either OVA or activated CM-dextran. 
The linear range of detection for the scFv was found to be 39 - 156 ng/ml (IC50 of 117 
ng/ml) on the M3G-OVA surface and 9.8 - 78 ng/ml (IC50 of 30 ng/ml) on the M3G - 
coated surface (Figure 4.3.3.2.1 and Figure 4.3.3.2.2). The linear range of detection for 
the Fab was found to be 4.8 - 39 ng/ml (IC50 19 ng/ml) and 4.8 - 78 ng/ml (IC50 14 
ng/ml) on M3G-OVA and M3G surfaces, respectively (Figure 4.3.3.2.1 and Figure 
4.3.3.2.2).  
 
The data described above suggest that the Fab fragment is consistently more sensitive in 
measurement of free M3G than the scFv fragment in SPR assay, where it is ~2 to 6-fold 
more sensitive (Figure 4.3.3.2.1 and Figure 4.3.3.2.2) and also in ELISA assay where it 
is 11.5-fold more sensitive (Figure 4.3.2.2). The respective sensitivities for Fab and 
scFv in ELISA analysis and SPR assay were highly similar, suggesting that an SPR 
assay for M3G can be designed which is as sensitive and reproducible as an optimised 
plate assay. These data also suggest that the differences observed between Fab and scFv 
responses in ELISA were not mediated by the different secondary antibodies used to 
detect binding. The use of direct M3G conjugation on the SPR surface appears to be 
more effective and reliable than an M3G-OVA surface as it promotes greater linearity in 
scFv competition assay response (Figure 4.3.3.2.1 and Figure 4.3.3.2.2). The surface 
directly coated with M3G also gave the most sensitive and highly correlated recognition 
of free M3G, by both constructs. Indeed, logit transformation of the data and subsequent 
two-tailed t-test showed that on the surface directly coated with M3G, values for Fab 
and scFv were not significantly different (p> 0.05) whereas, the values for both 
constructs differed greatly on the M3G-OVA surface (p< 0.001). 
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Figure 4.3.3.2.1 Biacore inhibition assays performed on an M3G-OVA-coated CM5 
chip surface, comparing Fab (blue) and scFv (red) binding response versus free M3G 
concentration. Data expressed as R/R0 (i.e. signal at different free analyte concentrations 
are espressed as a proportion of signal in the presence of no competing analyte). All 
analyses were preformed in triplicate on three separate occasions. Standard deviations at 
all points examined were < 5% (mean deviation scFv = 1.2%; mean deviation Fab = 
0.8%). 
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Figure 4.3.3.2.2 Biacore inhibition assays performed on an M3G-coated CM5 chip 
surface, comparing Fab (blue) and scFv (red) binding response versus free M3G 
concentration. Data expressed as R/R0 (i.e. signal at different fee analyte concentrations 
are espressed as a proportion of signal in the presence of no competing analyte). All 
analyses were preformed in triplicate on three separate occasions. Standard deviations at 
all points examined were < 5% (mean deviation scFv = 1.9%; mean deviation Fab = 
1.1%). 
 
This further suggests that direct hapten-labelled SPR surfaces may be more appropriate 
for the comparative analysis of the assay sensitivities of different antibody constructs. 
Interestingly, in both the Fab and scFv assays a lower concentration of antibody was 
required for use on the directly immobilized M3G chip surface. This surface also 
exhibited much greater stability after regeneration, with only 50 regenerations possible 
for the conjugate surface, as previously observed (Brennan et al., 2003), but over 200 
regenerations possible when using the directly immobilized chip, suggesting that the 
directly immobilized M3G surface will be more appropriate for ‘real-world’ assay 
conditions. 
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While carrying out the comparative ELISA and Biacore competition assays described 
above, it was observed that not only do the anti-M3G Fab and ‘monomeric’ scFv 
preparations have considerably different IC50 values, but they also exhibit considerably 
different dose-response profiles in both ELISA and Biacore (depending on the sensor 
surface type). When examined on the M3G-OVA surface, the two antibody constructs 
do not exhibit parallelism in their ranges of response, with only the Fab giving a clearly 
linear profile (Figure 4.3.3.2.1). However, their parallelism, linearity and sensitivity 
become highly similar when the same assays are performed on the M3G surface (Figure 
4.3.3.2.2). Given that scFv molecules have been shown to be prone to the formation of 
multimeric intermediates (Griffiths et al., 1993; Kortt et al., 1997), while Fabs are 
obligately monomeric (Borrebaeck et al., 1992), we therefore examined the scFv and 
Fab preparations by HPLC and non-reducing SDS-PAGE to investigate the extent of 
antibody fragment multimerisation.  
 
4.3.4 scFv multimerisation studies 
 
4.3.4.1 Native SDS-PAGE and Western blot analysis 
 
There was a concern that the assumed monomeric scFv purified samples may contain 
some dimeric binding characteristics, as shown in the Biacore data. The first stage in 
examining the degree of multimerisation of the scFv compared to the Fab was non-
denaturing gel electrophoresis. Urea and sodium dodecyl sulfate cause the denaturation 
of proteins through dissociation of oligomers to their subunits. Excluding the β-
mercaptoethanol ensures the disulphide bonds between the chains are kept intact and 
excluding SDS allows migration of the proteins based on their native charge. If there is 
more than one protein fragment present, as determined from the SEC-HPLC, they 
should show up as separate bands on a native gel (Figure 4.3.4.1.1). The Fab sample 
revealed a single band while the scFv sample revealed 2/3 separate bands. These bands 
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were not seen in the non native SDS-PAGE. A western blot was carried out on a 
duplicate gel and all antibody fragments where detected with the secondary antibody, 
indicating that the tag was intact in all fragments. 
 
Figure 4.3.4.1.1 Western blot of both scFv and Fab fragments transferred from a native 
gel indicating multiple bands in the Fab land and only one in the scFv lane at 2 different 
dilutions. Antibody fragments were detected with anti-His HRP-labeled secondary 
antibody and developed with TMB liquid substrate. 
 
Mol.
Weight
marker
 Fab
 1/50
Fab
1/100
  scFv
  1/50
scFv
1/100
- Multiple bands
evident in scFv
lanes
185 
4.3.4.2 Size exclusion chromatography 
 
Size exclusion chromatography permits the examination of various sized proteins in a 
sample. It works on the principal that smaller molecules pass through tiny pores in the 
column thus having a longer retention time than larger molecules not permitted through 
the pores which pass through the column at a faster rate. All assays were performed at a 
flowrate of 0.5ml/min with an injection volume of 50µl. The mobile phase was 
phosphate buffer saline (PBS). Both scFv and Fab antibody fragments were examined at 
stock dilutions in PBS. Standards to ensure the efficiency of the column were employed 
(Table 4.3.4.2.1)  
 
Table 4.3.4.2.1 Molecular weight markers were run through the Phenomenex, BioSep-
SEC-S-3000, 300nm x 7.80nm column at a flowrate of 0.5 ml/min with an injection 
volume of 50 µl. Individual molecular weights and  retention times are listed above. 
 
Protein Molecular Weight Retention time (min) 
BSA 66kD 16.0 
Trypsin 29kD 18.8 
Carbonic anhydrase 24kD 18.0 
Cytochrome C 12kD 21.8 
 
 
The molecular weight of an scFv is ~ 30kD while the molecular weight of a Fab 
fragment is close to double this at ~ 60kD. Only one clear peak would be expected in 
both cases as the samples were previously IMAC purified via the His-tag in each 
antibody fragment (Figure 4.3.2.1). However, the chromatographs obtained for the scFv 
indicate a second distinct peak with a shorter retention time than that of the primary 
peak. This second peak has a retention time in between that of the Fab and the scFv 
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(Table 4.3.4.2.2 and Figure 4.3.4.2.1). This was strongly indicative of the spontaneous 
formation of multimers within a monomeric scFv population.  
 
Table 4.3.4.2.2 Antibody fragments were run through the column at a flowrate of 0.5 
ml/min with an injection volume of 50 µl. All retention times are listed above. 
 
Sample Peak number Retention time (min) 
scFv 1 16.96 
 2 18.15 
Fab 1 17.35 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.4.2.1 Antibody fragments were run through the column at a flowrate of 0.5 
ml/min with an injection volume of 50 µl. The scFv population is clearly a mixture of 
monomeric and dimeric antibody fragments 
4.3.4.3 ELISA analysis of size exclusion chromatography (SEC) fractions 
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The possibility that these additional peaks and bands merely represent aggregated 
inactive protein had to be investigated. For this purpose an ELISA was performed on 
HPLC output fractions collected at 1min intervals (Figure 4.3.4.3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.4.3.1 ELISA assay performed on M3G-OVA coated wells comparing scFv 
(a) and Fab (b) samples collected from HPLC. Samples for analysis were collected from 
the HPLC column at 1 min intervals. Antibody activity was examined via detection of 
binding of each sample to the M3G – OVA coated surface. Signal developed using 
TMB chromogenic substrate and montitored by optical density at 450nm. Data is 
expressed as absorbance read. 
 
The figure above clearly illustrates activity spanning 4 minutes, thus covering the exact 
time at which the two significant peaks are seen on the chromatograph. This would 
indicate that the scFv has spontaneously multimerised and has retained activity in these 
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multimeric forms, while the Fab is inherently monomeric. The apparent time difference 
observed between the HPLC and ELISA samples is an effect of the manual sample 
collection. 
 
 
4.3.4.4 Influence of the scFv multivalency on SPR analysis 
 
To compare the influence that multimerisation (and therefore multivalency) might have 
on the Biacore profiles of the scFv and Fab constructs, kinetic analysis was performed 
for each construct. Kinetic analyses were performed on the directly immobilised M3G 
surface rather than the M3G-OVA surface. For the purpose of kinetic analysis, the 
immobilised surface used and the concentration of antibody injected over the surface is 
sufficient only to obtain an RUmax = 100RU  
 
Under the optimised competition assay conditions on the M3G-OVA surface, the Fab 
exhibited faster association and dissociation rate constants than the scFv (Figure 
4.3.4.4.1(a)). In kinetic analyses the contrast between the two constructs was even more 
noticable, with the scFv exhibiting a considerably different dissociation profile to that of 
the the Fab (Figure 4.3.4.4.1(b)). Although rates of association are similar for both 
antibody constructs, the anti-M3G Fab fragment shows a significantly faster 
dissociation rate 4.8 x 10-2, when compared to 1.03 x 10-3 for the anti-M3G scFv.  
 
These observations are of particular interest in the context of anti-hapten recombinant 
antibody development. Recombinant antibody technology can lead to the rapid 
development of large panels of antigen-specific antibodies of differing sensitivity. To 
accelerate the screening of these panels, several groups have employed kinetics 
screening of initial cones by SPR, to rapidly identify the highest affinity binders (Li et 
al., 2000, Lu et al., 2003, Stacy et al., 2003, Fredericks et al., 2004). However, the 
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purpose of this SPR screening is typically to identify antibodies for subsequent use in 
competition assays, which rely on antibody recognition of free molecule in solution.  
 
It has been previously shown that ‘monomeric’ antibody fragments (scFv, ~90 % 
monomeric) demonstrate a more rapid dissociation profile than ‘dimeric’ (~90 % 
dimerized) fragments. However, our observations suggest that a predominantly 
monomeric scFv form can still exhibit a considerably slower dissociation rate than a 
truly monomeric Fab fragment. Due to the common occurrence of antibody 
concentration and/or pH-based multimerisation in scFv populations (Arndt et al., 
(1998)), any individual scFv sample is likely to contain an unknown proportion of 
dimeric antibody, which is functionally bivalent and can lead to a profound change in 
off rate kinetics profiles. Indeed, it has been shown that different antibodies with linkers 
of the same length may dimerise to different extents (Griffiths et al., 1993, Raag and 
Whitlow 1995, Wu et al., 1996). It is therefore arguable, that the ranking of scFv 
molecules by off-rate kinetics on hapten-coated SPR surfaces may be misleading and 
may give an unreliable estimation of binding affinity for free hapten, even under the 
stringent SPR conditions designed for kinetics analyses.  
Therefore this poses a question that must be addressed: is it possible that avidity masks 
the true affinity in multimeric scFv populations? 
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Figure 4.3.4.4.1 (a) Representative sensogram demonstrating the difference between 
Fab (Red) and scFv (Blue) binding response under normal assay conditions described 
previously, when examined on the M3G-OVA-coated CM5 chip surface. On-line 
reference subtraction was performed against a flow-cell coated with OVA. An antibody 
sample buffer mimic, containing no anti-M3G, was used as a secondary negative 
control. (b) Kinetics sensograms demonstrating the difference between Fab (dark) and 
scFv (light) binding response when examined on the M3G – coated surface. ‘On-line’ 
reference subtraction was performed against a flow cell, which was activated and 
capped as for the M3G-coated cell. An antibody sample buffer mimic, containing no 
anti-M3G, was used as a secondary negative control.  
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4.3.5 Sequencing  
 
Plasmid DNA was sent to MWG Biotec (Germany), for sequencing. Comfort reads 
were performed in triplicate using the primers ompseq (5’ AAG ACA GCT ATC GCG 
ATT GCA G 3’) and pelseq (5’ ACC TAT TGC CTA CGG CAG CCG 3’). The nucleic 
acid sequences were analysed using the chromaslite 200 software package and the 
expasy nucleic acid translation tool (http://www.expasy.org/tools/dna.html). The CDR’s 
were identified (Figure 3.3.5.1) using Kabat rules for identifying antibody CDR regions 
from linear amino acid sequences, which are summarized at 
http://www.rubic.rdg.ac.uk/abeng/cdrs.html. The final demonstration in this comparison 
between the Fab and scFv constructs is the sequence alignment of the two VH and VL  
sequences. Figure 4.3.5.2, illustrates the almost 100% homology between the two 
purified clones. This further demonstrates the influence of antibody structure on SPR 
analysis. 
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Figure 4.3.5.1 Sequence analysis of anti-M3G Fab fragment. Both heavy and light chain 
CDR’s are highlighted in Red and Framework regions are in black. 
Figure 4.3.5.2 Alignment of anti-M3G scFv (Brennan et al., 2003) and anti – M3G Fab 
variable heavy chain regions demonstrating almost 100% homology. 
 
 
Framework 1 CDRL1
S A SA V V T Q E S A L T T S P G E T V T L T C R S S T G A V T T S N Y A N W V
 Framework 2 CDRL2 Framework 3
Q E K P D H L F T G L I G G T N N R A P G V P A R F S G S L I G D K A A L T I T
CDRL3
G A Q T E D E A I Y F C V L W Y S N H L V F G G G T K L T V L G Q P K………..
Framework 1 CDRH1
E V Q L Q E S G A E L M K P G A S V K I S C K A T G Y T F S R Y W I E W V K Q
Framework 2 CDRH2
R P G H G L E W I G E I L P G S G S T K Y N E K F K G R A T F T A D T S S N T V
Framework 3 CDRH3
Y M Q L S S L T S E D S A V Y H C A R W S Q V H V M D Y W G Q G T T V T V S……….
Constant
chain
Constant
chain
ScfvVH   EVQLQQSGAELMKPGASVKISCKATGYTFSRYWIEWVKQRPGHGLEWIGEILPG
FabVH    EVQLQESGAELMKPGASVKISCKATGYTFSRYWIEWVKQRPGHGLEWIGEILPG
Cons     ***** ******************************************************
ScfvVH   SGSTKYNEKFKGRATFTADTSSNTVYMQLSSLTSEDSAVYHCARWSQVHVMDYW
FabVH    SGSTKYNEKFKGRATFTADTSSNTVYMQLSSLTSEDSAVYHCARWSQVHVMDYW
Cons     ************************************************************
ScfvVH   GQGTTVTVSSAS
FabVH    GQGTTVTVSSAS
Cons     ************
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4.4 Conclusion 
 
If kinetic ranking of recombinant anti-hapten antibody fragments assumes monomeric 
binding interaction, and the ranking is performed to rapidly isolate antibodies which are 
good for competition assay, then this method will only be truly reliable for Fab 
constructs, where monomeric binding status is guaranteed. The influence of multimeric 
scFv is starkly illustrated in Figure 4.2.4.4.1(a), where the off-rate apparent in the 
kinetics sensorgrams of the Fab and scFv constructs are strikingly different, leading to a 
40-fold difference in calculated off-rate values. This suggested higher affinity of the 
scFv for M3G is not borne out, however, on subsequent assay development, as the Fab 
can actually out-perform the scFv molecule in both plate and SPR assay formats (Figure 
4.2.2.2 and Figure 4.3.3.2.1). Moreover, the scFv and Fab constructs are found to have 
highly similar affinity for the free M3G molecule under optimised assay conditions 
(Figure 4.3.3.2.2). 
 
This research described the development of an immunoassay using an alternative 
genetically derived Fab antibody fragment, for the detection of M3G, constructed from 
a previously described scFv (Brennan et al., 2003). The Fab construct displayed a 
marginal improvement in affinity for the free drug. During Biacore assay development 
it became evident that the directly labelled hapten SPR surface may be more appropriate 
for comparative analysis of different constructs i.e. scFv and Fab. It was shown that the 
Fab construct performed better in ELISA and Biacore assay formats, through, either the 
changes in valency when using the Fab format or through the increased rigidity of the V 
regions. The influence of increased rigidity and scaffolding on anti-hapten antibody 
binding is further examined and exploited in chapter 5 (mutagenesis). 
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Chapter 5 
 
5.0 Generation of anti-
tetrahydrocannabinol recombinant 
antibodies and their application, in 
conjunction with other anti-drug 
antibodies, on a multi-drug detection 
platform 
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5.1 Introduction 
 
5.1.1 Species selection 
 
The antibodies described previously were generated using murine genetic template 
material. This was primarily because there were pre-existing murine IgG structures 
available. However, in the case of tetrahydrocannabinol, there were no pre-existing 
antibodies available in the laboratory nor are there any reports of successful generation 
or application of anti-THC recombinant antibodies currently in the public domain. With 
this in mind it presented the ideal opportunity to investigate the benefits of using a 
leporine model in place of the typical murine model for the generation of anti-
tetrahydrocannabinol recombinant antibodies. 
 
5.1.1.1 Leporine immune response 
 
Rabbits have a limited V(D)J gene repertoire formed primarily by the rearrangement of 
a single VH gene (VH1). The crucial first stage of a functional immune response is the 
generation of a primary antibody response sufficiently diverse so as to recognise a vast 
array of antigens (Crane et al., 1996). This is also true for the generation of a functional 
recombinant antibody immune library. Most species form a diverse primary response 
via the combinatorial joining of multiple V, D and J segments (section 1.9). However, 
combinatorial recombining only has a very limited impact on the diversity of the rabbit 
response. Rearrangment is minimal and the same VL and JL genes are used in all B cells. 
A very limited number of VH, JH and  DH gene combinations are also utilised. The 
leporine system utilises a mechanism known as somatic gene conversion, as do 
chickens, the only difference being that somatic gene conversion occurs in chickens 
before they are born while it occurs after birth in rabbits.  
At the loci of both the heavy and light chains there are upstream families of 
psuedogenes that lack the necessary functional recombination signal sequences required 
to undergo rearrangment. However they can donate sequences to the functionally 
recombined VJL and VDJH genes. Somatic gene conversion is a powerful tool in the 
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generation of antibody repertoires (Ratcliffe, 2006). This notion was first described by 
Reynaud et al. (1987) in relation to the avian immune response. The upstream donor 
remains un-altered, in that it donates gene segments but does not receive any in return 
thereby acting as a resevoir of diversity for the recombined gene segments (VJ and 
V(D)J). 
 
5.2 Rationale for the construction of an anti-tetrahydrocannabinol scFv recombinant 
antibody 
 
Previous chapters have discussed the benefits of Fab construction from IgG genetic 
templates. The implication of using a Fab instead of an scFv fragment were described in 
chapter four. However, the work described herein, involved the construction of a scFv, 
from a leporine immune library, in preference to a Fab fragment. The generation of an 
scFv is less laborious than a Fab and it displays significantly better on phage (Barbas et 
al., 2001). Rabbit variable chains have been shown to be unstable and often require the 
stablising impact of the presence of the disulphide linkage which is available in the scFv 
construct (Rader et al., 2003). Also, taking into consideration, the findings in earlier 
chapters (Chapter three and four) that the structural conversion of a Fab to an scFv is 
more difficult than the converse, it was decided that an anti-THC scFv would be 
constructed.  
Aside from the obvious construction and display advantages of the development of an 
anti-THC scFv fragment, the future potential to convert it to alternative recombinant 
structures such as a Fab fragment is also provided. The generation of an anti-THC 
recombinant antibody fragment is the last of the three anti-drug antibodies to be 
constructed in the work outlined in this thesis. Both the anti-amphetamine and anti-
M3G antibodies are in the Fab format, thus it was ideal to have alternative antibody 
structural formats for eventual application to a multi-drug detection platform. This is 
important where the antibodies developed have the potential to be applied to a number 
of assay platforms.  
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5.3 Results and Discussion 
 
5.3.1 Production of a recombinant antibody library against Tetrahyrdocannabinol  
 
5.3.1.1 Serum analysis and cDNA synthesis 
 
The standard rabbit immunisation sechedule was followed here (Section 2.3.3). A direct 
ELISA was carried out to determine if the antiserum was of sufficiently high titre prior 
to sacrifice and collection (figure 5.3.1.1). The antibodies that were raised against THC-
BSA were screened against THC-BTG so as to eliminate false positives as a result of 
non-specific binding to the carrier protein. The serum titred out at approximately a 1 in 
300,000 dilution of neat serum. A pre-immunisation serum sample was included as a 
control. The RNA was extracted (total RNA extracted was approximately 10mg), the 
cDNA was synthesised and the scFv gene was amplified according to the protocols 
outlined in section 2.4.1, 2.4.2 and 2.4.8, respectively.   
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Figure 5.3.1.1 Titre of antibody from rabbit immunised with THC-BSA. The antibody 
was titred against THC-BTG in 1% (w/v) BSA to eliminate any antibodies specific to 
the carrier protein. Pre-immunised serum was included as a control. Bound antibodies 
were detected using a peroxidase-labelled anti-rabbit secondary antibody and signal was 
developed using a TMB chromogenic substrate. Absorbance was read at 450nm. 
 
5.3.1.2 Isolation of scFv fragments from rabbit library 
 
5.3.1.2.1 Digestion and ligation of scFv and vector fragments 
 
The scFv fragment and the pComb3x vector were digested with Sfi 1 in parallel and a 
1:2 ratio of antibody DNA to vector DNA was included in the ligation reaction. After 
ethanol precipitation to concentrate the DNA, two full-size electroporations were 
prepared (section 2.4.10.2). The transformed library was titred and yielded a library size 
of 1.06 x 108 which was sufficently large for this work. 
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5.3.1.2.2 Bio-panning  
 
The bio-panning strategy employed here was in accordance with the protocal 10.5 in the 
Barbas manual (Barbas et al., 2001) with the exception that immunotubes were used in 
place of immunosorbent wells for the first two rounds. An elevated concentration of the 
drug (50µg/ml) was used in the early rounds of the panning process to ensure that no 
loss of positive phage occurred as a result of the inaccessibility of this particularly 
difficult target antigen due to its solubility issues.  
In rounds one and two phage were incubated on immunotubes coated with 20µg/ml 
THC-BTG for 2.5 hours and 1.5 hours, respectively. In rounds three and four duplicate 
immunosorbent wells replaced the use of immunotubes for phage incubation. The 
smaller surface area, in conjunction with a more extensive washing steps (15 x PBS 
followed by 15 x PBST) led to an increase in the panning stringency. Input and output 
titres were analysed after round four to assess the enrichment of the phage population 
prior to moving onto a further round of panning. Input and output titres, plotted in figure 
5.3.1.2.2.1, indicated appropriate enrichment of phage after each round and also that an 
enrichment plateau had not yet been reached. Phage were incubated for 45 min on a 
single immunosorbent well in round five and the washing steps were 15 x PBS followed 
by 15 x PBST.  
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5.3.1.2.3 Single clone analysis of the panned library 
 
A polyclonal phage ELISA was carried out for all five rounds of selection. An anti-
M13-HRP-labelled secondary antibody was used for detection. Figure 5.3.1.2.3.1 
illustrates the enrichment of positive anti-THC-binding phage after round two. There is 
a slight decrease of approximately 10% in signal between round three and round five, 
therefore, it was concluded that the maximum tolerable stringency had been reached and 
that colonies would be selected randomly from rounds three, four and five for 
monoclonal analysis.  
Single colonies from each round were chosen at random and seeded for use in single 
clone soluble analysis, as described in section 2.6.4. Two 96-well microtitre plates were 
inoculated and each plate included the appropriate control wells. A high, relatively 
uniform, signal was produced across the two plates (data not shown). Twenty random 
clones were selected to assess single clone target specificity further. These 20 clones 
were grown in 5 ml culture volumes, induced and lysed via three rounds of 
freeze/thawing. Each lysed preparation was applied to the plate at a final 1 / 4 dilution 
and incubated with 3 different concentrations of free THC (10 µg/ml, 1 µg/ml and 100 
ng/ml) to investigate the competition properties of the expressed antibodies. The results 
are illustrated in figure 5.3.1.2.3.2. Four out of twenty clones demonstrated 
displacement by free THC and also showed an increase in signal intensity inversely 
proportional to a decrease in THC concentration.   
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Figure 5.3.1.2.2.1 The number of colony forming units formed after each round of 
panning of the rabbit anti-THC scFv library. Panning stringency was increased with 
each successive round with significant enrichment of potential positive clones evident in 
rounds three and four.  
 
Figure 5.3.1.2.3.1 Results of a polyclonal phage ELISA following five sucessive 
rounds of panning of the rabbit anti-THC scFv library. Phage binding was detected with 
an anti-M13-HRP-labelled secondary antibody.  
203 
 
 
 
Figure 5.3.1.2.3.2 Representation of single clone soluble expression analysis via an 
inhibition ELISA performed on THC-BTG-coated wells. Data is expressed as 
absorbance. 
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5.3.2 Characterisation of positive clones 
 
5.3.2.1 Sequence analysis and inhibition ELISA 
 
A competitive ELISA was performed with the four positive clones TB4, TC2, TE7 and 
TH11. This competitve ELISA incorporated a larger range with smaller increments in 
free THC concentration, (10,000 – 9.7 ng/ml). An antibody dilution factor of 1/ 2 final 
concentration was used for each clone (figure 5.3.2.1.1). Clone TB4, did not 
demonstrate any displacement when analysed and as such it was eliminated from further 
analysis. All three remaining clones displayed similar displacement profiles with IC50’s 
of approximately 600 ng/ml. A pick PCR was carried out to confirm the presence of the 
correct size DNA band using the standard pComb scFv amplification primers. The 
correct 800 bp band was amplified for the three clones TC2, TE7 and TH11 (figure 
5.3.2.1.2). Each of the three clones was sequenced and it was revealed that each was the 
same clone (figure 5.3.2.1.3). 
The anti-THC scFv was grown in large-scale and purified via metal affinity 
chromatography as outlined in sections 2.7.1 and 2.7.2. In direct ELISA, the IMAC-
purified and concentrated (to 750µl final volume) antibody preparation provided a titre 
of 1/64,000. ELISA conditions for the antibody were optimized for maximal sensitivity 
(data not shown). At an optimal dilution of 1/8,000 the scFv was shown to have a 
detection range of 156 – 1,250 ng/ml for free THC, with an IC50 value of 600 ng/ml 
(figure 5.3.2.1.4).  
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Figure 5.3.2.1.1. An ELISA inhibition assay was performed on THC-BTG-coated wells 
comparing TH11 (blue), TC2 (purple) and TE7 (yellow) binding response versus 
competing free THC concentration. Signal developed using TMB chromogenic 
substrate and monitored by optical density at 450nm. Data is expressed as A/A0 (i.e. the 
signal at different free analyte concentrations are expressed as a proportion of signal in 
the presence of no competing analyte). 
Figure 5.3.2.1.2  A colony pick PCR using standard scFv amplification primers and 
conditions revealed the presence of an 800bp band in each of the three clones TC2, TE7 
and TH11.  
206 
 
 
CDRL1    CDRL2 
TC2     QAAELDLTQTPASVEVAVGGTVTIKCQASQSISSRLAWYQQKPGQPPKLLIYAASTLESG 
TH11    QAAELDLTQTPASVEVAVGGTVTIKCQASQSISSRLAWYQQKPGQPPKLLIYAASTLESG 
TE7     QAAELDLTQTPASVEVAVGGTVTIKCQASQSISSRLAWYQQKPGQPPKLLIYAASTLESG 
      ************************************************************ 
 
CDRL3   LINKER 
TC2     VPSRFRGSGSGTDFTLTISGMKAEDAATYYCQSADASTVAFGAGTNVEIKSSGGGGSGGG 
TH11    VPSRFRGSGSGTDFTLTISGMKAEDAATYYCQSADASTVAFGAGTNVEIKSSGGGGSGGG 
TE7     VPSRFRGSGSGTDFTLTISGMKAEDAATYYCQSADASTVAFGAGTNVEIKSSGGGGSGGG 
        ************************************************************ 
             CDRH1 
TC2     GGGSSRSSQSLEESGGRLVTPGTPLTLTCTASGFSLTSNVVTWVRQAPGEGLEWIGTIAY 
TH11    GGGSSRSSQSLEESGGRLVTPGTPLTLTCTASGFSLTSNVVTWVRQAPGEGLEWIGTIAY 
TE7     GGGSSRSSQSLEESGGRLVTPGTPLTLTCTASGFSLTSNVVTWVRQAPGEGLEWIGTIAY 
        ************************************************************ 
 
     CDRH2      CDRH3 
TC2     GAATYYATWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARGYPGHIAADIWGPGTLVT 
TH11    GAATYYATWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARGYPGHIAADIWGPGTLVT 
TE7     GAATYYATWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARGYPGHIAADIWGPGTLVT 
        ************************************************************ 
 
 
TC2     VSLGQPKAPSVTSGQAGQHHHHHH 
TH11    VSLGQPKAPSVTSGQAGQHHHHHH 
TE7     VSLGQPKAPSVTSGQAGQHHHHHH 
        ************************ 
 
Figure 5.3.2.1.3 T-coffee alignment of three anti-THC scFv clones; TC2, TE7 and 
TH11. Sequence analysis revealed that all three clones were identical. The individual 
CDR’s are highlighted in bold and labelled in pink,. The serine-glycine linker is labelled 
in pink also.  
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Figure 5.3.2.1.4 ELISA inhibition assay performed on THC-BTG-coated wells showing 
the scFv’s binding response versus competing free THC concentration. Data is 
expressed as A/A0. All analyses were preformed in triplicate on three separate occasions. 
 
5.3.3 Comparative studies on the performance characteristics of the anti-THC 
recombinant scFv and a commercially available anti-THC monoclonal antibody. 
 
The scFv’s performance in ELISA was compared to that of the commercially available 
monoclonal anti-THC antibody (Europa Bioproducts Ltd). The data suggested that the 
anti-THC scFv is two fold more sensitive on ELISA when compared to the anti-THC 
monoclonal antibody (figure 5.3.3.1). The scFv has a significantly more reproducible 
linear range of detection (figure 5.3.2.4.4), a factor that becomes extremely important in 
a situation where the accurate detection limits have legal consequences. It was 
concluded that the scFv was more suitable for use in the development of a biacore 
inhibition assay due to its higher affinity for the free molecule, its reproducibility (low 
standard deviations) and its cost effective ‘in-house’ expression and purification. 
Although it was clear at this point that there would be issues with the stability of the 
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free drug in solution, the results obtained for the monoclonal antibody were less 
reproducible than those for the scFv. The platforms in this study utilized an aqueous 
solution and as such a highly lipophilic target causes problems. THC naturally adheres 
to the glass or plastic vessel in which it is stored for the duration of the assay. The 
inclusion of solvent in the assay resulted in significantly reduced reproducibility and 
was therefore eliminated as a possible solution to the problem. Furthermore, in view of 
the aim of developing a multi-analyte detection platform it is ideal to have all antibodies 
functioning in the same storage and analysis buffer (PBS).   
 
Figure 5.3.3.1 ELISA inhibition assay performed on THC-BTG-coated wells 
comparing monoclonal antibody (blue) and scFv (brown) binding response versus 
competing free THC concentration. Data is expressed as A/A0 (i.e. signal at different 
free analyte concentrations are expressed as a proportion of signal in the presence of no 
competing analyte).  
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5.3.4  Biacore analysis of constructs  
 
5.3.4.1 Preconcentration analysis and immobilisation 
 
The pH range used in this study was 3.8 - 5.0. Solutions of THC-BSA were made up in 
each pH buffer and injected over an underivatised flow cell at a flow rate of 5 µl / min 
for 2 minutes. The optimal pH for THC-BSA immobilisation was determined to be 4.0 
and immobilisation strategies were carried out as outlined in section 2.9.2 and 2.9.3.  
 
Figure 5.3.4.1.1 Sensogram respresenting the immobilisation of THC-BSA onto a CM5 
dextran chip surface. (1) HBS buffer injection and baseline measurement recorded. (2) 
The carboxymethylated surface was activated when a mixture of EDC and NHS was 
injected over the flow cell at a flow rate of 5 µl per min for 7 minutes. (3) HBS 
injection. Activation was confirmed by the increase of ~ 150 RU from baseline (1). (4) 
A solution of 100 µg / ml of THC-BSA in sodium acetate buffer, pH 4.0, was injected 
over the flow cell at a flow rate of 5 µl / min for 20 minutes. (5) A HBS injection 
removed all unbound conjugate and the quantity of immobilised THC-BSA was 
recorded as the change in response units from (3). (6) – The flow cell was capped / 
deactivated with an injection of 1M ethanolamine, pH 8.5. All non-covalently attached 
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conjugate was also removed at this injection point. (7) A HBS injection permited the 
recording of the new (immobilised surface) baseline. Approximately 8,000 RU’s of 
THC-BSA were immobilised on the flow cell. 
 
5.3.4.2 Inhibition assay development 
 
A similar range of free THC (10,000-9.7ng/ml) was employed as in the ELISA 
inhibition assay, with samples being injected over each chip in a pre-programmed order 
and each injection followed by a regeneration step. Both antibodies displayed negligible 
non-specific interactions with immobilized BSA and the modified CM-dextran surface, 
negating the need for pre-incubation steps of antibodies with either BSA or activated 
CM-dextran. The linear range of detection for the scFv was found to be 156 – 2500 
ng/ml (IC50 of 625 ng/ml) on the THC-BSA surface (figure 5.3.4.2.1).  
The sensitivity of the scFv is highly similar in both ELISA (figure 5.3.2.4.4) and 
Biacore assays (figure 5.3.4.2.1). This would suggest that there is potential to develop 
and validate an SPR assay similar to the work carried out in chapter four with the anti-
M3G antibody fragments. While the inhibition curves are highly comparable and 
reproducible across replicate assays there is an inherent issue with the solubility of the 
free drug. With aggregation observed in the free drug stock, it is highly possible that the 
antibodies described have a higher affinity than the data observed and reported here. 
Further analysis and exact concentration determination of the THC by the forensics 
laboratory is an essential next step 
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Figure 5.3.4.2.1 Biacore inhibition assays performed on an THC-BSA-coated CM5 
chip surface, comparing the scFv’s binding response versus free THC concentration. 
Data is expressed as R/R0 (i.e. signal at different free analyte concentrations are 
expressed as a proportion of signal in the presence of no competing analyte). All 
analyses were preformed in triplicate on three separate occasions. 
 
This research described here has focused on the generation of the third anti-drug 
recombinant antibody fragment. At this stage each of the three antibodies (anti-M3G, 
anti-amphetamine and anti-THC) were fully characterized on both ELISA and Biacore 
assay formats. The next phase of the work entailed the application of the antibodies 
generated to a multi-analyte detection assay. This is an important step in research of this 
kind, where the detection of the target antigens is necessary to counteract anti-social or 
illegal behavior etc., moreover, the application of these antibodies to a multi-drug 
detection assay was vital to the successful completion of the aims of the research grant.  
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5.4 Multi-drug chip-based SPR inhibition assay  
 
5.4.1 Rationale for the development of a mutli-drug detection assay 
 
The previously developed and well-defined immunoassay strategies, such as those 
mentioned in section 1.4, have paved the way for recombinant antibody microarrays in 
terms of the major issues such as methods of immobilization and detection. There is a 
major need for the development of a cost-effective, reliable and sensitive test to screen 
for drugs of abuse. The use of recombinant antibodies offers greater sensitivity and 
specificity, as illustrated in chapters three, four and earlier in this chapter. Furthermore, 
the feasibility of applying affinity maturation methods to these antibodies is 
demonstrated in the work outlined in chapter six. Microarrays have already been 
exploited in the fields of both proteomics and genomics, however, they are a potential 
lead-technology in point-of-care diagnostics. Biochips may be generated via spotting 
low-density antibody-arrays onto plastic chips. This technology can be produced for 
multiple illicit drug detection. Signals are generated on the chip through enhanced 
signal amplification e.g. fluorescence. This type of assay is particularly advantageous, 
as it offers high sensitivity, large sample throughput and low cost analysis. Testing is 
still very much biased towards the more classical quantification techniques e.g. GC-MS, 
despite the requirement of expensive equipment, highly trained personnel and laborious 
sample preparation. Currently despite their performance such novel screening methods 
are still only regarded as preliminary tests requiring further verification. Here an SPR 
based assay was chosen as a proof of concept platform for the detection of three 
alternative drugs on a single platform. This SPR-based assay was designed to determine 
if the antibodies developed and characterized specifically for their application in a 
multi-drug detection assay could perform as intended. It also provides a comparative 
study between their performance in a single-drug assay and a multi-drug assay. 
 
5.4.1.1 Influencing factors on assay design 
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The feasibility of a multi-analyte assay was examined using the three recombinant 
antibody fragments developed against the targets; morphine-3-glucuronide, 
amphetamine and tetrahydrocannabinol. They were optimized in both plate and SPR 
assay formats. There are a number of parameters to consider when designing any multi-
analyte detection method.  
 
The antibody storage buffer: 
Each of the antibodies produced in this work (anti-amphetamine Fab, anti-M3G Fab and 
anti-THC scFv) are stable in PBS. Each of the antibodies have been buffer exchanged 
and concentrated to storage volumes of less than 1 ml and therefore, are used at high 
dilution factors (1 in 8000, 1 in 5000 and 1 in 8000, respectively). This eliminated any 
potential problems when preparing a single, multi-analyte solution. 
 
Antibodies performance in a single analyte assay: 
The antibody fragments described have been assayed in an inhibition format rather than 
a competitive format, i.e. all analyses were performed on an antigen immobilized 
surface and the antibody / free drug mix was passed over it. Also, all antibodies had a 
linear range of detection on the Biacore assay format in the region of 1.22 – 1250 ng/ml, 
and, as a consequence, a single concentration range of drugs can be used in a multi-drug 
assay. 
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Cross reactivity: 
None of the antibodies demonstrate any problematic cross reactivity towards the non-
target drugs when assayed in a single analyte assay. However, this must be included as a 
control on the multi-analyte chip where all three antibodies and all three drugs are 
mixed in a single solution.  
 
The solubility of the free drugs (M3G, Amp and THC): 
The solubility of the amphetamine and MG3 has never been an issue when designing 
single drug assays. The THC molecule has proven to be extremely problematic in every 
aspect of analysis unless in its conjugated form. It is difficult to maintain a precise 
concentration range as the drug has a tendency to fall out of solution when diluted in 
PBS prior to assaying. In a single analyte assay it is possible to address the insolubility 
issues via the inclusion of small concentrations of solvents etc. However, in this case, 
where the THC molecule will be mixed with an assortment of other antigens and 
antibodies prior to the binding event it is not as simple. Further investigation would be 
required on the stability and solubility of the drug prior to assay validation.  
 
5.4.1.2 Chip design and assay conditions 
 
The multi-drug assay was designed based on the formats used in the single-drug 
detection assays described throughout this work (chapters 3, 4 and 5). This involved the 
immobilisation of the three drug conjugates on three flow cells on a single CM5-sensor 
chip along with BSA immobilised on a reference flow cell as a control (figure 
5.4.1.2.1). BSA was chosen as the reference because both the THC and amphetamine 
drugs are conjugated to BSA and although the M3G molecule is linked to ovalbumin 
the antibody has not demonstrated any non-specific binding to the protein used in the 
conjugation (section 4.3.3.2).  
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Figure 5.4.1.2.1 Diagramatic representation of mult-drug assay on a Biacore CM5 
sensor chip. Section 1-4 illustrate the functionalitly of the chip and the generation of 
responses on Biacore. 
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5.4.2 Results 
 
Each antibody was passed across each flowcell to determine its specificity for its 
corresponding conjugate. After extensive optimisations assay conditions were 
determined and the sample mix containing the three antibodies (anti-M3G, anti-
amphetamine and anti-THC) and the three drug compounds was prepared for the 
Biacore inhibition assay (figure 5.4.1.2.1).  
The inhibition curves produced as a result of the multi-analyte detection assay (figure 
5.4.2.1(a), (b) and (c)) were comparable to the performance of the antibodies when 
analysed in individual detection assays as illustrated in previous chapters and sections. 
In short, no decrease in sensitivity or comprise in detection range was observed when 
the antibodies were applied to the multi-drug detection assay compared to those results 
achieved in the single-analyte assay.  
This result is indicative of the potential use of the antibodies produced in this project on 
a multi-analyte assay format. All three antibodies proved to be appropriately stable and 
specific for their intended use. The biacore assay presented here may also be viewed as 
a proof of concept and is illustrative of the practical opportunities for using these three 
recombinant antibodies on a single mutli-drug detection platform in the future. 
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Figure 5.4.2.1 Each data point on the curves represents a sample taken from a mixed 
solution containing free THC, amphetamine, M3G and antibody fragments specific for 
THC, amphetamine, M3G. (a) Biacore inhibition assays performed on a THC-BSA-
coated CM5 flow cell surface, comparing the anti-THC scFv’s binding response versus 
free THC at various concentration. (b) Biacore inhibition assays performed on a M3G-
OVA-coated CM5 flow cell surface, comparing the anti-M3G Fab’s binding response 
versus free M3G. (c) Biacore inhibition assays performed on a AMP-BSA-coated CM5 
flow cell surface, comparing the anti-Amp Fab’s binding response versus free 
amphetmaine. Data expressed as R/R0. All analyses were preformed in triplicate on 
three separate occasions. 
5.5 Conclusion 
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Previous work in this area reported serious problems in obtaining soluble anti-THC 
scFv fragments. Brennan (2004, unpublised data) reported on the difficulties developing 
recombinant antibodies against THC. While phage-bound scFv’s were described, there 
was no success in generating soluble recombinant antibody fragements with potential 
for assay application reported. However, this chapter has described the successful 
production and characterisation of an anti-THC scFv fragment on ELISA and Biacore. 
The resultant scFv out-performed commercially available monoclonal antibody with 
respect to its detection of THC. Furthermore its application to a multi-analyte assay has 
been demonstrated. The linear range of detection was found to be 156 – 1250 ng/ml in 
both ELISA and Biacore analysis.  
The influence of the lipophilic nature of the drug on the assay and the limits of detection 
requires further investigation in order to validate this method of detection. The exact 
concentration of the drug present in samples over the course of an assay must be 
determined to ensure accurate reproducible results, especially, if the intended outcome 
were to commercialise such an antibody.  It is also very possible that the anti-THC scFv 
is more sensitive than is reported here due to the fact that the drug readily falls out of 
solution and adheres to the side of the glass or plastic receptacle in which the assay is 
performed. 
In chapter six, the genetic engineering via in-vitro mutagenesis of the anti- M3G Fab 
fragment was described. This anti-THC scFv is an ideal candidate for affinity 
maturation based on a number of important factors. Unlike the anti-M3G Fab it was not 
derived from a monoclonal parent but instead selected from an immune library, as such 
it may be more susceptable to in-vitro maturation as it did not undergo significant 
functional optimisation in-vivo prior to selection.  
Secondly, based on the findings in chapters three and four, the structural conversion of 
this anti-THC scFv to a Fab fragment may also influence the sensitivity of the the 
recombinant antibody fragment. In previous chapters this affinity improvement has been 
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attributed to the link between the increased structural rigidity of the anti-hapten Fab and 
its affinity for the target.  
Finally, the anti-THC scFv along with antibodies described in chapter’s three and four 
were characterised with regard to their application to a multi-drug detection assay. 
While the primary goal was to develop an assay in collaboration with the optical-
sensory group, due to differences is project time-lines etc. this became unfeasible at this 
time.  
There are a number of lateral flow based multi-drug test kits comercially available, for 
example, oratect (BMCTM), a lateral flow based assay with a testing time of 15 minutes. 
Intercept® (Orasure technologies inc.), an EIA based test and also the Ontrack oratube 
(Varian inc.), based on GC/MS assay techniques, both of which require a number of 
days to obtain results. All of these test kits yield a positive / negative result for the 
presence or absence of the individual drugs but do not provide any quantitative data. 
However, the demonstration of a successful biacore based multi-drug inhibition assay 
illustrates the capabilities of the antibodies developed and described throughout this 
work for use in such a multi-analyte assay. A quantitative result would be extremely 
useful where very low levels of the drug are detected as a result of ingestion of over-the-
counter medication and is not indicative of substance abuse. The high specificity 
observed in this assay is strongly indicative of their potential application to a rapid, 
sensitive, specific and cost effective low-density microarray that will be developed in 
future collaborations.  
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Chapter 6 
6.0 Antibody engineering - mutagenesis of 
the anti-Morphine-3-Glucuronide Fab 
fragment. 
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6.1 Introduction 
 
The immune system is the fundamental mechanism used for generating novel, multiple 
affinity antibodies against almost any target imaginable. The first phase of the response 
results in the selection of moderate affinity antibodies displayed on the surface of B 
cells. Thus, the B cell represents a single entity comprising both the phenotype and the 
genotype of the particular antibody in question. The principles of phage display, 
described previously in chapters 1, 3 and 4, illustrate the likeness between the natural 
immune system and phage display technology. The second phase of the response 
involves the affinity maturation of specific antibodies via somatic hypermutation and 
class switching. All in – vitro antibody engineering strategies to date are in some way 
modeled on the natural functioning of the immune system and its ability to affinity 
mature specific antibodies.  
The immune system naturally selects for the highest affinity binders after somatic 
hypermutation through class switching. After this first somatic affinity maturation step 
the antibodies are switched from the multivalent IgM to the bivalent IgG. This class 
switch enhances the selection bias towards higher affinity antibodies, as selection 
cannot rely on avidity when in an IgG format.  
Recombinant antibody technology is continuously developing and new ways to mimic 
and improve on the natural immune system are being discovered. In B cells, antibodies 
undergo successive rounds of mutation and affinity selection. The concept of improving 
or modifying recombinant antibody affinity in vitro is examined throughout this 
chapter. There are numerous methods of affinity maturation, each of which is explained 
in section 6.1.1. 
 
6.1.1 Methods for the affinity maturation of antibodies. 
 
A number of techniques have been used for the successful mutagenesis of antibodies 
against many different targets. These include the use of bacterial mutator strains (Coia 
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et al., 2001), error prone PCR (Daugherty et al., 2000), DNA shuffling / chain shuffling 
(Boder et al., 2000) and site directed mutagenesis (Zimmerman et al., 2006). 
 
6.1.1.1 Bacterial mutator strains 
 
The use of bacterial mutator strains for affinity maturation of proteins is often used as a 
starting point for random mutagenesis. After the clone of interest is infected into the 
mutator strain the culture is grown and re-inoculated repeatedly until the desired number 
of rounds of replication is achieved. The choice of growth media used is a key factor in 
the rate of mutation with a 105 fold difference between growth in minimal media 
compared to rich media (Cox, 1976), the latter achieving the highest rate of mutation. 
Low et al. (1996) reported the improved affinity of an anti-hapten scFv (anti-2-phenyl-
5-oxazolone) through a 100-fold decrease in the off-rate. This was achieved 
predominantly via mutations in the CDR loops and to a lesser extent in the framework 
regions. The improvements are attributed to, but not limited to, mutations in the 
CDRH1 and CDRL2 while no improving mutations in the CDRH3 are reported. 
However, a significant disadvantage with this system is the introduction of mutations in 
the entire phagemid and not just in the antibody encoding region of the gene. Hence, a 
large library would be required to get a good representation of all positive mutations. In 
this case large library construction is dependant on transformation efficiency of the E. 
coli.  
 
6.1.1.2 Error prone PCR 
 
Error prone PCR is a method used to introduce random sequence copying mutations 
through imprecise reaction conditions along with the addition of Mn2+ and Mg2+ to the 
reaction.  Error  prone PCR is commonly used with previously randomised libraries or 
in combination with a second mutagenesis technique (Dong et al., 2002; Zahnd et al., 
2004 and Razai et al., 2005). These random insertions, deletions or substitutions are 
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often deliterious, but increases in affinity can result. The merits of the technique were 
investigated by Daugherty et al. (2000) who reported on the unexpectantly high number 
of functional clones obtained from a hypermutated library and also on the  distance of 
the majority of these positive mutations from the antigen binding site (ABS). 
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6.1.1.3 DNA shuffling and chain shuffling 
 
DNA shuffling is a method in which the gene of interest is enymatically digested with a 
high frequency cutting enzyme, DNase I. The DNA fragment is repaired via several 
rounds of PCR in the absence of any specific oligonucleotides. A full length fragment is 
achieved via site-specific-recombination of the individual 100bp fragments. Chain 
shuffling is a method which involves the sequential recombination of different light 
chains with a single specific heavy chain resulting in the selection of mutants comprised 
of VH genes which are target specific and random light chains and vice versa. Chain 
shuffling has facilitated the investigation of the impact of substituting non-specific light 
chains in order to reduce cross reactivity, reduce immune responses in therapy and 
improve affinity (Parks et al., 2000). 
 
6.1.1.4 Site-directed mutagenesis  
 
Site directed mutagenesis is the chosen method in this work. It requires knowledge of 
the gene of interest. This permits substitutions of specific amino acids or groups of 
amino acids in specific locations on any one of the CDR’s in order to achieve a higher 
affinity antibody. Extensive research was carried out in this area since it was first 
discovered by Smith in 1993. A 16 – fold increase in antibody affinity was observed by 
Schier et al., (1996), following sequential introduction of random substitutions into the 
CDR’s of an anti-c-erbB-2 scFv using standard primer-directed mutagenesis. After 
selection, the highest affinity mutant was subjected to heavy chain randomization. This 
led to a 1200 - fold improvement in antibody affinity.  
Generally, segmental mutagenesis is performed using oligonucleotides synthesized with 
degeneracy’s at the position where randomization is desired. The most common 
oligonucleotide doping strategies use NNK or NNS where N is an equal mix of G and 
C, K is a mix of G and T and S is a mix of G and C. Both strategies encode all 20 amino 
acids and a single amber stop codon within a total of 32 codons. In order to facilitate 
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sequencing the NNK strategy is preferred to the NNS due to the higher G/C content 
which can complicate DNA sequencing (Barbas et al., 2001).  
For example, randomizing 5 codons will give a peptide diversity (20n) 3.2 x 106, DNA 
diversity 32n 3.4 x 107 and would require 1.6 x 108 transformants. These figures give a 
99% confidence rating of obtaining at least one copy of a rare polypeptide sequence 
(Table 6.1.1.1). 
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Table 6.1.1.1 Number of transformants required to represent a degenerate library 
mutated with either NNK or NNS at a given number of codons (ή). These confidence 
values and table are based on the Poisson distribution calculation of Lowman and Wells 
(1991) and sourced from Barbas et al. (2001). 
No. codons ή Peptide 
diversity (20n) 
DNA diversity 
(32n) 
Transformants 
required for 
90% 
confidence 
Transformants 
required for 
99% 
confidence 
1 20 32 74 149 
2 400 1.0 x 103 2.4 x 104 4.8 x 104 
3 80 x 103 3.3 x 104 7.6 x 104 1.5 x 105 
4 1.6 x 105 1.1 x 106 2.4 x 106 4.9 x 106 
5 3.2 x 106 3.4 x 107 7.7 x 107 1.6 x 108 
6 6.4 x 107 1.1 x 109 2.5 x 109 5.0 x 109 
7 1.3 x 109 3.4 x 1010 7.9 x 1010 1.6 x 1011 
8 2.6 x 1010 1.2 x 1012 2.5 x 1012 5.1 x 1012 
16 6.6 x 1020 1.2 x 1024 2.8 x 1024 5.6 x 1024 
  
There are two strategies of CDR walking; in parallel and in sequence. Parallel walking 
involves several CDR’s targeted at the same time and all mutated CDR’s are combined 
to give the best antibodies, assuming avidity. Sequential involves any improvements 
generated from one CDR library selection being incorporated into the antibody 
sequence before constructing the next CDR library. In both strategies, free energy 
changes are expressed:   
 
!!GAB = !! GA + !! GB +
 !! G1
where:
!! GA  and !! GB are free changes in the free energy of CDR mutants A and B.
!! G1  represents the change in interaction energy between the two residues.
!! GAB is the change in free energy of the protein encompasing the two mutated CDR’s
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Parallel and sequential differ in their dependence on combined mutants ΔΔG1. Parallel 
assumes ΔΔG1 is negligible while sequential takes into account that ΔΔG1 may not 
always be negligible and that optimal binding may result from the interdependence of 
CDR loops. 
In the absence of structural data, as is often the case, site directed ‘random’ mutagenesis 
may be employed on all or just specifically chosen CDR loops. Valjakka et al. (2002) 
reported a 40-fold increase in affinity when an anti-testosterone monoclonal antibody 
was subjected to random mutagenesis of the CDR regions. Mutations in CDRL1 and 
CDRH3 are considered to have been involved in the improvements observed. This will 
be discussed later in the chapter. 
 
6.2 Rationale of mutagenesis strategy adopted 
 
The natural immune system can produce antibodies against an enormous range of 
foreign molecules from a relatively restricted set of germ-line segments. The “lock and 
key’ theory was used to describe antibody - antigen interactions. However, the 
realization that there is a vast population of polyreactive antibodies in the primary 
immune response suggests that this concept needs to be very critically assessed. 
(Notkins, 2004). It was suggested that these antibodies produced as a result of the 
primary response are capable of binding multiple targets due to their ability to form 
more than one antigen-combining site (Wedemayer et al., 1997). Their flexibility 
permits recognition of self and non – self antigens albeit at low affinities (Comtessa et 
al., 2000). It is thought that antibody evolution alters the conformation of the antibody 
rendering it more rigid and restricted in structure producing specific higher affinity 
antibodies.  
The specificity of the antibody is determined by the structure of its antigen - binding site 
which is formed by the 3 CDR’s from both the heavy and the light chains acting 
together by heterodimerisation (Padlan et al., 1994). This binding site results from 6 
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hypervariable loops converging. In vivo diversity in antibody binding sites is initially 
encoded in the germ-line by multiple variable (V) diversity (D) and joining (J) gene 
segments. CDR1 and CDR2 of the heavy and light chains are encoded within the V 
regions. Light chain CDR3 is produced by the genetic recombination of V and J regions 
while the heavy chain CDR3 is formed by the recombination of V, D and J regions. The 
heavy chain CDR3 can carry from between 2 – 26 amino acids. 
This chapter describes two alternative strategies for mutating anti-M3G Fab, an anti-
hapten recombinant antibody fragment, and the impact each strategy has on the affinity 
of the antibody for its target. There are a number of reports indicating that the CDRH3 
is the most relevant region for antigen binding due to its huge diversity. Therefore, this 
was the first target for mutagenesis. However, it is apparent that regions outside of the 
antigen-binding site could have an impact on the affinity of an anti-hapten antibody 
(Daugherty et al., 2000; Persson et al., 2006; Zimmermann et al., 2006 and Low et al., 
1996).  
The second strategy changed focus, moved away from looking at the highly evolved 
CDRH3 and targeted the CDRL2, CDRL3 and CDRH1 all of which have been reported 
by various groups as having significant importance in anti-hapten antibody binding. A 
vital element in antibody affinity maturation is in understanding the difference between 
anti-hapten antibodies and anti-protein/peptide antibodies. Herein the key question of 
the impact of forcing mutations into the primary point of antigen contact is examined. 
This is then followed through with an investigation of site directed mutagenesis in the 
more peripheral regions of the fragment relative to the binding sites. 
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6.3 Results and Discussion 
 
6.3.1 Mutagenesis strategy 1: CDR walking  
  
6.3.1.1 Primer design for CDR walking 
 
Sequence analysis of the anti-M3G Fab revealed the CDR3 of the light chain to be 9 
codons in length (section 4.3.5). It was decided to introduce random mutations into the 
central 5 codons and to keep the two flanking codons constant. M-VH1-RAN-F 
introduces this randomized gene segment (NNK X 5) into CDR3 – 5` GAC TCT GCC 
GTC TAT CAC TGT GCA AGA TGG TCC NNK NNK NNK NNK NNK GAC TAC 
TGG GGT C 3`. The second primer, M-VH1-FR3-B, was designed to contain a 27 bp 
overlap with the forward primer – 5` TCT TGC ACA GTG ATA GAC GGC AGA GTC 
3`. Using this overlap in sequence only two PCR steps were required to amplify the 
mutated gene. The other two primers, Ompseq and g-back are common to the pComb3X 
vector.   
 
Figure 6.3.1.1.1 Site-directed mutagenesis in the CDRH3, of the anti-M3G Fab 
fragment in pComb3X, showing the randomized and overlapping regions of the gene. 
Ompseq and M-VH-FR3-B are used to amplify the light chain with an overlapping 
region of 27bp’s into the variable region of the heavy chain. M-VH-Ran-F and G-Back 
are used to amplify the heavy chain. The forward primer M-VH-Ran-F introduces the 
randomized gene segment into the CDR3 of the variable heavy chain. 
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The CDR3 was targeted as the first step in a series of sequential mutating steps as the 
CDR3 of both the heavy and light chains have been shown to contain the hypervariable 
joints of the V/J and V/J/D gene arrangements. These regions participate in direct 
antigen contact in many studied antigen / antibody complexes (Wilson and Stanfield, 
1993).  
 
6.3.1.2 Amplification of anti- M3G mutant gene  
 
The PCR’s were carried out using high fidelity polymerase taq to encourage specific 
binding. This is more important when using heavily mutating primers such as in this 
case. There were only two PCR steps required to amplify the mutated gene. The first 
amplified each of the heavy and light chains, including the new randomized region in 
the CDR3 of the heavy chain. The second PCR overlapped the whole Fab fragment.  
 
Table 6.3.1.2.1 Basic PCR mix used in all CDR walking amplifications 
Component Concentration 
Template DNA 100ng (of each chain) 
Primers 50 pmol of each 
10x HIFI buffer 1X 
10mM dNTP 0.2 mM 
50mM MgSO4 2mM 
Platinum Taq 5 U / reaction 
Molecular grade H2O Up to 50 µl 
 
 
It was deemed necessary to eliminate any background amplification, selection or 
expression of the parent clone due to its high affinity and good expression 
characteristics. The method outlined to achieve this was to select a new template clone 
that encoded the anti-M3G Fab with the exception of the mutated CDR3 and one that 
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expressed in E. coli but one that did not recognize the target antigen. The first round of 
amplifications would be carried out and the new template would be selected based on 
ELISA (target recognition analysis) and western blot (expression analysis). 
 The first round of amplifications were completed and the library was transformed into 
XL-1 Blue, as normal. Random clones were chosen for pick PCR and all selected clones 
revealed the amplified band to be the expected 1600bp.  
The vector was digested as before however, the gel was run for 2 hours 30min to ensure 
sufficient separation of the stuffer from the cut vector thus avoiding stuffer fragment 
contamination. A pick PCR was carried out throughout the process, at various stages, 
acting as the control. 
Random clones were picked and examined on western blots (figure 6.3.1.2.1), ELISA 
(data not shown) and further test PCR’s (data not shown). The western blot confirmed 
the expression of a Fab fragment from clone no. 2 and the ELISA demonstrated this 
clones inability to bind the target through the lack of any positive signal when assayed 
on a plate coated with M3G-OVA. The combination of both the ELISA and western 
blot confirmed the presence of a non-parental anti-M3G Fab fragment expressed in 
clone no. 2. This was used as the new template for the construction of the mutated anti-
M3G Fab library. 
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Figure 6.3.1.2.1 Western blot performed on small-scale induced clones. Binding was 
detected with anti-HA HRP-labelled secondary antibody. Lane 1: positive control 
(parent antibody), Lane 2: clone no. 7, Lane 3: clone no. 10, Lane 4: pre-stained 
molecular weight marker, and Lane 5: clone no. 11. 
 
6.3.1.3 Construction of mutated library: Using clone no. 2 as template DNA in place 
of wild-type gene 
 
After library construction and before panning the transformed library was examined 
using pick PCR and Alu 1 digest to ensure the stuffer had not contaminated the process 
again. All clones examined amplified bands of the correct size with no extra bands on 
the gels indicating that the correct Fab fragment was present. The resulting gel 
demonstrated that using the new template eliminated the non - specific amplification of 
the stuffer fragment (figure 6.3.1.3.1). Additionally, 5 random clones were picked from 
the library titre plates for sequencing to ensure the library was mutated in the correct 
regions (figure 6.3.1.3.2). The data revealed conservation of all sequences outside of the 
5-codon region of the CDRH3 that was intentionally randomized via NNK doping 
strategies. The bio-panning strategy was then carried out with confidence that the 
library had been mutated successfully. 
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Figure 6.3.1.3.1 PCR verification of Fab insert using randomly picked clones from 
library transformation plates. Ompseq and gback primers were used along with standard 
Fab amplification PCR reaction conditions. Lanes 1-10: random clones picked from titre 
plates. 
 
M3G-Mutated 1:                
GTGCAAGATGGTCCCATGCTGTTACGTTTGACTACTGGGGTCAAGGAACCACGGTCACCG 
GTGCAAGATGGTCCCAAGTGCATGTTATGGACTACTGGGGTCAAGGAACCACGGTCACCG 
**************** *    *    * ******************************* 
M3G-Mutated 2:                    
GTGCAAGATGGTCCCGTGCTAATCGGTGTGACTACTGGGGTCAAGGAACCACGGTCACCG 
GTGCAAGATGGTCCCAAGTGCATGTTATGGACTACTGGGGTCAAGGAACCACGGTCACCG 
**************** *   **      ******************************* 
 
M3G-Mutated 3:                     
GTGCAAGATGGTCCTTGGGTTGGTGTAGGGACTACTGGGGTCAAGGAACCACGGTCACCG 
GTGCAAGATGGTCCCAAGTGCATGTTATGGACTACTGGGGTCAAGGAACCACGGTCACCG 
**************   *       ** ******************************** 
 
M3G-Mutated 4:                      
GTGCAAGATGGTCCGCTAATCGGGTGATGGACTACTGGGGTCAAGGAACCACGGTCACCG 
GTGCAAGATGGTCCCAAGTGCATGTTATGGACTACTGGGGTCAAGGAACCACGGTCACCG 
**************      *  ** ********************************** 
 
M3G-Mutated 5:                  
GTGCAAGATGGTCCGGGGTTGCGCGTCA-GGACTACTGGGGTCAAGGAACCACGGTCACC 
GTGCAAGATGGTCCCAAGT-GCATGTTATGGACTACTGGGGTCAAGGAACCACGGTCACC 
**************   ** **  ** * ******************************* 
 
Figure 6.3.1.3.2 The conserved regions of the CDRH3 are maintained through the use 
of primers M-VH1-Ran-F and M-VH1-FR3-B and are highlighted in blue. The 
sequence mismatches in the CDRH3 are highlighted in pink, spanning a 5 codon length 
of sequence. Underlining indicates those bases that are present in 4/5 of the mutated 
antibody. 
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6.3.1.4 Bio-panning  
 
The first round of panning was carried out in accordance to protocol 10.5 in the Barbas 
manual after which a different panning strategy was employed based on work carried 
out by Lu et al. (2003), this strategy is outlined in table 6.3.1.4.1. The inclusion of the 
extra free drug incubation and washing step after the first round helped to eliminate any 
parental clone contamination, which would naturally exist in such a library. This 
panning strategy was established with the aim of pushing the selection to the limits of 
the wild-type anti-M3G Fab fragment. The IC50 of the parent clone (Chapter 4) was 
determined to be ~ 8 nM and so each successive round of selection included various 
concentrations and increased washing times of free M3G. The input and output titres of 
the panning process are given in Table 6.3.1.4.2.  
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Table 6.3.1.4.1 Panning strategy for selection of positive clones from the CDRH3 
mutated anti-M3G Fab library. All rounds of selection were carried out in 300µl 
capacity immunosorbent wells and 100µl volumes are incubated at each step except 
during the washing steps where the wells are filled to capacity. 
 
Parameter Round 1 Round 2 Round 3 Round 4 Round 5 
M3G-OVA conc. 9 µg/well 3µg/well 3µg/well 3µg/well 3µg/well 
Input phage 
binding 
2 hours 2 hours 1 hour 1hour 1 hour 
Washes 
(PBST + PBS) 
5 + 5 5 + 5 10 + 10 10 + 10 10 + 10 
Extensive 
washes 
with M3G 
0 min 
0µM 
15min 
0.1µM 
30min 
0.1µM 
3 hours 
1µM 
24 hours 
1µM 
Washes 
(PBST + PBS) 
0 0 5 + 5 5 + 5 5 + 5 
Trypsin elution 
(30 min) 
10 µg/ml 10 µg/ml 10 µg/ml 10 µg/ml 10 µg/ml 
 
Table 6.3.1.4.2 Input and output titres for all rounds of panning of the anti-M3G 
mutated Fab library. 
 
 Pan 0 Pan 1 Pan 2 Pan 3 Pan 4 
Input - 3.3 x 1011 1.9 x 1011 2.2 x 1012 1.0 x 1011 
Output 8.8 x 108 3.16 x 106 1.5 x 105 6.1 x 105 2.0 x 104 
 
Pan 4 was the final round of selection calculated as there were no colonies on titre plates 
after round 5. This was mostly likely due to the stringency of the final round of 
selection. The next stage in the process was to assess single colonies from the panned 
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population. Single colonies were picked at random from rounds 3 and 4 and a 
monoclonal ELISA displayed zero positives from either round. This prompted the 
assaying of round 1-output colonies in order to determine whether or not the selection 
process had been so stringent as to eliminate all potential binders early on in the 
selection.  
The monoclonal soluble expression ELISA on 2 x 96 well plates of single clones 
revealed a very poor result with only 4.5 % positive binders. This combined with a very 
low signal from the polyclonal phage ELISA caused concern. Nevertheless, each of the 
5 positive clones from round 1 (P18H, P211H, P21B, P22A and P29C) were grown in 
10ml cultures, induced and subjected to lysis via multiple freeze - thaw steps. A direct 
ELISA was carried out. However, uniform low signal was observed. Round one was 
examined via monoclonal phage ELISA and the result revealed a lack of M3G binders 
even at that early stage in the panning process. 
This final result forced a re-examination of the mutagenesis strategy employed. It was 
possible to conclude that while the panning strategy may have been at its maximum 
possible stringency the presence of no target specific clones in the first round indicated 
that targeting the CDRH3 of the anti-M3G Fab fragment resulted in the complete loss of 
antigen recognition.  
The CDRH3 is widely reported as being the dominant region of antigen – antibody 
contact. Persson et al. (2006) reported that anti-hapten antibodies have 5 less contact 
points than those antibodies raised against peptides or proteins. If this is the case, 
targeting the CDRH3 of the anti-M3G Fab fragment could very possibly have knocked 
out the entire antigen-binding site. This implied that this particular Fab relies very 
heavily on the CDRH3 and alternative regions of the antibody should be targeted for in 
vitro affinity maturation. Furthermore, Daugherty et al. (2000) commented on the lower 
tolerance of an antibody to mutation directly in the binding site. It is possible that 
similar conclusions may be drawn here in this work. The wild type has come from a 
monoclonal antibody, which is of relatively high affinity and would have undergone 
functional optimisation in vivo. It was also reported that the majority of the affinity 
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improving mutations in the scFv were residues located at a certain distance from the 
antigen-binding site (Daugherty et al., 2000). 
Spiking of the wildtype Fab fragment into this mutant library could act as an additional 
control for the assessment of the panning stringency. Without this “wild-type spiking”, 
the severe stringency of the panning strategy must also be considered as an influencing 
factor in loss of binding of the polyclonal library population. 
A new approach was adopted. This focused on CDR’s / residues that are not directly 
involved with the antigen point of contact and instead they may play a role in the 
rigidity of the structure. Initially, the most logical option was mutating the CDRH3, as 
this is the CDR primarily involved in antigen contact. Zimmerman et al. (2006) reported 
that while increasing the affinity of an antibody, through restricting its conformation to 
fit the antigen, such as in somatic evolution, has yielded high affinity and high 
expressing antibodies it has not yet been optimised. In this strategy for mutating the anti 
–M3G Fab antibody the CDR3 of the heavy chain was to be retained as wild-type, while 
the CDR1 of the heavy chain and the CDR2 and CDR3 of the light chain were mutated, 
using similar NNK doping strategies to those described earlier in this chapter. 
 
6.3.2 Mutagenesis strategy 2: site directed mutagenesis - Kunkel style 
 
Kunkle (1985) proposed a method of site directed mutagenesis, which eliminated the 
use of PCR and resulted in greater transformation efficiency, and the method was used 
successfully for mutating anti-peptide antibodies (Sidhu et al., 2000). It was proposed 
that improvements in affinities of anti-hapten antibodies may be mediated by changes in 
the rigidity of the antibodies structure and not by the formation of new antigen contact 
points (Zimmermann et al., 2006). It is possible that focused mutagenesis on CDR’s 
other than the primary point of contact, the CDRH3, will have a beneficial effect on the 
anti-M3G Fab. Zimmermann (2006) reported on mutations, that pushed the antibody 
into a single conformation fitting tightly around the antigen compared to the looser wild 
type conformation.  
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While the CDRH2 is important in antigen recognition (Persson et al., 2006), the sheer 
length of this CDR made it unattractive as a target in this case. Persson and coworkers 
had access to extensive modeling facilities which allowed them to focus on particular 
residues within the lengthy CDR. The majority of academic laboratories do not have 
access to such facilities. It was therefore, decided not to include the CDRH2 in this 
study. In that same study carried out by Persson et al. (2006), the CDRH1 was targeted 
for the construction of a focused anti-hapten library and it was both feasible and 
desirable to include it here also. CDRL2 rarely contributes towards antigen binding 
(Wilson and Stanfield. 1994), however, based on findings by Zimmerman et al. (2006) 
it is probable that the CDRL2 located in the periphery, would have potential in altering 
the affinity of the antibody. Improvements may be seen by changing the overall rigidity 
of the antibody and stabilizing the antigen-binding site. Alternative mutagenesis 
strategies outlined by Daugherty et al. (2000), reported that affinity improving amino 
acid substitutions were not found in regions that came in direct contact with the target 
but instead they were located in peripheral CDR’s and also in framework residues. In 
this study the framework regions were considered to be important to the structural 
integrity of the antibody and therefore, they would not be mutated.  
It was highlighted in the first section of this chapter that targeting the CDRH3 may have 
proved to be too severe with respect to engineering this antibody. It indicated that the 
central combining site was already highly evolved. Hence it was decided that the 
CDRL3 would be targeted in this second strategy. However as it may also be heavily 
evolved with the potential to knock out antigen recognition entirely it was included in 
the strategy but not forced to mutate as with the CDRH3 CDR walking method. Of the 
three CDR’s that were targeted only the CDRL2 was first mutated to a “stop” coding 
mutant (section 6.3.2.3). This provided a control on the severity with which the highly 
evolved CDR’s such as CDRL3 would be mutated. While mutations in the CDRL2 
would be required in order to achieve functional antibodies from the library, mutations 
in the CDRL3 and CDRH1 would only be retained if they were improvements or at 
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minimum null mutations. Any mutations in these regions that were detrimental to the 
antibodies activity would then be lost in the selection process.  
With this in mind primers were designed to target CDRH1, CDRL2 and CDRL3. 
 
6.3.2.1 Primer design 
 
In the CDR walking strategy (section 6.3.1) parental DNA contamination was 
eliminated via selection of a non-wild type template. This was achieved by: 
a) Early sequencing and selection of a non-wild type gene for library 
template. 
b) Confirmation of protein expression via western blot analysis. 
c) Confirmation of the lack of target recognition via ELISA analysis. 
The approach taken in this second strategy to wild type elimination was the construction 
of a stop mutant template. Based on the CDR sequences obtained for the anti-M3G Fab 
fragment (figure 6.3.2.1.1) oligonucleotides encoding stops (TAA) in place of the 
functional codons in each of the targeted CDR’s were designed (Table 6.3.2.1.1). The 
anti-M3G antibody was originally derived by phage display and expresses very well in 
E. coli. Without a stop-mutant template wild type carryover can outgrow and dominate 
selections (Yang et al., 1995 and Lee et al., 2004).  
The mutating oligonucleotides were designed to incorporate full-length CDR mutations 
in the CDRL3, CDRL2 and CDRH1. The CDRL2 and L3 were 7 codons and 9 codons, 
respectively, in length and the CDRH1 was 5 codons in length (figure 6.3.2.1.1). It was 
essential for the success of this strategy that the correct strand of dsDNA was packaged. 
Since M13 packages only lead strand DNA it was necessary to confirm that the lead 
strand in the pComb3x vector was indeed the forward strand and so two sets of primers 
were designed for each step (a forward and a reverse primer) (Table 6.3.2.1.1). 
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Figure 6.3.2.1.1 Sequence analysis of the antibody binding regions CDRL2, L3 and 
CDRH1 of the wild type anti-M3G Fab fragment. CDRL2 and CDRL3 contain 7 and 9 
codons, respectively, while the CDRH1 is formed by 5 codons. CDR’s are highlighted 
in purple with framework regions flanking each. 
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Table 6.3.2.1.1 Primers designed for Kunkel style mutagenesis strategy focused on 
CDRL2, CDRL3 and CDRH1. Forward stand and reverse strand primers were 
synthesized in order to confirm lead strand on the vector. Stop oligonucleotides were 
designed to eliminate wild type antibody contamination. 
Primer 
name 
Primer sequence 
CDRH1-
Fstop 
ACTGGCTACACATTCAGTTAATAATAATAATAATGGGTAAAGCAGAGGCCT 
CDRH1-
Rstop AGGCCTCTGCTTTACCCAATTATTATTATTATTACTGAATGTGTAGCCAGT 
CDRL2-
Fstop TTCACTGGTCTAATAGGTTAATAATAATAATAATAATAAGGTGTTCCTGCCAGATTC 
CDRL2-
Rstop GAATCTGGCAGGAACACCATTATTATTATTATTATTATTACCTATTAGACCAGTGAA 
CDRH1-
Fmut ACTGGCTACACATTCAGTNNSNNSNNSNNSNNSTGGGTAAAGCAGAGGCCT 
CDRH1-
Rmut AGGCCTCTGCTTTACCCASNNSNNSNNSNNSNNACTGAATGTGTAGCCAGT 
CDRL2-
Fmut TTCACTGGTCTAATAGGTNNSNNSNNSNNSNNSGCTCCAGGTGTTCCTGCC 
CDRL2-
Fmut GGTCTAATAGGTGGTACCNNSNNSNNSNNSNNSGGTGTTCCTGCCAGATTC 
CDRL2-
Rmut GAATCTGGCAGGAACACCSNNSNNSNNSNNSNNGGTACCACCTATTAGACC 
CDRL2-
Rmut GGCAGGAACACCTGGAGCSNNSNNSNNSNNSNNACCTATTAGACCAGTGAA 
CDRL3-
Fmut TTCTGTCTTCTATGGTACNNSNNSNNSNNSNNSTTCGGTGGAGGAACCAAA 
CDRL3-
Fmut GAGGCAATATATTTCTGTNNSNNSNNSNNSNNSAACCATTTGGTGTTCGGT 
CDRL3-
Rmut TTTGGTTCCTCCACCGAASNNSNNSNNSNNSNNGTACCATAGAAGACAGAA 
CDRL3-
Rmut ACCGAACACCAAATGGTTSNNSNNSNNSNNSNNACAGAAATATATTGCCTC 
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6.3.2.2 Strategy overview 
 
This strategy utilises an ung - E. coli  strain CJ236 which was obtained from NEB. Its 
genotype is listed as: 
FΔ(HindIII)::cat (Tra+ Pil+ CamR)/ ung-1 relA1 dut-1 thi-1 spoT1 mcrA 
Upon addition of uracil to the overnight growth culture, this ung- strain allows uricil to 
exist instead of thymine in plasmid DNA. This permits the accurate mutatgenesis of the 
lead strand and the generation of  heteroduplex CCC-DNA, as illustrated schematically 
in figure 6.3.2.2.1. However, when the plasmid is transformed into a non-suppressor 
ung+ strain of  E. coli  the dU-ssDNA is destroyed and only the mutated lead strand 
ssDNA is replicated. The resulting mutated plasmid was then subjected to numerous 
rounds of selection to pull out the optimal mutant clone.  
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Figure 6.3.2.2.1 Kunkle-style strategy: The phagemid replicates, in the ung- E. coli host, 
as double – stranded plasmid. On co-infection with a helper phage (M13 in this case), 
single – stranded DNA replication is initiated and the phagemid ssDNA is preferentially 
packaged into the phage particles. This ssDNA is purified from phage, allowing 
production of large quantities of ssUracil-DNA which can be mutated using 
complimentary oligos, containing randomised codons. Filling in the rest of the 
complementary strand using T7 or T4 polymerase creates covalently-closed circular 
DNA When heteroduplex CCC-DNA is introduced into an ung+ strain, the dU-ssDNA 
strand is preferentially destroyed and the synthetic strand is replicated. 
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6.3.2.3 Generation of stop mutant genetic template 
 
CDRL2 was used to generate the stop mutant to be used as the genetic template for 
mutant library construction in place of the wild type clone. The individual stages in this 
strategy are outlined in section 2.11.2 – 2.11.3.4. Figure 6.3.2.3.1 illustrates the 
conversion of purified dU – ssDNA to CCC-DNA incorporating the uricil containing 
strand and the stop mutant lead strand. Confirmation that the lead strand is in fact the 
forward strand was achieved via sequence analysis (figure 6.3.2.3.2). Only the forward 
strand had the “stop” codons substituted into the replicated strand while the reverse 
strand remained as wild type.  
 
 
Figure 6.3.2.3.1 The complete conversion of ssDNA to CCC-DNA is demonstrated in 
this gel. Lane 1: the dU-ssDNA runs at ~1200bp. Lane 2: 1Kb ladder. Lane 3: the 
covalently closed circular DNA runs alongside the top of the ladder. An exact size is 
unattainable as the DNA is running as circular.  
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Wild Type anti – M3G Fab light chain: 
 
A V V T Q E S A L T T S P G E T V T L T C R S S T G A V T T S N Y A N W V Q E K P D H L F T G 
L I G G T N N R A P G V P A R F S G S L I G D K A A L T I T G A Q T E D E A I Y F C V L W Y S 
N H L V F G G G T K L T V L G Q P K 
 
Wild Type anti – M3G Fab heavy chain: 
 
E V Q L Q E S G A E L M K P G A S V K I S C K A T G Y T F S R Y W I E W V K Q R P G H G L E 
W I G E I L P G S G S T K Y N E K F K G R A T F T A D T S S N T V Y M Q L S S L T S E D S A V 
Y H C A R W S Q V H V M D Y W G Q G T T V T V S S A S 
 
Forward mutant 2; light chain: 
 
A V V T Q E S A L T T S P G E T V T L T C R S S T G A V T T S N Y A N W V Q E K P D H L F T G 
L I G S S S S S S S G V P A R F S G S L I G D K A A L T I T G A Q T E D E A I Y F C V L W Y S N 
H L V F G G G T K L T V L G Q P K  
 
Forward mutant 2; heavy chain: 
 
E V Q L Q E S G A E L M K P G A S V K I S C K A T G Y T F S R Y W I E W V K Q R P G H G L E 
W I G E I L P G S G S T K Y N E K F K G R A T F T A D T S S N T V Y M Q L S S L T S E D S A V 
Y H C A R W S Q V H V M D Y W G Q G T T V T V S S A S 
 
Reverse mutant 4; light chain: 
 
A V V T Q E S A L T T S P G E T V T L T C R S S T G A V T T S N Y A N W V Q E K P D H L F T G 
L I G G T N N R A P G V P A R F S G S L I G D K A A L T I T G A Q T E D E A I Y F C V L W Y S 
N H L V F G G G T K L T V L G Q P K 
 
Reverse mutant 4; heavy chain: 
 
E V Q L Q E S G A E L M K P G A S V K I S C K A T G Y T F S R Y W I E W V K Q R P G H G L E 
W I G E I L P G S G S T K Y N E K F K G R A T F T A D T S S N T V Y M Q L S S L T S E D S A V 
Y H C A R W S Q V H V M D Y W G Q G T T V T V S S A S 
 
Figure 6.3.2.3.2 Sequence analysis of random clones picked from transformation plates. 
Heavy chain CDR’s are highlighted in blue, light chain CDR’s are highlighted in pink 
and mutated sections are underlined (bold). The wild type (wt) is included as it is 
illustrative of the comparison between the mutated sequences and the original unaltered 
sequence. The forward mutant shows the mutated region in CDRL2 which is completely 
mutated with 7 stop codons (S). The reverse mutant illustrates no mutations in the 
CDRL2 as it is NOT the lead strand and was not packaged by the M13. 
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6.3.2.4 Generation of small scale CDRL2 mutant library. 
 
Once the first set of CDRL2 primer reactions were performed random clones were sent 
for sequencing to confirm the replacement of stop codons for sense codons using the 
mutagenic primers (figure 6.3.2.4.1). The results demonstrated the requirement to 
eliminate the possibility of  wild-type carry over in the construction of a mutated 
antibody library. It can be clearly seen (below) that one of the clones sequenced, 
CDRL2-P1C has retained the stop codons in the CDR and was not effected by the 
mutagenic primers. This indicated how the final library would contain a percentage of 
this type of sequence. The consequence of this inclusion in the library would have been 
significant if the wild type had not been eliminated by the generation of a stop template 
instead. This is especially important in a case like this one where the wild-type is a very 
strong expresser with a high affinity for the target and could potentially take over the 
selection process. Figure 6.3.2.4.1. also illustrates the diversity seen from two of the 
other clones sequenced. 
 
     CDRL1 
CDRL2_P2B  AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFT 
WILDTYPE_STOP    AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFT 
CDRL2_P2C        AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFT 
CDRL2_P1C       AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFT 
                 ********************************************** 
 
   CDRL2    CDRL3 
CDRL2_P2B       GLIGVNGNSAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCVLWYSNHLVFGGG 
WILDTYPE_STOP   GLIGSSSSSSSGVPARFSGSLIGDKAALTITGAQTEDEAIYFCVLWYSNHLVFGGG 
CDRL2_P2C       GLIGTRKALAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCVLWYSNHLVFGGG 
CDRL2_P1C       GLIGSSSSSSSGVPARFSGSLIGDKAALTITGAQTEDEAIYFCVLWYSNHLVFGGG 
                ****     :.*********************************************  
 
Figure 6.3.2.4.1 T-coffee alignment of 3 random clones from the small scale 
mutagenesis of the CDRL2 and the wild type stop template. The mutated CDR of clone 
P1C is highlighted in green, all other mutated CDR’s are highlighted in pink and the 
unchanged are highlighted in blue. The retention of the stop codons in clone P1C shown 
here is illustrative of the impact of wild-type carry-through in a library.  
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6.3.2.5 Sequence analysis of final large scale library. 
 
It is possible to generate large libraries using the library construction method outlined in 
section 6.3.2.2 (Sidhu et al., 2000) and this is one of the reasons that made it an 
attractive technique. In order to sample the diversity created by a mutagenesis strategy 
such as the one outlined here it was important to create a large enough library to 
incorporate the number of codons targeted. The method outlined here may at first glance 
appear to use the mutation in parallel theory, as discussed previously (section 6.1.1.4), a 
theory that is not ideal given the additive affects of mutating multiple CDR’s. However, 
when the displacement activity of the polymerase is taken into account it becomes 
apparent that the strategy may actually be biased towards targeting one, two or all three 
CDR’s. This is illustrate in figure 6.3.2.5.1, where in just five clones analyzed clone 
no.5 was mutated in CDRL2 and CDRH1 but CDRL3 remains unchanged by the 
mutating primer.  
The large scale library was constructed so as to include mutagenic regions in CDRH1, 
CDRL2 and CDRL3. Figure 6.3.2.5.1 illustrates the sequence analysis of the library 
population prior to biobanning. These sequences confirm the vast diversity that was 
introduced into the targeted regions.  
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Figure 6.3.2.5.1 Sequence analysis of random clones picked from the transformation 
plates of the large scale library prior to panning. Mutated CDR’s are highlighted in pink 
and unaltered CDR’s are highlighted in blue. The wild type (wt) is included as it is 
illustrative of the comparison between the mutated sequences and the unaltered 
sequence. 
 
 
 
Light chain alignment: 
 
clone_1  AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTAFAARGVP  
clone_3  AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGLVFLGAPGVP 
wildtype AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVP 
clone_5  AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTESLSLGVP 
         ****************************************************     *** 
 
clone_1   ARFSGSLIGDKAALTITGAQTEDEAIYFCGALSRNHLVFGGG 
clone_3   ARFSGSLIGDKAALTITGAQTEDEAIYFCGQRELSNNVFGGG 
wildtype  ARFSGSLIGDKAALTITGAQTEDEAIYFCVLWYSNHLVFGGG 
clone_5   ARFSGSLIGDKAALTITGAQTEEEAIYFCVLWYSNHLVFGGG 
          **********************:******     ******** 
 
 
Heavy chain alignment: 
 
clone_5  EVQLQESGAELMKPGASVKISCKATGYTFSRVRWRWVKQRPGHGLEWIGEILPGSGSTKY 
wildtype EVQLQESGAELMKPGASVKISCKATGYTFSRYWIEWVKQRPGHGLEWIGEILPGSGSTKY 
clone_1  EVQLQESGAELMKPGASVKISCKATGYTFSRRGSLWVKQRPGHGLEWIGEILPGSGSTKY 
clone_3  EVQLQESGAELMKPGASVKISCKATGYTFSGGARMWVKQRPGHGLEWIGEILPGSGSTKY 
         ******************************     ************************* 
 
clone_5  NEKFKGRATFTADTSSNTVYMQLSSLTSEDSAVYHCARWSQVHVMDYWGQG 
wildtype NEKFKGRATFTADTSSNTVYMQLSSLTSEDSAVYHCARWSQVHVMDYWGQG 
clone_1  NEKFKGRATFTADTSSNTVYMQLSSLTSEDSAVYHCARWSQVHVMDYWGQG 
clone_3  NEKFKGRATFTADTSSNTVYMQLSSLTSEDSAVYHCARWSQVHVMDYWGQG 
         *************************************************** 
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6.3.2.6 Biopanning 
 
The panning strategy was carried out in general accordance to section 6.3.1.4, with the 
exception that an immunotube was used in the first and second round of panning, only 
switching to an immunosorbent well for the third and final rounds. We were unable to 
generate the optimal large library and a library size of 2 x 107  was achieved. Very large 
libraries are not generally achieved in academic laboratory environments and this type 
of mutagenesis strategy in particular has not been attempted in laboratories outside of 
large institutes such as Genentech (Sidhu et al., 2000) and the Scripps Institute. In order 
to sample the entirety of this moderately sized library we were required to calculate the 
desired inoculum volume needed for infection to facilitate the display of the maximum 
diversity that the library could offer in the selection process. This was determined based 
on the cell density of the initial transformed library stocks, which allowed the 
calculation of the amount of cells and therefore volume of that stock required to over-
represent the theoretical diversity of the library 10-fold. Even where large libraries have 
been constructed it is not often that the entire diversity is sampled in the biopanning 
process. Despite the moderate size of the library used in this study, ever effort was made 
to ensure maximum possible display of its diversity, although it must be taken into 
account that targeting 3 CDR’s and with a total combined length of 21 codons would 
require a library size of >1 x 1030. The input and output titres of the panning process are 
outlined in Table 6.3.2.6.1. 
 
Table 6.3.2.6.1 Input and output titres for all rounds of panning for anti-M3G mutated 
Fab library. 
 Pan 0 Pan 1 Pan 2 Pan 3 Pan 4 
Input - 2.5 x 1011 7.2 x 1011 3.2 x 1011 1.9 x 1012 
Output 1 x 107 5 x 105 1.5 x 105 1.2 x 104 4.9 x 105 
 
6.3.2.7 Single clone analysis of the panned library 
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Single colonies from Pan 4 output plates were grown and induced in small scale in 
microtitre wells. Two 96-well plates were seeded and used for single clone direct 
ELISA analysis on plates coated with 5µg/ml free M3G (figure 6.3.2.7.1(a) and (b)). 
Five clones demonstrated absorbance above 0.2. This was above the background signal 
of approximately 0.1, as determined by a control well demonstrating binding between 
the bound M3G-OVA and an anti-amphetamine Fab fragment. There were 6 clones, 
which expressed antibody that resulted in a high signal; P1C5, P1G4, P1H12, P2C2, 
P2C3 and P2E7. The maximum signal observed was that of P2C3 at >0.9. The same set 
of clones were then carried forward for a “single concentration” competition ELISA 
using 5µg/ml competing free M3G concentration across all wells (figure 6.3.2.7.2 (a) 
and (b)). Total background signal remained <0.1 while each of the 6 clones showed 
competitive inhibition with free M3G. It was concluded at this point that a number of 
clones (six) were expressing at a good rate and also demonstrated good inhibition when 
incubated with free M3G at the relatively high concentration of 5µg/ml. 
Each of the positive binders was grown up in 10ml cultures, induced and an expression 
titre was carried out to investigate each clone for false positives and expression 
characteristics (figure 6.3.2.7.3). Five of the 8 clones examined proved to be false 
positives and three, P1C5, P2E7 and P2C3, were carried on for further analysis. 
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Figure 6.3.2.7.1 (a) and (b) represent the single clone (pan 4) soluble expression ELISA 
performed on M3G-OVA-coated wells. Data was expressed as absorbance (Abs). 
(a) 
 (b) 
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Figure 6.3.2.7.2 Inhibition ELISA assay performed on M3G-OVA-coated wells. Data 
was expressed as absorbance.  
Figure 6.3.2.7.3 Direct ELISA performed on M3G-OVA-coated wells performed to 
calculate the titre of the P2C3 Fab fragment. Data was expressed as absorbance.  
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6.3.2.8 Characterisation of positive clones 
 
 
A pick PCR was carried out in order to confirm the presence of a 1600 bp band using 
the standard Fab amplification primers (Chapter 3). A clean 1600 bp band was 
amplified from P2C3. However, there was no correct fragment size amplified from the 
P1C5 plasmid and there were multiple bands amplified along with the 1600bp band 
from the P2E7 plasmid. Hence, it was decided that while all three clones would be sent 
for sequencing (figure 6.3.2.8.1), only P2C3, would be further characterised, expressed 
and purified on a larger scale.  
The sequence results for the three clones were of mixed quality and only P2C3 could be 
interpreted with any success. The poor sequence quality of the clones was confirmed 
with the mixed amplification pattern (data not shown) and as such the sequence quality 
was not queried. It can be concluded that the positive clones, other than P2C3, 
contained contaminating DNA and did not contain pure anti-M3G fab fragment genetic 
material.  
The sequence analysis of the clone P2C3 revealed that two amino acids had been 
mutated compared to the wild type anti-M3G Fab fragment. These two amino acids are 
located in the CDR2 of the light chain (figure 6.3.2.8.1). Two asparagines are located at 
position 2 and 3 of the 7-base CDRL2 in the wild-type, these have been mutated to an 
electrically charged arginine followed by a hydrophobic glycine in the mutated gene. 
The substitution of the charged amino acid here clearly has an influence on the on-rate 
(Ka) of the antibody. However, the full impact of this change, albeit minor, could not be 
investigated without being able to put an exact value on the Ka. The fact that the change 
in on-rate appears to be very small, when visually examined, and that the mutant and 
wild type exhibit similar affinity would indicate that there has not been a significant 
impact on the characteristics of the antibody as a result of the amino acid changes.  
The DNA sequence (figure 6.3.2.8.2) reveals the presence of 7 base substitutions, which 
translate to only two amino acid substitutions. The remaining base changes have an 
insignificant effect on protein folding. The actual pre-panned library carried extensive 
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and complete mutation of the targeted CDR’s (figure 6.3.2.5.1) so the fact that the best 
clone post-panning revealed the presence of only 2 amino acid substitutions is strongly 
indicative that the wild-type Fab has already achieved its maximum sensitivity. It is 
possible that the mutations observed here are merely tolerated by the antibody fragment 
rather than enhancing the affinity. 
In direct ELISA, the His-purified and concentrated (to 500µl final volume) antibody 
preparations provided a titre of 1/25,600 (figure 6.3.2.8.3). ELISA conditions for each 
antibody were optimised (data not shown). At an optimal antibody dilution of 1/6400, 
the Fab was shown to have a detection range of  ~ 4 ng/ml (figure 6.3.2.8.4) very 
similar to that of the wild type Fab fragment (~ 3 ng/ml) (chapter 3).  
An inhibition assay, based on similar conditions as set out in section 3.3.3.2, was set up 
on the Biacore. The linear range of detection of both wild type and mutant Fab 
fragments were very similar and comparable to the ELISA results (data not shown). 
Kinetic off rate analysis revealed very similar off rates for both Fab’s with the wild-type 
showing a dissociation rate of 4.7 x 10-2 and the mutant Fab showing a dissociation rate 
of 2.9 x 10-2 (figure 6.3.2.8.5).  
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Light chain: 
           CDRL1                          CDRL2 
P2C3  AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTRGRAPGVP 
WT    AVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVP 
      ****************************************************  ****** 
 
                CDRL3 
P2C3  ARFSGSLIGDKAALTITGAQTEDEAIYFCVLWYSNHLVFGGGTKLTVLGQPK 
WT    ARFSGSLIGDKAALTITGAQTEDEAIYFCVLWYSNHLVFGGGTKLTVLGQPK 
      **************************************************** 
Heavy chain: 
                 CDRH1         CDRH2 
WT    SGAELMKPGASVKISCKATGYTFSRYWIEWVKQRPGHGLEWIGEILPGSGSTKYNEKFKG 
P2C3  SGAXLMKPGASVKXSCKATGYTFXRYWIEWVKQRPGHGLEWIGEILPGSGSTKYNEKFKG 
      ************************************************************ 
 
                       CDRH3 
WT    RATFTADTSSNTVYMQLSSLTSEDSAVYHCARWSQVHVMDYWGQGTTVTVSSAS 
P2C3  RATFTADTSSNTXYMQLSSLTSEDSAVYHCARWSQVHVMDYWGQGTTVTVSSAS 
      ************ ***************************************** 
 
Figure 6.3.2.8.1 Protein equence analysis of clone P2C3, obtained through 4 rounds of 
panning. Mutated CDR’s are highlighted in pink and unaltered CDR’s are highlighted in 
blue. Changes in the mutated P2C3 are in bold and underlined in CDRL2. The wild type 
(wt) is included for comparison between the mutated sequences and the unaltered 
sequence.  
 
P2C3 GGGACGAGG GGCCGGGCTCCA 
WT   GGTACCAAC AACCGAGCTCCA 
 
Figure 6.3.2.8.2 DNA sequence analysis of the CDRL2, with 7 base substitutions in 
total. 
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Figure 6.3.2.8.3 Direct ELISA performed on M3G-OVA coated wells performed to 
calculate the titre of the P2C3 Fab fragment. Data was expressed as absorbance.  
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Figure 6.3.2.8.4 ELISA inhibition assay performed on M3G-OVA-coated wells 
comparing wild-type Fab (pink) and P2C3 Fab (blue) binding response versus 
competing free M3G concentration. Concentration range of 610 – 5,000,000 pg/ml) 
Data is expressed as A/Ao (i.e. the signal at different free analyte concentrations are 
expressed as a proportion of signal in the presence of no competing analyte). 
Figure 6.3.2.8.6 Representative sensogram demonstrating the slight difference between 
wt Fab (pink) and the mutated Fab (red) binding response under normal assay 
conditions described previously. On-line reference subtraction was performed against a 
flow-cell coated with OVA.   
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6.4 Conclusion  
 
This chapter focused on the construction of two alternative mutagenesis libraries. The 
first attempt used a CDR walking approach based on methods outlined in Barbas et al. 
(2001). This strategy focused on the CDR3 of the heavy chain, a region of the antibody 
regarded as the primary point of contact with the antigen. The method resulted in total 
loss of antigen recognition. It is possible that the CDRH3 may have been heavily 
evolved and ultimately too critical to the function of the anti-M3G Fab to be targeted for 
mutagenesis, however, it is also acknowledged that panning  stringency could also be a 
factor. A second strategy was designed based on a method outlined in Sidhu et al. 
(2000) which eliminated the use of PCR and focused on CDR2 and 3 of the light chain 
and CDR1 of the heavy chain of the anti – M3G Fab fragment. The CDR’s targeted in 
this technique are generally thought to be involved in stabilising the antigen binding site 
(section 6.3.2) and possibly influencing the rigidity of the antibody structure, which 
may be more appropriate to anti-hapten antibody affinity maturations.  
The resultant mutated library was successful in retaining target (M3G) recognition as a 
polyclonal population. Sequence analysis revealed that the antibody structure was 
tolerant to two amino-acid substitutions in the CDRL2 and that the other CDR’s 
retained the wild type sequence. This result strongly suggested that the wild-type had 
the optimal sequence, and, given that it has already undergone functional mutation in 
vivo since it came from a monoclonal parent structure, this would hold true.  
There is tremendous scope for future work here. The effects of the substitution of 
further charged amino acids into the peripheral CDR’s would be very interesting with 
regard to examining ‘off-rate’ changes in the anti-M3G Fab fragment. Given that the 
small change in ‘on-rate’ seen in figure 6.3.2.8.6 has clearly had some impact on the 
dissociation rate, one could hypothesise that substitution of more charged amino acids 
may result in significantly slowing down the ‘off-rate’ and, therefore, improving the 
affinity of the Fab fragment.  
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We have clearly demonstrated the value of this anti-hapten engineering strategy. The 
anti-M3G antibody was already highly characterised and as such provided an ideal 
template for this work. While the strategy did not result in a significantly improved 
antibody binding site, it did result in a new antibody fragment that retains binding of the 
target molecule and more importantly demonstrates excellent expression and inhibition 
characteristics (section 6.3.2.8). Scope is provided for more focused mutagenesis 
involving specific residues with potential to achieve improved binding. In earlier 
chapters important discoveries were made regarding the choice of recombinant structure 
to use (scFv / Fab). In this chapter, important discoveries were made regarding the 
improvement of anti-hapten antibodies. These include, the significance of the CDRH3 
in an antibody raised against a hapten which does not possess multiple binding sites and 
the significance of not forcing multiple mutations in parallel but instead creating bias 
for one CDR via the stop mutant strategy laid out in section 6.3.2.3, and further 
discussed in section 6.3.2.5. 
The optimised mutagenesis strategies outlined throughout this chapter have significant 
potential for use for improvement of the lower affinity anti-amphetamine Fab fragment. 
In addition, the anti-THC scFv fragment, that was not cloned from a monoclonal but 
instead selected from a leporine immune library, could benefit enormously from such 
in-vitro maturation techniques.  
262 
 
 
 
 
 
 
 
 
 
Chapter 7 
7.0 Overall Conclusions 
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7.1 Overall Conlcusions 
 
The research in this thesis describes the succcessful production and characterisation of 
novel genetically-derived antibody fragments to morphine-3-glucuronide (M3G), 
amphetamine and tetrahydrocannibinol, their structural modification, in-vitro 
mutagenesis and application in a multi-analyte assay.  
 
Chapter 3 focused on the production and characterisation of a genetically derived Fab 
fragment specific to amphetamine. A previously described anti-amphetamine antibody-
secreting hybridoma was the source of the cDNA used to isolate the DNA encoding the 
antibodies variable heavy and variable light chains. The constant heavy and constant 
light chains were cloned from the pComb3xTT vector. The anti-amphetamine Fab 
fragment was successfully used in the development of a Biacore inhibition assay and the 
Fab fragment demonstrated superior sensitivity to that of the parent IgG molecule. 
Under optimised conditions the Fab demonstrated an IC50 of 200 ng/ml compared to an 
IC50 of ~ 600 ng/ml for the monoclonal antibody. The purified antibody provided 
excellent titres with working dilutions in the range of 1 in 2000 when purified from a 
500ml culture volume, further increasing its superiority over the IgG, where lower 
concentrations of antibody were obtained following purification. The second part of this 
chapter described the potential of producing an anti-amphetamine scFv fragment by 
similar means. Several attempts were made but no specific scFv was isolated. It is 
probable that the antibody encoded in the parent IgG was heavily reliant on the 
stabilising nature of the whole IgG structure. The Fab fragment, with the presence of the 
human constant chains, was able to retain and in fact improve the affinity while the 
‘floppy’ nature of the scFv molecule was not capable of retaining the critical cavity 
shaped binding epitope common to anti-hapten antibodies.  
 
In chapter 4 the prodruction of an anti-M3G Fab fragment via the structural conversion 
of an anti-M3G scFv was described. The genes encoding the variable regions were 
amplified from the scFv fragment and the human constant regions for the Fab were 
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amplifed from the pComb3xTT vector, as in chapter 3. The successful generation of an 
M3G-specific Fab fragment directed the research towards the examination of the 
influence of scFv multimerisation, Fab constant region stability and SPR chip surface 
coating chemistry, on anti-hapten surface plasmon resonance (SPR) assay development. 
Under optimised conditions, the anti-M3G scFv was found to have an IC50 value of 30 
ng/ml, while the Fab construct exhibited an IC50 value of 2.4 ng/ml. In an SPR-based 
competitive assay on an M3G-OVA-coated chip surface, the two constructs again 
differed in sensitivity, with IC50 values of 117 and 19 ng/ml for the scFv and Fab, 
respectively. However, when M3G was directly immobilized onto the SPR chip surface, 
both antibody constructs exhibited good linearity of response, with similar high 
sensitivity IC50 values (scFv 30 ng/ml; Fab 14 ng/ml). During SPR assay development 
it was noticed that scFv and Fab constructs gave differing off-rate profiles. Subsequent 
HPLC, ELISA and electrophoretic analyses confirmed that a portion of the scFv 
population multimerises. Bivalent scFv was found to profoundly affect the dissociation 
curve for scFv in stringent SPR kinetic analyses, leading to a 40-fold difference in 
calculated off-rate values. This finding has significant implications when ranking 
recombinant antibodies libraries via off-rate analysis.  
 
Previous investigations (Brennan, 2004; unpublished data) into the production of novel 
recombinant antibody fragments against tetrahydrocannabinol were reported as 
unsuccessful. However, chapter 5, details the successful generation of an anti-THC scFv 
fragment. A rabbit immune library was constructed and panned yielding a soluble 
secreting anti-THC scFv clone.  The affinity of this anti-THC scFv and that of the 
commercially available monoclonal antibody were compared on ELISA. While their 
affinities were comparable, the reproducibility achieved with the scFv in competitive 
assay was superior. The anti-THC scFv applied to a SPR inhibition assay on Biacore 
demonstrated an 1C50 of 625 ng/ml. Future work could entail the conversion of the 
scFv to a Fab fragment in order to investigate if any improvement would be observed 
(as in chapters 3 and 4). However, solubility issues with the free drug require further 
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investigation prior to any extensive work on increasing the affinity of the antibody 
fragment or on improving the SPR assay using different surface chemistries as 
described for the anti-M3G Biacore assay.  
 
A low-density SPR-based assay array on a Biacore chip was designed and 
characterized. The success of this assay is illustrative of the potential of these novel 
recombinant antibodies for use in a multi-drug detection format and their potential for 
commercialization. These assays may eventually be used to combat a rapidly increasing, 
social, health and legal problems related to drug abuse. Future work envisaged would 
include a novel microfluidics-based bio-chip with a larger number of antibodies against 
a range of drugs of abuse. 
 
 
Mutagenesis of the anti-M3G Fab fragment is discussed in chapter 6. Two alternative 
approaches were investigated. The first utilised CDR walking and focused on the 
primary region of antigen binding, the CDRH3. The second strategy used the PCR 
eliminating method described by Kunkle (1985), and targeted the more peripheral 
CDR’s such as the CDRL2, CDRL3 and CDRH1. Several attempts were made to obtain 
a functional clone from the mutated CDRH3 library. However, it was concluded that the 
CDRH3 was simply too critical to the function of the anti-M3G Fab fragment and no 
mutation in this region was tolerated. The second strategy which investigated regions of 
the antibody fragment that are thought to be more involved in stabilisation and 
structural rigidity were found to be more  tolerant of mutation. With functionality of the 
anti-M3G Fab retained, sequence analysis revealed mutations in the CDRL2 while all 
other regions retained wildtype sequence.  
 
This research records important discoveries with regard to anti-hapten antibodies. These 
include the optimal recombinant antibody structure to use, the impact of this structural 
choice on library screening and assay development (chapters 3 and 4 and 5), and the 
significance of  the CDRH3 in anti-hapten binding compared to that of an anti-protein 
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(i.e. large antigen) antibody where multiple binding sites are available on the target. 
Moreover, these discoveries have lighthighlighted the need for careful analysis of 
strategy when working with recombinant antibodies. Here, antibodies against all three 
targets were achieved through target-specific tailoring of all experimental strategies. 
 
Future work could entail the application of methods outlined in chapter 6 to improve  
the lower affinity anti-amphetamine antibody fragment. Similar methods should also be 
applied to the improvement of the anti-THC scFv, where the potential is even more 
signifcant due to its lack of in-vivo functional mutation, as discussed in chapter 6. There 
is enormous scope for the further development of the multi-drug assay outlined in 
chapter 5, each of the antibodies described here have been fully characterised by ELISA 
and Biacore on a single analyte assay format and then further characterised in the multi-
drug SPR assay format. Each antibody has proven robust and functionally stable to 
perform in this multi-analyte assay with no compromise in sensitivity. The next step 
would be their application to a low-density micro-array for on-site testing allowing for 
sensitive, specific, rapid and simultaneous detection of multiple drug classes. 
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7.1 Overall Conlcusions 
 
The research in this thesis describes the succcessful production and characterisation of 
novel genetically-derived antibody fragments to morphine-3-glucuronide (M3G), 
amphetamine and tetrahydrocannibinol, their structural modification, in-vitro 
mutagenesis and application in a multi-analyte assay.  
 
Chapter 3 focused on the production and characterisation of a genetically derived Fab 
fragment specific to amphetamine. A previously described anti-amphetamine antibody-
secreting hybridoma was the source of the cDNA used to isolate the DNA encoding the 
antibodies variable heavy and variable light chains. The constant heavy and constant 
light chains were cloned from the pComb3xTT vector. The anti-amphetamine Fab 
fragment was successfully used in the development of a Biacore inhibition assay and the 
Fab fragment demonstrated superior sensitivity to that of the parent IgG molecule. 
Under optimised conditions the Fab demonstrated an IC50 of 200 ng/ml compared to an 
IC50 of ~ 600 ng/ml for the monoclonal antibody. The purified antibody provided 
excellent titres with working dilutions in the range of 1 in 2000 when purified from a 
500ml culture volume, further increasing its superiority over the IgG, where lower 
concentrations of antibody were obtained following purification. The second part of this 
chapter described the potential of producing an anti-amphetamine scFv fragment by 
similar means. Several attempts were made but no specific scFv was isolated. It is 
probable that the antibody encoded in the parent IgG was heavily reliant on the 
stabilising nature of the whole IgG structure. The Fab fragment, with the presence of the 
human constant chains, was able to retain and in fact improve the affinity while the 
‘floppy’ nature of the scFv molecule was not capable of retaining the critical cavity 
shaped binding epitope common to anti-hapten antibodies.  
 
In chapter 4 the prodruction of an anti-M3G Fab fragment via the structural conversion 
of an anti-M3G scFv was described. The genes encoding the variable regions were 
amplified from the scFv fragment and the human constant regions for the Fab were 
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amplifed from the pComb3xTT vector, as in chapter 3. The successful generation of an 
M3G-specific Fab fragment directed the research towards the examination of the 
influence of scFv multimerisation, Fab constant region stability and SPR chip surface 
coating chemistry, on anti-hapten surface plasmon resonance (SPR) assay development. 
Under optimised conditions, the anti-M3G scFv was found to have an IC50 value of 30 
ng/ml, while the Fab construct exhibited an IC50 value of 2.4 ng/ml. In an SPR-based 
competitive assay on an M3G-OVA-coated chip surface, the two constructs again 
differed in sensitivity, with IC50 values of 117 and 19 ng/ml for the scFv and Fab, 
respectively. However, when M3G was directly immobilized onto the SPR chip surface, 
both antibody constructs exhibited good linearity of response, with similar high 
sensitivity IC50 values (scFv 30 ng/ml; Fab 14 ng/ml). During SPR assay development 
it was noticed that scFv and Fab constructs gave differing off-rate profiles. Subsequent 
HPLC, ELISA and electrophoretic analyses confirmed that a portion of the scFv 
population multimerises. Bivalent scFv was found to profoundly affect the dissociation 
curve for scFv in stringent SPR kinetic analyses, leading to a 40-fold difference in 
calculated off-rate values. This finding has significant implications when ranking 
recombinant antibodies libraries via off-rate analysis.  
 
Previous investigations (Brennan, 2004; unpublished data) into the production of novel 
recombinant antibody fragments against tetrahydrocannabinol were reported as 
unsuccessful. However, chapter 5, details the successful generation of an anti-THC scFv 
fragment. A rabbit immune library was constructed and panned yielding a soluble 
secreting anti-THC scFv clone.  The affinity of this anti-THC scFv and that of the 
commercially available monoclonal antibody were compared on ELISA. While their 
affinities were comparable, the reproducibility achieved with the scFv in competitive 
assay was superior. The anti-THC scFv applied to a SPR inhibition assay on Biacore 
demonstrated an 1C50 of 625 ng/ml. Future work could entail the conversion of the 
scFv to a Fab fragment in order to investigate if any improvement would be observed 
(as in chapters 3 and 4). However, solubility issues with the free drug require further 
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investigation prior to any extensive work on increasing the affinity of the antibody 
fragment or on improving the SPR assay using different surface chemistries as 
described for the anti-M3G Biacore assay.  
 
A low-density SPR-based assay array on a Biacore chip was designed and 
characterized. The success of this assay is illustrative of the potential of these novel 
recombinant antibodies for use in a multi-drug detection format and their potential for 
commercialization. These assays may eventually be used to combat a rapidly increasing, 
social, health and legal problems related to drug abuse. Future work envisaged would 
include a novel microfluidics-based bio-chip with a larger number of antibodies against 
a range of drugs of abuse. 
 
 
Mutagenesis of the anti-M3G Fab fragment is discussed in chapter 6. Two alternative 
approaches were investigated. The first utilised CDR walking and focused on the 
primary region of antigen binding, the CDRH3. The second strategy used the PCR 
eliminating method described by Kunkle (1985), and targeted the more peripheral 
CDR’s such as the CDRL2, CDRL3 and CDRH1. Several attempts were made to obtain 
a functional clone from the mutated CDRH3 library. However, it was concluded that the 
CDRH3 was simply too critical to the function of the anti-M3G Fab fragment and no 
mutation in this region was tolerated. The second strategy which investigated regions of 
the antibody fragment that are thought to be more involved in stabilisation and 
structural rigidity were found to be more  tolerant of mutation. With functionality of the 
anti-M3G Fab retained, sequence analysis revealed mutations in the CDRL2 while all 
other regions retained wildtype sequence.  
 
This research records important discoveries with regard to anti-hapten antibodies. These 
include the optimal recombinant antibody structure to use, the impact of this structural 
choice on library screening and assay development (chapters 3 and 4 and 5), and the 
significance of  the CDRH3 in anti-hapten binding compared to that of an anti-protein 
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(i.e. large antigen) antibody where multiple binding sites are available on the target. 
Moreover, these discoveries have lighthighlighted the need for careful analysis of 
strategy when working with recombinant antibodies. Here, antibodies against all three 
targets were achieved through target-specific tailoring of all experimental strategies. 
 
Future work could entail the application of methods outlined in chapter 6 to improve  
the lower affinity anti-amphetamine antibody fragment. Similar methods should also be 
applied to the improvement of the anti-THC scFv, where the potential is even more 
signifcant due to its lack of in-vivo functional mutation, as discussed in chapter 6. There 
is enormous scope for the further development of the multi-drug assay outlined in 
chapter 5, each of the antibodies described here have been fully characterised by ELISA 
and Biacore on a single analyte assay format and then further characterised in the multi-
drug SPR assay format. Each antibody has proven robust and functionally stable to 
perform in this multi-analyte assay with no compromise in sensitivity. The next step 
would be their application to a low-density micro-array for on-site testing allowing for 
sensitive, specific, rapid and simultaneous detection of multiple drug classes. 
 
 
 
 
 
 
Chapter 8 
8.0 Bibliography 
Alt, F. W., Blackwell, T. K. and Yancopoulos, G. D. (1987). Development of the 
primary antibody repertoire. Science. 238, 1079-1087.  
Barbas, C. F. (1993). Recent advances in phage display. Current Opinion in 
Biotechnology. 4, 526-530 
Benjamini, E., Coico, R. and Sunshine, G. (2000). Immunology: A short course. 4th. 
New York, USA: Wiley and sons.  
Biermann, T., Schwarze, B., Zedler, B. and Betz, P. (2004). On-site testing of illicit 
drugs: the use of the drug-testing device “Toxiquick®”. Forensic Science International. 
143, 21-25.  
Braithwaite, R. A., Jarvie, D. R. and Minty, P. S. B, Simpson D, Widdop B. (1995). 
Screening for drugs of abuse. I: Opiates, amphetamines and cocaine. Annals of Clinical 
Biochemistry. 32, 123-153.  
Brennan, J., Dillon, P. and O'Kennedy, R. (2003). Production, purification and 
characterisation of genetically derived scFv and bifunctional antibody fragments capable 
of detecting illicit drug residues. Journal of chromatography.B, Analytical Technologies 
in the Biomedical and Life Sciences. 786, 327-342.  
Brichta, J., Hilova, M. and Viskovic, T. (2005). Generation of hapten-specific 
recombinant antibodies: antibody phage display technology: a review. Veterinary 
Medicine-Czech. 231-252.  
Campbell, F. A., Tramer, M. R. and Carroll, D, Reynolds D. J. M., Moore R. A., 
McQuay H. J. (2001). Are cannabinoids an effective and safe treatment option in the 
management of pain? A qualitative systematic review. British Medical Journal (Clinical 
research ed.). 323, 13-16.  
Chames, P., Coulon, S. and Baty, D. (1998). Improving the affinity and the fine 
specificity of an anti-cortisol antibody by parsimonious mutagenesis and phage display. 
Journal of Immunology. 161, 5421-5429.  
Charlton, K., Harris, W. J. and Porter, A. J. (2001). The isolation of super-sensitive anti-
hapten antibodies from combinatorial antibody libraries derived from sheep. Biosensors 
and  Bioelectronics. 16, 639-646.  
Cirimele, V., Villain, M. and Mura, P., Bernard, M. and Kintz, P. (2006). Oral fluid 
testing for cannabis: On-site OraLine® IV s.a.t. device versus GC/MS. Forensic Science 
International. 161, 180-184.  
Clarke, J. and Wilson, J. F. (2005). Proficiency testing (external quality assessment) of 
drug detection in oral fluid. Forensic Science International. 150, 161-164.  
Click, E. M. and Webster, R. E. (1997). Filamentous phage infection: Required 
interactions with the Tol A protein. Journal of Bacteriology. 179, 6464-6471. 
Batra, S. K.,  Jain, M., Wittel, A. U., Chauhan, S. C. and Colcher, D. (1998) 
Pharmacokinetics and biodistribution of genetically engineered antibodies 
Current Opinion in Biotechnology, 13, 603-608.  
Cone, E. J., Darwin, W. D. and Wang, W. L. (1993). The occurrence of cocaine, heroin 
and metabolites in hair of drug abusers. Forensic Science International. 63, 55-68.  
Cone, E. J., Presley, L. and Lehrer, M. (2002). Oral fluid testing for drugs of abuse: 
positive prevalence rates by Intercept immunoassay screening and GC-MS-MS 
confirmation and suggested cutoff concentrations. Journal of Analytical Toxicology. 26, 
541-546.  
Connell, J. A., Parry, J. V., Mortimer, P. P. and Duncan, J. (1993). Novel assay for the 
detection of immunoglobulin G antihuman immunodeficiency virus in untreated saliva 
and urine. Journal of Medical Virology. 41, 159-164.  
Dillon, P., Manning, B. and Daly, S., Killard, T. and O'Kennedy, R. (2003). Production 
of a recombinant anti-morphine-3-glucuronide single-chain variable fragment (scFv) 
antibody for the development of a “real-time” biosensor-based immunoassay. Journal of 
Immunological Methods. 276,151-161.  
Dooley, H., Flajnik, M. F. and Porter, A. J. (2003). Selection and characterization of 
naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks 
by phage display. Molecular Immunology. 40, 25-33.  
Eliasson, C., Macleod, N. A. and Matousek, P. (2008). Non-invasive detection of 
cocaine dissolved in beverages using displaced Raman spectroscopy. Analytica Chimica 
Acta. 607, 50-53.  
Elliott, C. T., Baxter, G. A. and Hewett, S. A. (1998). Use of biosensors for rapid drug 
residue analysis without sample deconjugation or clean-up: a possible way forward. The 
Analyst. 123, 2469-2473.  
Ewald, A. H., Fritschi, G. and Maurer, H. H. (2007). Metabolism and toxicological 
detection of the designer drug 4-iodo-2,5-dimethoxy-amphetamine (DOI) in rat urine 
using gas chromatography–mass spectrometry. Journal of Chromatography B. 857, 170-
174.  
Endemann, H. and Model, P. (1995). Location of Filamentous Phage Minor Coat 
Proteins in Phage and in Infected Cells. Journal of Molecular Biology. 250, 495-506. 
Freund, C., Ross, A. and Guth, B., Pluckthun, A. and Holackt, A. (1993). 
Characterization of the linker peptide of the single-chain Fv fragment of an antibody by 
NMR spectroscopy. FEBS letters. 320, 97-100.  
Fucci, N., De Giovanni, N. and Chiarotti, M. (2003). Simultaneous detection of some 
drugs of abuse in saliva samples by SPME technique. Forensic Science International. 
134, 40-45.  
Glockshuber, R., Malia, M., Pfitzinger, I. and Pluckthun, A. (1990). A comparison of 
strategies to stabilize immunoglobulin Fv-fragments. Biochemistry. 29, 1362-1367.  
Gross, J., Johnson, J., Sigler, L. and Stitzer, M. L. (1995). Dose effects of nicotine gum. 
Addictive Behaviors. 20, 371-381.  
Hofman, L. F. (2001). Human saliva as a diagnostic specimen. The Journal of Nutrition. 
131, 1621S-5S.  
Holliger, P. and Hudson, P. J. (2005). Engineered antibody fragments and the rise of 
single domains. Nature Biotechnology. 23, 1126-1136.  
Hoogenboom, H. R., de Bruïne, A. P. and Hufton, S. E., Hoet, R. M., Arends, J.W. and 
Roovers, R. C. (1998). Antibody phage display technology and its applications. 
Immunotechnology. 4, 1-20.  
Huestis, M. A. and Cone, E. J. (2004). Relationship of Delta 9-tetrahydrocannabinol 
concentrations in oral fluid and plasma after controlled administration of smoked 
cannabis. Journal of Analytical Toxicology. 28, 394-399.  
Huse, W. D., Sastry, L., Iverson, S. A., Kang, A. S., Alting-Mees, M., Burton, D. R., 
Benkovic, S. J. and Lerner, R. A. (1989). Generation of large combinatorial libraries of 
the immunoglobulin repertoire in phage lambda. Science. 246, 1275-1281. 
Hust, M. and Dubel, S. (2004). Mating antibody phage display with proteomics. Trends 
in Biotechnology. 22, 8-14.  
Huston, J. S., Margolies, M. N. and Haber, E. (1996). Antibody Binding Sites. Advances 
in Protein Chemistry. 49, 329-450. 
Kacinko, S. L.,  Reid, C.,  Cooper, G. A., Huestis, M. A.,  Baldwin, D., Moolchan, E. T.,  
Barnes, A. J., Hand, C. W., Wilson, L. and Kim, I. (2004). Performance characteristics of 
the Cozart® RapiScan Oral Fluid Drug Testing System for opiates in comparison to 
ELISA and GC/MS following controlled codeine administration. Forensic Science 
International. 141, 41-48.  
Kato, K., Hillsgrove, M. and Weinhold, L., Gorelick, D.A., Darwin, W.D. and Cone, E.J. 
(1993). Cocaine and metabolite excretion in saliva under stimulated and nonstimulated 
conditions. Journal of Analytical Toxicology. 17, 338-341.  
Kintz, P. and Samyn, N. (1999). Determination of “Ecstasy” components in alternative 
biological specimens. Journal of Chromatography B: Biomedical Sciences and 
Applications. 733, 137-143.  
Lazzaroni, J. C., Germon, P., Ray, M. C. and Vianney, A. (1999). The Tol proteins of 
Escherichia coli and their involvement in the uptake of biomolecules and outer membrane 
stability. FEMS Microbiology Letters. 177, 191-197. 
Lowman, H. B. and Wells, J. A. (1991). Monovalent phage display: A method for 
selecting variant proteins from random libraries. Methods. 3, 205-216. 
Li, Y., Cockburn, W., Kilpatrick, J. B. and Whitelam, G. C. (2000). High affinity ScFvs 
from a single rabbit immunized with multiple haptens. Biochemical and Biophysical 
Research Communications. 268, 398-404.  
Li, Z., Woo, C. J. and Iglesias-Ussel, M. D. (2004). The generation of antibody diversity 
through somatic hypermutation and class switch recombination. Genes and Development. 
18, 1-11.  
Lu, D., Shen, J. and Vil, M. D. (2003). Tailoring in vitro selection for a picomolar 
affinity human antibody directed against vascular endothelial growth factor receptor 2 for 
enhanced neutralizing activity. The Journal of Biological Chemistry. 278, 43496-43507.  
Lu, H., Kreuzer, M., Takkinen, K. and Guilbault, G. (2007). A recombinant Fab 
fragment-based electrochemical immunosensor for the determination of testosterone in 
bovine urine. Biosensors and Bioelectronics. 22, 1756-1763.  
Lu, N. T. and Taylor, B. G. (2005). Drug screening and confirmation by GC–MS: 
Comparison of EMIT II and Online KIMS against 10 drugs between US and England 
laboratories. Forensic Science International. 157, 106-116.  
Lubkowski, J., Hennecke, F., Plückthun, A. and Wlodawer, A. (1999). Filamentous 
phage infection: crystal structure of g3p in complex with its coreceptor, the C-terminal 
domain of TolA. Structure. 7, 711-722. 
Lurie, I. S. (1998). Capillary electrophoresis of illicit drug seizures. Forensic Science 
International. 92, 125-136.  
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., Mc Cafferty, J., Griffiths, A. D. and 
Winter, G. (1991). By-passing immunization. Human antibodies from V-gene libraries 
displayed on phage. Journal of Molecular Biology. 222, 581-597.  
Moore, L., Wicks, J., Spiehler, V. and Holgate, R.(2001). Gas chromatography-mass 
spectrometry confirmation of Cozart RapiScan saliva methadone and opiates tests. 
Journal of Analytical Toxicology. 25, 520-524.  
Niedbala, R. S., Kardos, K. W., Fritch, D. F. (2001b). Detection of marijuana use by oral 
fluid and urine analysis following single-dose administration of smoked and oral 
marijuana. Journal of Analytical Toxicology. 25, 289-303.  
Ogert, R. A., Kusterbeck, A. W., Wemhoff, G. A., Burke, R. and Ligler, F. S. (1992). 
Detection of cocaine using flow immunosensors. Analytical Letters. 25, 1999-2019.  
Persson, H., Wallmark, H., Ljungars, A., Hallborn, J. and Ohlin, M. (2008). In vitro 
evolution of an antibody fragment population to find high-affinity hapten binders. Protein 
Engineering, Design and Selection: PEDS. 21, 485-493.  
Petersen-Mahrt, S. K., Harris, R. S. and Neuberger, M. S. (2002). AID mutates E. coli 
suggesting a DNA deamination mechanism for antibody diversification. Nature. 418, 99-
103.  
Poltoratsky, V., Goodman, M. F. and Scharff, M. D. (2000). Error-prone candidates vie 
for somatic mutation. The Journal of Experimental Medicine. 192, 27-30.  
Puder, K. S., Kagan, D. V. and Morgan, J. P. (1988). Illicit methamphetamine: analysis, 
synthesis, and availability. The American Journal of Drug and Alcohol Abuse. 14, 463-
473.  
Roth, D. B. and Craig, N. L. (1998). VDJ recombination: a transposase goes to work. 
Cell. 94, 411-414.  
Popkov, M., Mage, R. G., Alexander, C. B., Thundivalappil, S., Barbas, C. F. and Rader, 
C. (2003). Rabbit Immune Repertoires as Sources for Therapeutic Monoclonal 
Antibodies: The Impact of Kappa Allotype-correlated Variation in Cysteine Content on 
Antibody Libraries Selected by Phage Display. Journal of Molecular Biology. 325, 325-
335. 
Raag, R. and Whitlow, M. (1995). Single-chain Fv’s. FASEB,J. 1, 73-80. 
Roitt I. M. (1989). Immunology. Gower Medical Publishing, London. 
Reynaud, C. A., Anquez, V., Grimal, H. and Weill, J. C. (1987). A hyperconversion 
mechanism generates the chicken light chain preimmune repertoire. Cell. 3, 379-388. 
Samyn, N. and van Haeren, C. (2000). On-site testing of saliva and sweat with Drugwipe 
and determination of concentrations of drugs of abuse in saliva, plasma and urine of 
suspected users. International Journal of Legal Medicine. 113, 150-154.  
Santala, V. and Saviranta, P. (2004). Affinity-independent elution of antibody-displaying 
phages using cleavable DNA linker containing streptavidin beads. Journal of 
Immunological Methods. 284, 159-163.  
Schmitz, U., Versmold, A., Kaufmann, P. and Frank, H. G. (2000). Phage display: a 
molecular tool for the generation of antibodies--a review. Placenta. 21, 106-12.  
Sheedy, C., Roger MacKenzie, C. and Hall, J. C. (2007). Isolation and affinity 
maturation of hapten-specific antibodies. Biotechnology Advances.  25, 333-352.  
Skerra, A. and Pluckthun, A. (1988). Assembly of a functional immunoglobulin Fv 
fragment in Escherichia coli. Science. 240, 1038-1041.  
Simons, G. F., Konings, R. N., and Schoenmakers, J. G. (1981). Genes VI, VII, and IX 
of phage M13 code for minor capsid proteins of the viron. PNAS. 78, 4194-4198. 
Townsend, S., Finlay, W. J. J., Hearty, S. and O'Kennedy, R. (2006). Optimizing 
recombinant antibody function in SPR immunosensing: The influence of antibody 
structural format and chip surface chemistry on assay sensitivity. Biosensors and 
Bioelectronics. 22, 268-274.  
Wan, S. H., Matin, S. B. and Azarnoff, D. L. (1978). Kinetics, salivary excretion of 
amphetamine isomers, and effect of urinary pH. Clinical Pharmacology and 
Therapeutics. 23, 585-590.  
Ward, E. S., Gussow, D. and Griffiths, A. D., Jones, P. T and Winter, G. (1989). Binding 
activities of a repertoire of single immunoglobulin variable domains secreted from 
Escherichia coli. Nature. 341, 544-546.  
Webster, R. L. (1996). Biology of the Filamentous Bacteriophage. Phage Display of 
Peptides and Proteins. 1-20 
Wish, E. D., Hoffman, J. A. and Nemes, S. (1997). The validity of self-reports of drug 
use at treatment admission and at followup: comparisons with urinalysis and hair assays. 
NIDA Research Monograph. 167, 200-226.  
Wu, A. M., Chen, W., Raubitschek, A., Williams, L. E., Neumaier, M., Fischer,R., Hu, 
S. Z., Odom-Maryon, T.,  Wong, J. Y. and Shively, J. E. (1996). Tumor localization of 
anti-CEA single-chain Fvs: improved targeting by non-covalent dimmers. 
Immunotechnology. 1, 21-36. 
Xu, L., Basheer, C. and Lee, H. K. (2007). Developments in single-drop microextraction. 
Journal of Chromatography A. 1152, 184-192.  
Yacoubian, G. S. (2000). A typology of St. Louis arrestees surveyed through the arrestee 
drug abuse monitoring (ADAM) program. Journal of Drug Education. 30, 247-264.  
Yacoubian, G. S., Wish, E. D. and Choyka, J. D. (2002). A comparison of the OnTrak 
Testcup-5 to laboratory urinalysis among arrestees. Journal of Psychoactive Drugs. 34, 
325-329.  
Yacoubian, G. S.,Jr, Wish, E. D. and Perez, D. M. (2001). A comparison of saliva 
testing to urinalysis in an arrestee population. Journal of Psychoactive Drugs. 33, 289-
294.  
Yau, K. Y., Groves, M. A. and Li, S. (2003). Selection of hapten-specific single-domain 
antibodies from a non-immunized llama ribosome display library. Journal of 
Immunological Methods. 281, 161-175.  
Zhang, Z., Zhang, C. and Su, X. (2008). Carrier-mediated liquid phase microextraction 
coupled with high performance liquid chromatography for determination of illicit drugs 
in human urine. Analytica Chimica Acta,. 621, 185-192.  
Zheng, M., McErlane, K. M. and Ong, M. C. (1998). High-performance liquid 
chromatography-mass spectrometry-mass spectrometry analysis of morphine and 
morphine metabolites and its application to a pharmacokinetic study in male Sprague–
Dawley rats1.  Journal of Pharmaceutical and Biomedical Analyses. 6, 971-980. 
Barbas, C. F., Kang, A. S., Lerner, R. A. and Benkovic, S. J. (1991). Assembly of 
combinatorial antibody libraries on phage surfaces: the gene III site. PNAS.  88, 7978-
7982.  
Bradbury, A., Velappan, N. and Verzillo, V., Ovecka, M. and Chasteen, L. (2003). 
Antibodies in proteomics I: generating antibodies. Trends in Biotechnology. 21, 275-281.  
Glockshuber, R., Malia, M., Pfitzinger, I. and Pluckthun, A. (1990). A comparison of 
strategies to stabilize immunoglobulin Fv-fragments. Biochemistry. 29, 1362-1367.  
Hust, M. and Dübel, S. (2004). Mating antibody phage display with proteomics. Trends 
in Biotechnology.22, 8-14 
Kirsch, M., Zaman, M. and Meier, D. (2005). Parameters affecting the display of 
antibodies on phage. Journal of Immunological Methods. 301, 173-185.  
Krebber, A., Bornhauser, S. and Burmester, J., Honegger, A., Willuda, J.,  Bosshard, H. 
R. and Pluckthun, A. (1997). Reliable cloning of functional antibody variable domains 
from hybridomas and spleen cell repertoires employing a reengineered phage display 
system. Journal of Immunological Methods. 201, 35-55.  
Persson, H., Lantto, J. and Ohlin, M. (2006). A focused antibody library for improved 
hapten recognition. Journal of Molecular Biology. 357, 607-620.  
Pluckthun, A. (1991). Antibody engineering: advances from the use of Escherichia coli 
expression systems. Biotechnology.  9, 545-551.  
Scott, J. K. and Smith, G. P. (1990). Searching for peptide ligands with an epitope 
library. Science. 249, 386-390.  
Smith, G. P. and Petrenko, V. A. (1997). Phage Display. Chemical Reviews. 97, 391-
410.  
Yau, K. Y., Groves, M. A. and Li, S. (2003). Selection of hapten-specific single-domain 
antibodies from a non-immunized llama ribosome display library. Journal of 
Immunological Methods. 281, 161-175.  
Lipsinki, C. A., Lombardo, F., Dominy, B. W. and Feeney, P. (1997). Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Advances in Drug Delivery. 23, 3-25.  
Ahmad, A., Ramakrishnan, A., McLean, M. A. and Breau, A. P. (2003). Use of surface 
plasmon resonance biosensor technology as a possible alternative to detect differences in 
binding of enantiomeric drug compounds to immobilized albumins. Biosensors and 
Bioelectronics. 18, 399-404.  
Andris-Widhopf, J., Rader, C., Steinberger, P., Fuller, R. and Barbas, III. C. F. (2000). 
Methods for the generation of chicken monoclonal antibody fragments by phage display. 
Journal of Immunological Methods. 242, 159-181.  
Arndt, K. M., Muller, K. M. and Pluckthun, A. (1998). Factors influencing the dimer to 
monomer transition of an antibody single-chain Fv fragment. Biochemistry. 37, 12918-
12926.  
Borrebaeck, C. A., Malmborg, A. C. and Furebring, C., Michaelsson, A., Ward, S., 
Danielsson, L. and Ohlin, M. (1992). Kinetic analysis of recombinant antibody-antigen 
interactions: relation between structural domains and antigen binding. Biotechnology. 10, 
697-698.  
Byfield, M. P. and Abuknesha, R. A. (1994). Biochemical aspects of biosensors. 
Biosensors and Bioelectronics. 9, 373-399.  
Barbas, C. F., Burton, D., Scott, J. K. and Silverman, G. J. (2001). Phage Display: A 
Laboratory Manual. Cold Spring Harbour Laboratory Press 
Daly, S. J., Keating, G. J. and Dillon, P. P., Manning, B. M., O'Kennedy, R., Lee, H. A. 
and Morgan, M. R. A. (2000). Development of surface plasmon resonance-based 
immunoassay for aflatoxin B(1). Journal of Agricultural and Food Chemistry. 48, 5097-
5104.  
Fredericks, Z. L., Forte, C. and Capuano, I. V. (2004). Identification of potent human 
anti-IL-1RI antagonist antibodies. Protein Engineering, Design and Selection: PEDS. 17, 
95-106.  
Frostell-Karlsson, A., Remaeus, A., Roos, H., Anderson, K., Borg, P., Hamalainen, M. 
and Karlsson, R. (2000). Biosensor analysis of the interaction between immobilized 
human serum albumin and drug compounds for prediction of human serum albumin 
binding levels. Journal of Medicinal Chemistry. 43, 1986-1992.  
George, A. J. T., French, R. R. and Glennie, M. J. (1995). Measurement of kinetic 
binding constants of a panel of anti-saporin antibodies using a resonant mirror biosensor. 
Journal of Immunological Methods. 183, 51-63.  
Griffiths, A. D., Malmqvist, M. and Marks, J. D., Bye, J. M., Embleton, M. J., 
McCafferty, J., Baier, M., Holliger, K.P., Gorick, B.D. and Hughes-Jones, N.C. (1993). 
Human anti-self antibodies with high specificity from phage display libraries. The EMBO 
journal. 12, 725-734.  
Karp, N. A., Edwards, P. R. and Leatherbarrow, R. J. (2005). Analysis of calibration 
methodologies for solvent effects in drug discovery studies using evanescent wave 
biosensors. Biosensors and Bioelectronics. 21, 128-134.  
Kortt, A. A., Lah, M. and Oddie, G. W. Gruen, C. L., Burns, J. E., Pearce, L. A., Atwell, 
J. L., McCoy, A. J., Howlett, G. J., Metzger, D. W., Webster, R. G. and Hudson, P. J. 
(1997). Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- 
and ten-residue linkers form dimers and with zero-residue linker a trimer. Protein 
Engineering. 10, 423-433.  
Leonard, P., Säfsten, P. and Hearty, S., McDonnell, B., Finlay, B., O'Kennedy R. 
(2007). High throughput ranking of recombinant avian scFv antibody fragments from 
crude lysates using the Biacore A100. Journal of Immunological Methods. 323, 172-179.  
Li, Y., Cockburn, W., Kilpatrick, J. B. and Whitelam, G. C. (2000). High affinity ScFvs 
from a single rabbit immunized with multiple haptens. Biochemical and Biophysical 
Research Communications. 268, 398-404.  
 MacKenzie, C. R., Hirama, T. and Deng, S. J., Bundle, D. R., Narang, S. A. and Young, 
N. M.  (1996). Analysis by surface plasmon resonance of the influence of valence on the 
ligand binding affinity and kinetics of an anti-carbohydrate antibody. The Journal of 
Biological Chemistry. 271, 1527-1533.  
Marazuela, D. and Moreno-Bondi, M. C. (2002). Fiber-optic biosensors--an overview. 
Analytical and Bioanalytical Chemistry. 372, 664-682.  
Maynard, J. and Georgiou, G. (2000). Antibody engineering. Annual Review of 
Biomedical Engineering. 2, 339-376.  
McGregor, D. P., Molloy, P. E., Cunningham, C. and Harris, W. J. (1994). Spontaneous 
assembly of bivalent single chain antibody fragments in Escherichia coli. Molecular 
Immunology. 31, 219-226.  
O'Shannessy, D. J. and Winzor, D. J. (1996). Interpretation of deviations from pseudo-
first-order kinetic behavior in the characterization of ligand binding by biosensor 
technology. Analytical Biochemistry. 236, 275-283.  
Quinn, J. G. and O'Kennedy, R. (2001). Biosensor-based estimation of kinetic and 
equilibrium constants. Analytical Biochemistry. 290, 36-46.  
Rader, C., Ritter, G. and Nathan, S., Elia, M., Gout, I., Jungbluth, A. A., Cohen, L. S., 
Welt, S., Old, L. J., Barbas, C. F. (2000). The rabbit antibody repertoire as a novel source 
for the generation of therapeutic human antibodies. The Journal of Biological Chemistry. 
275, 13668-13676.  
Rau, D., Kramer, K. and Hock, B. (2002). Cloning, functional expression and kinetic 
characterization of pesticide-selective Fab fragment variants derived by molecular 
evolution of variable antibody genes. Analytical and Bbioanalytical Chemistry. 372, 261-
267.  
Redshaw, N., Dickson, S. J., Ambrose, V. and Horswell, J. (2007). A preliminary 
investigation into the use of biosensors to screen stomach contents for selected poisons 
and drugs. Forensic Science International,. 172, 106-111.  
Rodriguez-Mozaz, S., Alda, M. J. L. d., Marco, M. and Barceló, D. (2005). Biosensors 
for environmental monitoring: A global perspective. Talanta,. 65, 291-297.  
Rogers, K. R. (2006). Recent advances in biosensor techniques for environmental 
monitoring. Analytica Chimica Acta. 568, 222-231.  
Rogers, K. R. (2000). Principles of affinity-based biosensors. Molecular Biotechnology. 
14, 109-129.  
Stacy, J. E., Kausmally, L. and Simonsen, B., Nordgard, S. H. Alsoe, L., Michaelsen T. 
E. and Brekke O. H. (2003). Direct isolation of recombinant human antibodies against 
group B Neisseria meningitidis from scFv expression libraries. Journal of Immunological 
Methods. 283, 247-259.  
Tout, N. L., Yau, K. Y. and Trevors, J. T. (2001). Synthesis of ligand-specific phage-
display ScFv against the herbicide picloram by direct cloning from hyperimmunized 
mouse. Journal of Agricultural and Food Chemistry. 49, 3628-3637.  
Crane, M. A., Kingzette, M. and Knight, K. L. (1996). Evidence for limited B-
lymphopoiesis in adult rabbits. The Journal of Experimental Medicine. 183, 2119-2121.  
Popkov, M., Mage, R. G. and Alexander, C. B., Thundivalappil, S., Barbas, C. F. and 
Rader, C. (2003). Rabbit immune repertoires as sources for therapeutic monoclonal 
antibodies: the impact of kappa allotype-correlated variation in cysteine content on 
antibody libraries selected by phage display. Journal of Molecular Biology. 325, 325-
335.  
Ratcliffe, M. J. (2006). Antibodies, immunoglobulin genes and the bursa of Fabricius in 
chicken B cell development. Developmental and Comparative Immunology. 30, 101-118.  
Boder, E. T., Midelfort, K. S. and Wittrup, K. D. (2000). Directed evolution of antibody 
fragments with monovalent femtomolar antigen-binding affinity. PNAS. 97, 10701-
10705.  
Coia, G., Hudson, P. J. and Irving, R. A. (2001). Protein affinity maturation in vivo using 
E. coli mutator cells. Journal of Immunological Methods. 251, 187-193.  
Comtesse, N., Heckel, D. and Maldener, E., Glass, B. and Meese, E. (2000). Probing the 
human natural autoantibody repertoire using an immunoscreening approach. Clinical and 
Experimental Immunology. 121, 430-436.  
Cox, E. C. (1976). Bacterial mutator genes and the control of spontaneous mutation. 
Annual Review of Genetics. 10, 135-156.  
Daugherty, P. S., Chen, G., Iverson, B. L. and Georgiou, G. (2000). Quantitative 
analysis of the effect of the mutation frequency on the affinity maturation of single chain 
Fv antibodies. PNAS.  97, 2029-2034.  
Dong, L., Chen, S., Richter, M. and Schachner, M. (2002). Single-chain variable 
fragment antibodies against the neural adhesion molecule CHL1 (close homolog of L1) 
enhance neurite outgrowth. Journal of Neuroscience Research. 69, 437-447.  
Kunkel, T. A. (1985). Rapid and efficient site-specific mutagenesis without phenotypic 
selection. PNAS. 82, 488-492.  
Lee, P. C., Mijts, B. N. and Petri, R. (2004). Alteration of product specificity of 
Aeropyrum pernix farnesylgeranyl diphosphate synthase (Fgs) by directed evolution. 
Protein Engineering, Design and Selection: PEDS. 17, 771-777.  
Low, N. M., Holliger, P. H. and Winter, G. (1996). Mimicking somatic hypermutation: 
affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator 
strain. Journal of Molecular Biology. 260, 359-368.  
Lu, D., Shen, J., Vil, M. D. (2003). Tailoring in vitro selection for a picomolar affinity 
human antibody directed against vascular endothelial growth factor receptor 2 for 
enhanced neutralizing activity. The Journal of Biological Chemistry. 278, 43496-43507.  
Notkins, A. L. (2004). Polyreactivity of antibody molecules. Trends in Immunology. 25, 
174-179.  
Padlan, E. A. (1994). Anatomy of the antibody molecule. Molecular Immunology. 31, 
169-217.  
Park, S. G., Lee, J. S. and Je, E. Y., Kim, I., Chung J. and Choi, I. (2000). Affinity 
maturation of natural antibody using a chain shuffling technique and the expression of 
recombinant antibodies in Escherichia coli. Biochemical and Biophysical Research 
Communications. 275, 553-557.  
Razai, A., Garcia-Rodriguez, C. and Lou, J., Geren, I. N., Forsyth, C. M., Robles, Y., 
Tsai, R., Smith, T. J., Smith L. A., Siegel, R. W., Feldhaus, M. and Marks, J.D (2005). 
Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin 
type A. Journal of Molecular Biology. 351, 158-169.  
Schier, R., McCall, A. and Adams, G. P., Marshall K.W., Merritt H., Yim M., Crawford 
R.S., Weiner L.M., Marks C. and Marks J. D. (1996). Isolation of picomolar affinity anti-
c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining 
regions in the center of the antibody binding site. Journal of Molecular Biology. 263, 
551-567.  
Sidhu, S. S., Lowman, H. B., Cunningham, B. C. and Wells, J. A. (2000). Phage display 
for selection of novel binding peptides. Methods in Enzymology. 328, 333-363.  
Valjakka, J., Hemminki, A. and Niemi, S. (2002). Crystal structure of an in vitro 
affinity- and specificity-matured anti-testosterone Fab in complex with testosterone. 
Improved affinity results from small structural changes within the variable domains. The 
Journal of Biological Chemistry. 277, 44021-44027.  
Wedemayer, G. J., Patten, P. A. and Wang, L. H., Schultz, P. G. and Stevens, R. C. 
(1997). Structural insights into the evolution of an antibody combining site. Science. 276, 
1665-1669.  
Yang, W. P., Green, K. and Pinz-Sweeney, S., Briones, A. T., Burton  D.R. and Barbas, 
C.F. (1995). CDR walking mutagenesis for the affinity maturation of a potent human 
anti-HIV-1 antibody into the picomolar range. Journal of Molecular Biology. 254, 392-
403.  
Zahnd, C., Spinelli, S. and Luginbuhl, B., Amstutz, P., Cambillau, C. and Plückthun, A. 
(2004). Directed in vitro evolution and crystallographic analysis of a peptide-binding 
single chain antibody fragment (scFv) with low picomolar affinity. The Journal of 
Biological Chemistry. 279, 18870-18877.  
Zimmermann, J., Oakman, E. L. and Thorpe, I. F., Shi, X., Abbyad, P., Brooks, C.L. 
3rd, Boxer, S.G. and Romesberg, F. E. (2006). Antibody evolution constrains 
conformational heterogeneity by tailoring protein dynamics. PNAS. 103, 13722-13727.  
 
